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Abstract 
 
Background 
It has been demonstrated, in 4 large randomised control trials (RCT), that 
screening for colorectal cancer (CRC) using annual or biennial guaiac faecal 
occult blood tests (gFOBT) reduces mortality and incidence. The faecal 
immunochemical test (FIT) uses technology that is analytically more 
sensitive and specific for human haemoglobin (Hb) than gFOBT.  
 
Methods 
An evaluation of the OC-Sensor Diana quantitative FIT analyser and 
prospective analysis of a single estimate of faecal haemoglobin 
concentration (f-Hb) in two clinical settings; the Scottish Bowel Screening 
Programme and patients referred from primary care to endoscopy services. 
 
Results 
Uptake, in the cohort offered screening with FIT as a first-line test, was 4.8% 
higher than that seen contemporaneously in the Scottish Bowel Screening 
Programme. This returned to pre study levels when the study ceased and 
gFOBT was reintroduced. The cohort offered quantitative FIT had a 
positivity of 2.4% compared to 2.1% in the programme overall. Clinical 
outcomes, during the evaluation period, in the study cohort and the 
screening programme were similar. 
 
40,125 participants returned a FIT sample device and 38,720 had their f-Hb 
measured. An observational study of f-Hb by sex and age, using the 97.5th 
percentile as a potential upper reference limit, and 90% confidence intervals 
(CI) showed 519 ng Hb/ml buffer (90% CI: 468 – 575) for men and 283 ng 
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Hb/ml buffer (90% CI: 257 – 316) for women. When the data was partitioned 
by age quintile, f-Hb increased with age in both sexes.  
 
Quantitative FIT and endoscopy were completed by 280 patients referred 
from primary care for endoscopy (median age: 63 years, range: 18 to 84 
years), 59.6% were female. Six (2.1%) participants had CRC, 23 (8.2%) 
high-risk adenoma (HRA: >3 adenomas or any > 1 cm), 31 (11.1%) low-risk 
adenoma (LRA), and 26 (9.3%) inflammatory bowel disease (IBD) as the 
most serious diagnosis. Those with CRC had median f-Hb of > 1000 ng 
Hb/ml buffer. Using f-Hb with a cut-off of 50 ng Hb/ml buffer, negative 
predictive values of 100%, 94.4%, 93.4% and 93.9% were found for CRC, 
HRA, LRA and IBD.  
 
Conclusions 
The introduction of quantitative FIT into population screening and 
symptomatic settings has the potential to optimise referral for endoscopy for 
those who have evidence of small amounts of bleeding, thereby improving 
outcomes and reducing the current burden on endoscopy services. 
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CHAPTER 1: Detection of Colorectal Cancer 
(CRC) 
 
1.1 Introduction 
 
Colorectal cancer (CRC) continues to be the third most commonly 
diagnosed cancer worldwide. It is ranked as the fourth most common cause 
of cancer deaths for men and women. Incidence varies greatly across the 
world with developed countries accounting for nearly 60% of cases. The 
developing countries are experiencing an increase in the incidence of CRC 
that may be due to recent changes in environmental factors such as 
adoption of a western diet, increased alcohol consumption and reduction of 
exercise (1). 
 
Annually, in the United Kingdom (UK), around 40,000 people are diagnosed 
with CRC. In 2012, there were approximately 16,000 deaths from CRC in 
the UK. The incidence of CRC rises sharply at age 50 years in men and 55 
years in women, with the sharpest increase seen in males. Incidence rates 
in men rose by an average of 1% each year between 1979 and 1999 (2). It 
might therefore be expected that the burden of CRC will increase as the 
population ages. 
 
Most cases of CRC present to primary care symptomatically or are detected 
during the investigation of a different condition, such as anaemia. Prognosis 
and outcome are related to the stage of the disease at presentation. Two 
staging systems are commonly used to classify CRC. The American Joint 
Committee on Cancer (AJCC) advocate using the size of tumour, lymph 
node involvement and whether there are metastases (TMN) to group bowel 
cancers into numerical stages 0 – I, II, III, IV. (3). The second method is 
Dukes’ staging which uses the depth of penetration through the gut wall – 
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A means the CRC has only penetrated the inner gut wall through to D where 
the CRC has spread to elsewhere in the body.  
 
Survival rates increase dramatically when CRC is detected early – in the 
symptomatic population, CRC diagnosed at Dukes’ stage A have a five year 
survival of 93.2%, whereas Dukes’ stage D CRC have a five year survival 
of 6.6% (4). Screening enables the detection of early disease in those who 
are apparently well and it has been shown that early detection through 
asymptomatic population screening reduces CRC mortality (5). In addition, 
removal of sufficient numbers of adenomas, possible precursors of CRC, 
also decreases disease incidence in the screened population (6).  
 
In this Chapter, the following topics are reviewed: models of CRC 
carcinogenesis, use of tumour markers, patients with symptoms presenting 
in primary care, the principles of screening, detection methods, initiatives to 
increase uptake in screening programmes, some of the adverse effects of 
screening and novel approaches to CRC detection. 
 
1.2 Models of CRC Carcinogenesis 
 
We can consider carcinogenesis as a process that results in the progression 
of a normal gut epithelial cell to a malignant CRC cell. Genetic changes 
accumulate within the affected cell line that confer a selective growth 
advantage over others.  The mechanisms underlying these transitions are 
complex and may involve genetic mutations or epigenetic changes affecting 
oncogenes, tumour suppressor genes or mutator genes (3). 
 
Fearon and Vogelstein (7) proposed a multistep, genetic basis for the 
development of CRC, and the adenoma-carcinoma sequence is generally 
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accepted as the stepwise model for the formation of most CRC. In this 
model, genetic mutations that allow cell proliferation to continue unchecked 
are accumulated. Apoptosis is switched off and angiogenesis occurs, 
leading to carcinogenesis. Although this provides a model for the pathway 
preceding carcinogenesis, it must be remembered that approximately 40% 
of the western population will develop adenomas, but that only 3% of these 
adenomas have malignant potential (8). Key tumour suppressor genes are: 
APC, p53 and DNA mismatch repair genes MSH2, MLH1 and PMS1 and 2. 
Key oncogenes are K-ras and DNA binding protein genes myc and myb. 
The absence or presence of these mutations varies from tumour to tumour 
and may have a bearing on disease prognosis and response to therapy (9). 
 
A ‘de novo’ pathway in which CRC do not derive from pre-existing 
adenomas, was suggested in the 1980s. However, this model remains 
controversial. It was first proposed in a retrospective review of patients 
undergoing follow-up of polyps over six years. It was estimated that this type 
of CRC may be responsible for one-third of all CRC detected (10). A second 
retrospective study of 1630 tumours found that these ‘de novo’ CRC were 
not a single group and were more often found in the right colon (11). When 
considering methods for the detection of CRC, this group must be taken into 
account since they may not bleed as in the adenoma-carcinoma sequence 
and they may be more difficult to visualise during endoscopy.  
 
1.3 The Presence of Haemoglobin (Hb) in Faeces as a 
Tumour Marker 
 
Tumour markers are usually proteins produced by normal cells in small 
amounts that may be over expressed in cancerous conditions. Examples of 
so called specific tumour markers are prostate specific antigen for prostate 
cancer and CA-125 for ovarian cancer. The diagnostic efficiency of those 
tests and other issues may however preclude their use in diagnostic or 
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screening contexts.   Detection of the presence of haemoglobin (Hb) in 
faeces, often described as faecal occult blood (FOB) may be an indicator of 
significant colorectal neoplasia (higher risk adenoma (HRA) and/or CRC) 
since many lesions go through a process of vascularisation during their 
development. In this case we are not witnessing over expression of a 
marker, but unusual release of blood by the affected tissue. Early studies 
using red calls labelled with Cr 51 showed that, in 555 faecal samples from 
80 patients with clinical suspicions of blood loss, there were detectable 
amounts of Hb in faeces measured by Cr 51 and guaiac methods (12). 
However, this early study indicated that the presence of Hb did not always 
indicate significant neoplasia and may be an indicator of the presence of 
other organic bowel disease, such as inflammatory bowel diseases (IBD) or 
may have no obvious underlying cause.  The diagnostic efficiency for 
colorectal cancer is therefore reduced because of false positive results. 
 
There is no perfect tumour marker and the benefits and disadvantages of 
examining a particular tumour marker must be weighed up when making a 
decision regarding whether or not to use it (13). The characteristics of the 
ideal tumour marker are shown in Table 1. 
 
Table 1 Characteristics of a tumour marker 
(1) The marker  must be produced by the tumour 
(2) Should be produced in sufficient quantities to be detected 
(3) Must have a half-life that allows monitoring to take place 
(4) Sampling must be relatively easy 
(5) Concentrations must be relative to tumour progression 
Adapted from Holland-Frei Cancer Medicine (13) 
 
Where there is blood loss into the bowel, the detection of Hb in faeces is 
dependent on several factors: the principle of the method used, site of blood 
loss, size of lesion and type of lesion. Microflora in the gut degrade Hb into 
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its constituent parts and these degradation products may become 
undetectable by any test for the presence of Hb in faeces, commonly called 
faecal occult blood tests (FOBT).  
 
Increased transit time will reduce the amount of Hb and this may be a 
particular issue in females who generally have increased transit time 
compared to males (14). Another consideration is whether the lesion in the 
bowel is developed enough to start bleeding or is a tumour that is prone to 
bleeding. The amount of Hb may also be below the analytical detection limit 
of the test method chosen or frequency of blood loss may be such that the 
bleed is missed at the time of sampling. It follows that the presence of Hb 
may enable detection of CRC, but that it may not be particularly sensitive. 
This issue will be explored later in this work.  
 
Focusing on the methods for testing for the presence of Hb in faeces, the 
characteristics of the two approaches most commonly used are compared 
in Table 2. Those are the guaiac faecal occult blood tests (gFOBT) and 
faecal immunochemical tests (FIT) for Hb.  
 
Table 2 Comparison of faecal occult blood tests (FOBT) 
 gFOBT FIT 
Target Haem Globin 
Principle peroxidase activity using guaiac as an 
indicator 
Immunochemical 
reaction 
Method Indirect Direct 
Interference Meat, some vegetables containing 
peroxidases, vitamin C 
None 
Detects Bleeding from stomach, small and large bowel Bleeding from large 
bowel 
Adapted from Colorectal Cancer in Clinical Practice (15) 
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1.4  Presentation of CRC in Primary Care  
 
Abdominal symptoms such as pain, change in bowel habit or rectal bleeding 
are common and while they may be used as potential indicators of CRC, 
they are recognised as being very non-specific. In a systematic review and 
meta–analysis of 47 diagnostic studies in primary care from 2010, Jellema 
et al. (16) found that the only single reported physical symptom that that had 
any significance in the diagnosis of CRC was weight loss. Other individual 
symptoms were not useful for predicting CRC: however, certain symptom 
combinations, such as rectal bleeding, abdominal pain and change in bowel 
habit increased the sensitivity of diagnosis of CRC. Including FIT in the 
algorithm increased specificity. The review concluded that, due to the 
heterogeneity of the studies, the results may not be directly applicable to all 
primary care settings and further focused studies were needed. 
 
An early Italian study assessed the effectiveness of primary care providers 
(PCP) at diagnosing patients presenting with symptoms (17). This study 
was conducted over a period of eight weeks, 159 primary care physicians 
were involved and 332 symptomatic patients underwent colonoscopy or 
double contrast barium enema (DCBE). From this group, 280 patients were 
eligible for inclusion in the study. The most frequent symptoms reported 
were lower abdominal pain (79.6%), bloating (59.6%), constipation (47.8%) 
rectal bleeding (40.7%), diarrhoea (30.3%) and iron deficiency anaemia 
(IDA) (24.6%): 90.3% of patients complained of more than one symptom 
and 73.2% complained of at least three symptoms. Clinicians were more 
likely to refer for colonoscopy if rectal bleeding was a symptom and DCBE 
if abdominal pain and bloating was a symptom.  
 
The study found that both these symptoms were not risk factors for CRC. 
The most common symptoms in patients with CRC were abdominal pain 
(73%), IDA (68%), bloating (54%), constipation (51%), rectal bleeding 
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(44%), weight loss (37%), diarrhoea (24%) and change in bowel habits 
(20%). The only variables significantly associated with a risk of CRC were 
age greater than 50 years, IDA and weight loss.  
 
Iron deficiency anaemia occurs in up to 5 % of the adult population in the 
developed world. In 5-10% of cases CRC is an underlying cause and may 
also be a presenting feature in primary care. Current guidelines, written by 
the British Society of Gastroenterology (BSG), indicate that, where there is 
no history of poor diet, use of nonsteroidal anti-inflammatory drugs 
(NSAIDs), family history or blood donation follow up should include 
colonoscopy to investigate the possibility of occult blood loss due to CRC 
(18).  
 
The National Institute for Health and Care and Excellence (NICE) is a 
special health authority set up in England who produce guidance and 
standards in relation to provision of health services. Within Scotland, the 
Scottish Intercollegiate Guidelines Network (SIGN) provide evidence based 
recommendations regarding referral strategies for patients presenting to 
primary care. Guidelines reduce variation and improve the quality of care by 
gathering and reviewing the most up to date evidence and presenting it in 
an accessible form for non-experts. Both organisations have produced 
guidance in relation to CRC. SIGN 126 Diagnosis and management of 
colorectal cancer and (19) NICE NG 12 Suspected Cancer: recognition and 
referral (20) recommend that patients over the age of 40 years, reporting to 
primary care with rectal bleeding are referred for colonoscopy, with NICE 
also including abdominal pain, weight loss and IDA in its list of symptoms 
requiring urgent referral.  
 
Offering all patients presenting to primary care with abdominal symptoms 
colonoscopy is expensive and potentially hazardous. In addition a woman 
presenting with abdominal distension or bloating with or without abdominal 
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pain, feeling full quickly, or difficulty eating, may have other serious causes 
of their symptoms requiring investigation via other pathways (e.g. ovarian 
cancer). As described above, most patients presenting to primary care with 
non-specific symptoms do not have CRC. Controversially, the most recent 
revision of the NICE guideline (20) includes an update that states that FOBT 
can be offered to this group, this could be considered a retrograde step as 
it encourages reintroduction of gFOBT in assessment of symptomatic 
patients. 
 
The use of a single faecal sample obtained by digital rectal examination 
using gFOBT in assessment of symptomatic patients has been discouraged 
in national guidelines (21). In fact, these tests have many serious 
disadvantages and should be considered obsolete as point-of-care tests 
since they may actually slow progression to endoscopy (22). Newer FIT and 
faecal calprotectin (inflammatory marker) tests may be able to replace the 
gFOBT in the assessment of those presenting at primary care. Analysis of 
400 patient samples from the cost-effectiveness of a decision rule for 
abdominal complaints in primary care (CEDAR) study found that the 
diagnostic accuracy of faecal calprotectin and faecal haemoglobin 
concentration (f-Hb) analyses depended on the size of the adenomas 
present and was not sufficient to detect lesions <1 cm in diameter. The tests 
were able to rule out organic bowel disease (OBD), but would not be useful 
for diagnosis of significant neoplasia (23). 
 
1.5 Screening for CRC  
 
Wilson and Jungner stated that the aim of screening is to diagnose disease 
during the early stages of its pathogenesis in people who do not have 
symptoms. They put forward 10 principles of screening as outlined in Table 
3 (24). CRC is an excellent candidate for screening; it has a well described 
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development, it is a significant health issue and there are interventions 
available that reduce morbidity and mortality. 
 
Table 3 Principles of screening 
(1)  The condition sought should be an important health problem.  
(2)  There should be an accepted treatment for patients with recognised disease.  
(3)  Facilities for diagnosis and treatment should be available. 
(4)  There should be a recognisable latent or early symptomatic stage.  
(5)  There should be a suitable test or examination.  
(6)  The test should be acceptable to the population.  
(7)  The natural history of the condition, including development from latent to 
declared disease, should be adequately understood.  
(8)  There should be an agreed policy on whom to treat as patients.  
(9)  The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible 
expenditure on medical care as a whole.  
(10)  Case-finding should be a continuing process and not a "once and for all" 
project. 
Adapted from WHO Report Principles and practice of screening for disease (24) 
 
The most robust evidence for screening for CRC comes from a meta-
analysis of randomised controlled trials (RCT) using triple card gFOBT 
followed by colonoscopy for those who had a positive test result (25). As a 
result the detection of Hb in faeces, including the use of FIT methods, is the 
approach used in many European countries (26). 
 
This type of screening is a two-step approach, where any person who has 
a positive faecal test result is referred for bowel visualization. However, in a 
one-step process the investigation is direct referral for bowel visualisation 
and includes flexible sigmoidoscopy and colonoscopy (27). The use of 
colonoscopy as the first-line test for the detection and removal of clinically 
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significant lesions was endorsed by the US Preventive Services Task Force 
in 2008 (28).  
 
In addition, testing may be performed on a selected population (mass 
screening) or efforts may be directed towards the individual. Countries in 
the European Union tend to adopt nationally organised mass screening 
whereas, in the United States (US), screening tends to be undertaken by 
case-finding or opportunistic interventions in primary care (29). The Survey 
of Colorectal Cancer Screening Practice in Healthcare Organisations and 
National Health Interview Survey, reported on adherence to screening 
guidelines among PCP (30). A total of 1175 PCP and 11365 adults > 50 
years of age responded to a questionnaire about FOBT implementation and 
follow-up of positive test results. It was recommended that home triple card 
gFOBT are used for screening: however, 32.5% of doctors responded to the 
questionnaire stating that they use once only digital rectal examination 
during the consultation. Full endoscopic examination of the bowel was 
recommended for patients with a positive test result, however, 29.7% of 
doctors followed up a positive result with a further gFOBT test.  
 
Of the adults who completed a questionnaire, one-third said they had a 
single test in the consultation and a further one-third said that they had no 
follow-up after a positive test result. One drawback to the study is that the 
results were self-reported and may contain inaccuracies. Poor adherence 
to stated guidelines can potentially reduce the effectiveness of screening 
and the reduction in disease specific mortality reported in the RCT may not 
be attained under these conditions. It is important to note that nationally 
organised programmes are easier to monitor through the central collection 
of data items which give an indication of effectiveness (31).  
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A comparison of US and European screening modalities concluded that the 
number and combination of screening modalities available could lead to 
variability in overall outcomes (29). However, sharing the outcomes of the 
different screening programmes at well organised international meetings 
could be a way to develop and improve future efforts (26). 
 
Screening, post-screening surveillance and increased awareness of signs 
and symptoms in the general population and subsequent presentation in 
primary care since the inception of screening programmes all put extra 
pressure on endoscopy services. A review of the demand for endoscopy 
capacity within England, showed increasing demand from baseline 
symptomatic referrals, general practitioner (GP) referrals, screening and 
awareness campaigns when they are run (32).  
 
Due to the recommendations that all these different groups of patients 
should be referred for bowel visualisation, the endoscopy requirement is 
increasing year on year and resources are struggling to keep up with 
demand. What is required is a way to triage those who are at higher risk of 
CRC and would benefit most from endoscopy. 
 
1.6 Evidence Base for Use of Guaiac Faecal Occult Blood 
Tests (gFOBT) as a Screening Modality  
 
Within a screening context, the sensitivity of gFOBT for CRC is difficult to 
estimate but, using interval cancer (IC) data (CRC that are diagnosed after 
a negative screening test in the interval until the next screening invitation), 
the most commonly used triple test (Hemoccult ® (Beckman Coulter, 
Fullerton, CA)) seems to detect in the region of 50% of CRC in a population 
that accepts screening (33). The accepted dogma is that this low clinical 
sensitivity is due partly to the relatively low analytical sensitivity of 
Hemoccult for blood and that CRC may bleed intermittently or not at all. On 
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the other hand, the specificity (percentage of disease free individuals with a 
negative test) is around 98%.  
 
Although this seems high, the majority of the population do not have CRC: 
and, because 2% of a large number in a population-based CRC screening 
programme is a considerable cohort, this results in a high false positive rate. 
It should also be noted that most studies used non-rehydrated Hemoccult: 
rehydration increases both analytical and clinical sensitivity by lysing red 
cells and exposing more haem to react with the peroxidase developer. 
However, the increase in clinical sensitivity has an adverse effect on 
specificity. This is an issue with all methods using FOB as a means of 
detecting colorectal neoplasia. 
 
The principles of screening indicate that CRC is a good candidate for 
screening. Data regarding early detection suggest that this leads to 
improved prognosis. Therefore, it could be concluded that detecting CRC 
through screening will have a positive effect for the whole population. 
However, the screening process is associated with biases that have the 
effect of making screen-detected disease appear to have a better prognosis 
than symptomatic disease. The terms used to describe these biases are 
volunteer bias (and non-responder bias), length bias and lead-time bias.  
 
Volunteer bias results from invitations to be screened being taken up more 
readily by people who are health conscious. In other words, people who 
accept screening invitations are more likely to experience a better outcome 
if disease is detected; for example, they may be more likely to take exercise 
and less likely to smoke. Those people who do not respond to the invitation 
to be screened may be different to those who did accept. Length bias is a 
consequence of intermittent screening tests tending to pick up slow growing 
disease that is more likely to be associated with a good prognosis than more 
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aggressive, fast growing disease that is likely to present between screening 
episodes. Finally, lead-time bias is an inevitable consequence of early 
diagnosis: detecting disease at an early stage of its development inevitably 
leads to an observed improved duration of survival simply by virtue of 
shifting the point of diagnosis forward in time (15). 
 
To prove that screening is effective, these biases must be eliminated and, 
to do this, population-based randomised controlled trials (RCT) are 
required. In these RCTs, it is essential that the group randomised to be 
offered screening must be analysed as a whole, including those who do not 
choose to participate in the process and those who are diagnosed with IC. 
The disease-specific mortality in this group must then be compared with that 
seen in a randomly selected control group which is not offered screening 
and, only if a significant improvement is seen in the test group, can 
screening be considered to be beneficial. 
 
The original population-based RCTs of CRC screening utilised gFOBT and, 
since the results of these trials proved unequivocally that screening for CRC 
is effective, it is worth examining them in detail. Five studies were carried 
out, in the United States, England, Denmark, France and Sweden, and all 
employed the gFOBT Haemoccult (Hemoccult in US market).  
 
The study from the United States, which took place in Minnesota, 
randomised volunteers into three groups, one group offered annual 
screening (15,930 men and women), one group offered biennial screening 
(15,587 men and women) and a third observation group (15,124 men and 
women). It should be noted that, uniquely amongst the RCT, the Hemoccult 
was rehydrated resulting in a 10% positivity and, as a result, in the group 
offered annual screening, 38% had a colonoscopy on at least one occasion. 
A positive test result was followed by colonoscopy and CRC mortality was 
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reduced by 21 % in the biennial group and by 33% in the annual group after 
13 and 18 years follow up (34). In addition, a significant reduction in 
incidence was noted in annual and biannual testing. This has not been 
observed in any of the other trials of gFOBT screening and is probably the 
result of the high colonoscopy rate leading to a high rate of polypectomy 
and removal of potentially neoplastic lesions (6). 
 
The study carried out in England took place in Nottingham and 150,000 
subjects were randomised by household (35). The group offered screening 
were aged between 50 and 74 years and offered biennial non-rehydrated 
Haemoccult. Colonoscopy was offered after a positive test result. In the first 
(prevalence) round, the positivity was 2.0% and, in the subsequent 
(incidence) rounds, it fell to 1.2%. In the course of five screening rounds, 
60% of the group which was offered screening completed at least one 
screening test. The screen-detected CRC were diagnosed at an earlier 
stage, 57% at Dukes’ stage A, with more favourable outcomes. However, 
there were a large number of IC with 50% of the CRC diagnosed in those 
who had accepted at least one screening test not detected. 
 
Thus, in this study, gFOBT was associated with a relatively low uptake and 
relatively poor sensitivity. Nevertheless, the CRC specific mortality in the 
group offered screening showing a significant reduction of 15% when 
compared to the control group after a median of 7.8 years of follow-up.  At 
a median of 19.5 years of follow-up, the reduction in CRC mortality was 
maintained at 13% and, when adjusted for non-compliance, the reduction 
was found to be 18% (36). It should be noted, however, that despite the fact 
that 615 adenomas greater than 10 mm in diameter were removed from 
individuals in the intervention arm, no significant difference in CRC 
incidence could be detected.  
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Screening programmes may have a “halo” effect and the Nottingham study 
illustrates this. In the control group, the percentage of patients presenting 
with CRC at Dukes’ stage A increased from 9% in the first half of the 
recruitment period to 28% in the second (37). Thus, it seems that the very 
presence of the screening programme had an effect on individuals who 
were not invited for screening and this may be related to increased 
awareness of the significance of rectal bleeding. On the same theme, 
significantly fewer emergency admissions for suspected CRC were seen in 
the group offered screening when compared to the control group indicating 
that screening also had the effect of reducing the number of individuals 
presenting as emergencies (38).  
 
In the Danish trial, in Funen, 61,933 subjects were randomised into a group 
that was offered screening by means of biennial Haemoccult testing or into 
a control group. The uptake in the first round was 67% and more than 90% 
accepted repeated screening invitations, presumably owing to the fact that 
those who did not accept the first invitation were excluded. As in the 
Nottingham study, screen detected CRC were picked up at an earlier stage 
with 48% at Dukes’ stage A and IC accounted for 30% of all CRC diagnosed 
in those offered screening at least once. Thus, screening in the Danish 
Study performed in a very similar way to that of the Nottingham Study and 
the disease specific mortality reduction after five years was 18% (39) (40). 
 
In the French study, in Burgundy, a randomised approach was not adopted 
(41). Rather, small geographical areas were identified and these were either 
offered screening or acted as controls. Again, a non-rehydrated Haemoccult 
gFOBT was used on a biennial basis and offered to individuals between the 
ages of 50 and 74 years. A total of 91,199 were offered screening. The 
positivity was 1.2% in the first round but increased slightly in further rounds 
and uptake in the first round was 52.8% remaining fairly constant thereafter. 
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Reflecting the results of the Nottingham and Funen studies, the mortality 
reduction seen in those offered screening was 16%. 
 
In Gothenburg, Sweden, 68,308 citizens aged 60 to 64 years were 
randomised into either a control group or a group that was offered biennial 
Hemoccult II (42). Uptake was 70% and those with a positive test result 
were investigated by means of flexible sigmoidoscopy (FS) and a DCBE. 
After a mean follow-up period of nine years from the last screening episode, 
a statistically significant reduction in CRC mortality of 16% was seen. 
 
These five studies are of the utmost importance since they are the only RCT 
of population screening for CRC using gFOBT. These studies are usefully 
compared in a systematic review (43). The consistent reduction in CRC 
specific mortality indicates that early detection of CRC is truly beneficial. In 
a meta-analysis of population screening by gFOBT, it was estimated to 
reduce CRC mortality by 16%, increasing to 23% when adjusted for uptake. 
These results demonstrate that the principle of screening for CRC is sound 
and, although gFOBT may be considered a sub-optimal test, these results 
can be used as benchmarks for newer tests (27). 
 
The United Kingdom National Screening Committee (UKNSC) advised that 
a demonstration pilot of biennial gFOBT screening was required to 
determine whether or not the results of the randomised trials could be 
reproduced within the UK National Health Services (44). This pilot was 
successfully carried out in two areas of the UK, one in Scotland and one in 
England (45). As a result, the UK Health Departments have now rolled out 
CRC screening programmes and the initial outcomes indicate that the 
national programmes should provide outcomes as predicted from the RCT 
(46) (47). 
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1.7 Flexible Sigmoidoscopy (FS) as a Screening Modality 
 
Bowel visualisation is the other predominant type of screening modality. FS 
employs a fibre-optic endoscope to visualise the distal third of the bowel and 
so is able to detect lesions in the left-sided portion of the large bowel. 
Biopsies of suspicious looking tissue can be carried out and small polyps 
may be removed. Approximately two-thirds of CRC are found here. In 
addition, the usual practice is to refer for colonoscopy when index lesions 
have been found on FS. The criteria for index or high risk lesions vary but 
the BSG advise: 1 cm or larger in diameter, three or more adenomas, 
tubovillous or villous histology, severe dysplasia or malignant disease, or 20 
or more hyperplastic polyps above the rectum (48). 
 
During the FS, no sedation is required and the procedure is commonly 
performed by a nurse endoscopist. The bowel preparation is often a single 
dose, liquid enema containing sodium phosphate as this is well tolerated by 
the majority of people and can be performed at home or at the clinic. The 
FS procedure usually takes less than 20 minutes, making it less onerous 
than full colonoscopy.  
 
The incidence of CRC starts to increase steeply at about 50 years. Thus, 
FS, or colonoscopy, performed between the ages of 50 and 60 years could 
be a valuable screening tool. Figure 1 shows the structure of the large 
bowel, this consists of the caecum, colon and rectum.  
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Figure 1 Diagram of the large bowel 
 
Source - Cancer Care Ontario (49). 
 
Holme et al report findings on once only FS or FS with FOBT compared to 
no screening from the NORwegian Colorectal CAncer Prevention trial 
(NORCCAP) (50). The cohort included 98,792 participants from three 
geographic areas, 78,220 in the control group and 20572 in the screening 
groups (split half and half between FS only and FS and FOBT). After a 
median of 10.9 years follow up, CRC mortality reduced by 27% and 
incidence by 20%. Reductions were similar in younger, 50 – 54 years old 
and older, 55 – 64 year age groups. The addition of FOBT led to a reduction 
in adherence compared with the FS group and so could be considered 
detrimental.  Atkin et al reported on the longest running UK study (51). This 
was based on a multicentre trial carried out in 14 centres with 170,432 
volunteers who agreed to take part in the trial. In this, the intervention group 
had a reduction in mortality of 31% and a reduction in incidence of CRC of 
23%. However, the group offered FS were essentially volunteers and this 
may have led to a bias in this study.  
 
The Italian SCORE trial, has reported on more than 10 years follow up. A 
total of 34,272 participants were included in the study and a non-significant 
reduction in mortality of 22% and a reduction in incidence of 18% were found 
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(52). The FS arm of the Prostate, Lung, Colorectal and Ovarian (PLCO) 
cancer screening trial reported on 77,465 subjects in the intervention group, 
finding that a high proportion of subjects (83.5%) accepted the initial 
invitation to have a screening FS. Diagnostic follow-up for those with index 
lesions varied according to local guidelines, but overall CRC and adenoma 
detection rates met expectations (53). These are significant results and offer 
positive insight into the effectiveness of offering endoscopy as a screening 
test to people in the UK.  
 
FS may be an attractive alternative to repeat faecal testing since a single 
examination may be offered and other recommendations suggest an 
interval of five years between FS examinations. However, in a study of 
patients with a negative FS who had a follow up within three years 0.8% had 
an advanced adenoma or cancer detected (54). The protective effect of FS 
is dependent on the quality of a number of factors including training, bowel 
preparation and depth of insertion of the sigmoidoscope. The guidelines on 
which pathological findings trigger a colonoscopy will also affect the overall 
outcome: many expert panels recommend any adenoma as the trigger for 
colonoscopy. 
 
Considering the advantages and drawbacks, there is great interest in 
screening with FS since it has the potential to significantly reduce the 
incidence of CRC, as well as mortality, in those who undertake the 
procedure through removal of polyps from the distal colon. Although uptake 
is not as high as for gFOBT it can be a quick procedure where bowel 
preparation is performed at home on the day of examination. Pain and 
complications are consistently reported as lower than for colonoscopy. 
However, this technique does not visualise the entire large bowel and the 
protective effect is dependent on the quality of the initial examination.  
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1.8 Is Colonoscopy the Reference Standard? 
 
Colonoscopy involves manipulation of a flexible endoscope around the 
transverse and ascending colon to reach the caecum – reaching this point 
being indicative of a ‘complete examination’. The bowel is prepared by 
modifying the diet up to two days before the procedure and administration 
of oral bowel cleansing preparation the day before. Patients are often 
offered sedation, the colonoscopy usually takes 30 – 60 minutes and must 
be performed by an experienced endoscopist. The bowel is inflated during 
the procedure and it may take 1 – 2 days for the effects of the insufflation to 
disappear. Colonoscopy offers a one stage screening solution, but, the 
procedure is not generally as acceptable to invitees as screening with 
gFOBT (55). 
 
Colonoscopy is widely accepted as the reference standard in screening for 
CRC and is the preferred method for screening in the United States. One of 
the benefits to offering an endoscopic procedure as a screening test is the 
screening interval recommended for colonoscopy is usually 10 years and 
for FS 5-10 years, whereas for many non-invasive tests annual or biennial 
testing is advised (56).  
 
In this setting participants who undergo colonoscopy can also benefit from 
prophylactic removal of polyps from the whole bowel. Removal of adenomas 
should reduce incidence since, according to the adenoma–carcinoma 
model, the presence of CRC adenoma is a predictor of risk. Analysis of data 
from the National Polyp Study and Surveillance, Epidemiology, and End 
Results (SEER) Program of the National Cancer Institute in the US reported 
a lower than expected incidence of colorectal cancer in those individuals 
who had had adenomas removed. In this programme, adenoma removal 
was performed at a level that was beneficial (57). 
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However, there are some issues. A study conducted in Southern Germany, 
from 2003 – 2007, comparing 78 IC and 433 CRC detected at screening, 
found that, although the risk of missing CRC at colonoscopy was low, a 
substantial number of cancers had been missed at colonoscopy 
Characteristics associated with IC were positive FOBT results and 
incomplete colonoscopy, particularly in women. This outcome suggests that 
IC could be prevented by improved quality of the colonoscopies (58). 
 
In the polypectomy study outlined above (57) three reference groups were 
followed up. These were from Mayo Clinic in Rochester, Minnesota, St. 
Mark's Hospital in London and the SEER database. The authors of the study 
acknowledge that generalisability could have been improved by performing 
a RCT and having a control group where the adenomas were left in situ and 
compared to those groups were polyps were removed, but recognition of 
the adenoma carcinoma sequence renders this approach unethical. 
 
There is a slightly higher risk of perforating the bowel during colonoscopy 
compared with FS, patients may require sedation, air insufflation is required 
and the acceptability of this procedure in screening populations is low (56). 
Colonoscopy is an expensive procedure to perform and developing capacity 
for screening is costly. 
 
As discussed earlier, the choice of screening modality effects outcomes. 
Table 4 shows indicative weightings for accuracy, acceptability, clinical risk 
and cost for gFOBT, FIT, FS and colonoscopy. 
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Table 4 Comparison of methods used to detect colorectal cancer (CRC)  
Investigation Accuracy Acceptability Risk Cost 
gFOBT + ++ - + 
FIT ++ +++ - ++ 
FS ++ ++ + +++ 
Colonoscopy +++ + +++ +++ 
(+ LOW, ++ MODERATE, +++HIGH) 
Adapted from Colorectal Cancer in Clinical Practice (15) 
 
1.9 Can Imaging Techniques be used in CRC Detection? 
 
DCBE has little evidence to support its use as a screening test: however, 
computed tomography (CT), sometimes called CT colonography, may have 
the potential to be used in CRC screening. This is a low risk procedure, 
although it uses ionising radiation, which offers the opportunity to visualise 
clinically significant lesions. New methods to do this without bowel 
preparation and using three dimensional technologies are being developed 
and, if proven to work effectively, such techniques could have a huge effect 
on the utility of CT, in this context. Sensitivity for lesions above 10 mm is > 
90%: however, it is poor at detecting lesions smaller than this (59). 
 
Bowel preparation for CT may be cathartic, or non-cathartic using radio-
labelled faecal tagging. It has been demonstrated that invitation for 
screening with non-cathartic CT colonography has a significantly increased 
uptake compared to colonoscopy: however, the colonoscopy identiﬁed 
signiﬁcantly more advanced neoplasia per 100 participants than CT 
colonography (60). Where cathartic bowel cleansing is used, this may offer 
the opportunity to equal the detection rates of colonoscopy for advanced 
neoplasia (61). 
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Although the procedure is low risk, relatively inexpensive and can identify 
polyps and other anatomical abnormalities, the main drawback to imaging 
techniques is that, if lesions or polyps are seen, the patient must then be 
referred for an endoscopic procedure or surgery for their removal. These 
techniques for bowel visualisation have been included in the 
recommendations of the US Preventive Services Task Force and the 
American Cancer Society as alternative screening tools, however they have 
not been widely adopted for use in population screening for CRC in other 
countries (29).  
 
1.10 Maximising Uptake 
 
The effectiveness of screening in detecting significant disease is a function 
of the sensitivity of the test and participation rates. There are issues 
regarding the perception of harm that may create barriers to participation in 
screening. In a survey of attitudes to screening modalities - colonoscopy, 
DCBE, FS and gFOBT - participants believed that colonoscopy was 
significantly more dangerous, embarrassing and inconvenient than gFOBT. 
It seems that, although colonoscopy might offer the best returns in CRC 
detection, it does not have the highest uptake of CRC screening 
investigations and so may not be the best strategy for population screening 
(55). 
 
However, a recent study in Italy offering FS to screening participants who 
did not respond to an invitation to screen with FIT reported an improvement 
in the overall uptake of screening. In this case, people did respond to the 
more invasive procedure. Offering a choice of invasive or non-invasive test 
as a first-line test might thus improve uptake in national screening 
programmes (62). 
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Methods used to improve uptake in programmes offering gFOBT screening 
through the postal service include sending a pre-notification letter to the 
participant advising that they are about to be invited to screening. This 
intervention consistently shows increases in uptake over and above the 
standard invitation to screen (63). Sending invitations with additional 
messages about risk and with advocacy messages from previous 
participants have been trialled in Australia and are also recommended to 
improve participation (64). 
 
There is evidence to suggest that participants who respond once will 
continue to respond to the invitation to screen. In the Danish RCT only 
participants who completed the first round of screening were invited again. 
Of the 67% who completed the first screening round 90% accepted further 
screenings. This would suggest that people who do accept screening are 
motivated to continue screening (39). Similarly, in the three pilot screening 
rounds performed in Scotland with gFOBT, initial uptake was 53%. Where 
those invited had not responded and were reinvited in the incident screening 
rounds, a further 15% and 12% responded and completed screening. It was 
also found that not responding to one round of screening did not infer that 
the person would decline all further invitations. The recommendation from 
this work was that reminders and invitations should be made to all those 
non responders identified, since this method can increase uptake (65) (66). 
 
1.11 Adverse Effects of Screening 
 
Although the primary aim of screening is to detect all CRC and significant 
adenomas, there are occasions where those who have participated in 
screening are diagnosed with CRC at a colonoscopy done outside the 
screening programme. In an annual/biennial gFOBT algorithm, IC is defined 
as those diagnosed after a negative gFOBT result, before they have the 
opportunity the next invitation to be screened. 
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The Nottingham study reported on IC in 1999 (67). CRC detected in the 
screened group and those not screened were investigated to determine 
whether there is a ‘certificate of health effect’ when a participant has 
participated in screening. It is argued that being given a negative screening 
test result may discourage a participant from seeking medical attention for 
symptoms of CRC between rounds of screening because they feel that they 
have already done a test and this leads them to believe that they will not 
have CRC. They found that rather than less favourable outcomes, the group 
who took part in screening and were given a negative result but 
consequently had an IC diagnosed had more stage A CRC and, 13 years 
after colonoscopy, had better survival than those who had not been offered 
screening. 
 
In the first publication of IC data from the three pilot rounds of screening in 
Scotland, IC were deﬁned as CRC diagnosed within two years of a negative 
gFOBT. IC rates were substantial: 31.2% in the first round, 47.7% in the 
second round and 58.9% in the third round. Although the percentages 
increased from round one to round three, this was due to a decrease in the 
numbers of screen-detected CRC rather than an increase in number of 
cases of IC. Examination of the clinical characteristics showed that the IC 
were associated with a better prognosis than CRC arising in a non-screened 
population and gFOBT appeared to preferentially detect CRC in men and 
the left side of the colon over CRC in women and in the right colon and 
rectum (33). 
 
Research in Germany, where gFOBT testing has been offered since 1977 
and colonoscopy has been offered through health insurance since 2002, 
indicates that more IC occur in women than men and that women are more 
likely to have an incomplete colonoscopy. It was also found that, in men, the 
finding of an IC was more likely to be associated with a positive gFOBT 
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result prior to colonoscopy. When the stage of CRC was reviewed, it was 
more likely to be more advanced than a CRC detected at screening 
colonoscopy. It was concluded, that the IC appeared to be more likely to be 
missed at colonoscopy than to be de novo after colonoscopy (58). 
 
The number of IC in people who have participated in screening are a cause 
for concern. It is also concerning that IC occur more often in women. Indeed, 
is it ethical to promote screening for CRC where almost half the CRC in a 
population are missed? This provides a good example of the tension 
between the principles of population screening and the health of the 
individual patient. Repeated screening with gFOBT can detect significant 
neoplasia and reductions in CRC mortality have been reported (5), but it is 
also true that some CRC that are not amenable to detection by gFOBT and 
may be better detected by other approaches. These should also be included 
in the repertoire of tests used to detect CRC. 
 
One way to decrease the number of IC would be to decrease the threshold 
for a positive result and refer more participants for colonoscopy. However, 
this presents the issue of over-diagnosis and increasing the exposure of 
healthy individuals to a risky procedure. In the Minnesota RCT, the positivity 
between the different variables of the study; rehydration and no rehydration 
of gFOBT cards were 9.8% and 2.4% respectively, however the PPVs for 
CRC were 2.2% and 5.6% (34).  
 
The issue of over-diagnosis has been documented in breast screening and 
outcome data have been reviewed in order to measure benefit and over 
diagnosis (68). It is possible that certain individuals with screen detected 
CRC would have died of other disease before their tumour became 
apparent. In the retrospective analysis of the Nottingham study 30 day 
mortality for those with screen detected CRC was investigated. Five patients 
27 
  
died four days postoperatively, one of whom had had an anastomotic leak. 
Of those dying after 30 days but within two years, only four had Dukes’ A 
disease, three of whom died of other malignancies. It would seem that, in 
this study, the scale of over diagnosis was small (67). 
 
1.12 Novel Approaches to CRC Detection 
 
Newer tests are emerging that may offer similar reductions in mortality and 
incidence to gFOBT. These tests involve analysis of DNA and newer tumour 
markers and may be undertaken on faeces, urine, blood or other tissue or 
fluid samples. 
 
Where a patient has been diagnosed with CRC, mutations present in the 
tumour may be excreted into other compartments. A small study looking at 
quantification of somatic mutations related to CRC in 25 patients 
demonstrated that purified DNA from faeces and plasma could detect 95% 
and 50% of the mutations detected in the tumour DNA respectively and that 
faeces was a superior matrix to extracted plasma in terms of detection of 
CRC at early stages. This superiority may be due to the higher frequency of 
mutant DNA than normal DNA in faeces: however, the extraction of relevant 
DNA is more difficult due to the background noise from bacterial DNA (69). 
 
The major benefit of finding a useful measurand in blood is that the sample 
can be taken immediately, in any clinical setting, and there may be more 
opportunity to take such samples during other visits to a healthcare provider. 
A comprehensive review of over 93 studies describing 70 different tumour 
markers detected in blood samples has been published (70). Aberrantly 
methylated genes are useful markers since they are cancer specific, occur 
early in cancer development, have an amplifiable signal and can be assayed 
with high accuracy. Case control studies have found the presence of 
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mSEPT9 to be highly correlated with colorectal cancer suggesting that it is 
a suitable candidate for developing a biomarker assay (71). Subsequently 
this assay was prospectively assessed in a cohort of asymptomatic 
individuals, > 50 years old and attending screening colonoscopy in 
Germany. The sensitivity for CRC was 48.2% and specificity was 91.5% 
(72).  
 
As mentioned earlier in this Chapter, a number of steps contribute to the 
genesis of CRC, other areas of investigation are mutations in the APC gene, 
the p53 tumour-suppressor gene, the K-ras oncogene and genes involved 
in DNA-mismatch repair. Imperiale et al conducted a large study using a 
faecal DNA panel which consisted of 21 mutations: 3 in the K-ras gene, 10 
in the APC gene, and 8 in the p53 gene, also the microsatellite instability 
marker BAT-26 and a marker of long DNA (73). This panel was able to 
detect 16 of 31 invasive CRC (TNM stages I, II, or III), giving a sensitivity of 
51.6 %; Hemoccult detected 4 of 31 CRC, giving a sensitivity of 12.9 %. The 
panel detected 22 lesions that were missed by Hemoccult, whereas 
Hemoccult detected three lesions missed by the panel. This difference in 
test results was significant (p <0.001). Among the 40 subjects who had 
adenomas with high-grade dysplasia, the faecal DNA panel detected 13 of 
the adenomas (32.5 %), whereas Hemoccult detected 6 (15.0 %). For the 
detection of other advanced adenomas (villous polyps and tubular 
adenomas 1 cm in diameter or larger) and for minor polyps, the sensitivities 
of both tests was consistently less than 20%. The sensitivity of the faecal 
DNA panel was four times that of Hemoccult for invasive CRC and more 
than twice as sensitive for adenomas. This increase in sensitivity was 
achieved without a loss of specificity among persons with no polyps on 
colonoscopy. 
 
This work has been developed further to suggest that combining the multi-
target faecal DNA test with FIT result would increase sensitivity while 
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keeping the numbers of patients referred for colonoscopy to a manageable 
level (74). In August 2014 the Food and Drug Administration approved the 
‘Cologuard’ test for non-invasive screening of adults of both sexes, over the 
age of 50 years with average risk of CRC. The test is available in all states 
in the US, Medicare and a growing number private healthcare providers 
include it in their billing: however, there exists no evidence of its 
performance in an organised screening programme or evidence of what 
intervals between screening tests should be used. 
 
A major challenge in the development of DNA tests for the detection of CRC 
is the selection of relevant markers. However, there is an opportunity to 
develop panels of markers related to all aerodigestive CRC, including those 
of the lungs, oesophagus, stomach, pancreas and bile duct. Clinical 
investigation could be directed to certain anatomical sites based on positive 
panel outcomes (75). 
 
Tumours leak mutated DNA into the lumen of the bowel. They also leak 
other proteins that could be used as tumour markers. Faecal calprotectin is 
released from neutrophils in the colon when there is inflammation present. 
A recent study evaluated the usefulness of calprotectin and FIT in patients 
presenting in primary care. Where a patient has a positive test result for 
calprotectin or FIT, or both, and all sizes of adenomas were considered, the 
test did not detect Organic Bowel Disease (OBD) very well. However, when 
adenomas >1 cm were considered, the tests were very good at ruling out 
OBD. These data concern the application of calprotectin and FIT in primary 
and secondary care, but it could be hypothesised that any utility in these 
settings could extend to screening programmes (23). 
 
Lactoferrin is a member of the transferrin family of iron binding proteins. It 
is active in fighting bacterial infections. Like calprotectin, elevated 
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concentrations can be useful in discerning whether bowel disease is organic 
or non-organic. Enzymes also have the potential to detect CRC. Pyruvate 
kinase (PK) has a regulatory role in glycolytic metabolism and the pyruvate 
kinase isoenzyme type M2 (M2-PK) is preferentially expressed by tumours. 
This makes it an ideal candidate for measuring tumour formation. A review 
of 10 studies assessing M2-PK showed that this could achieve an overall 
sensitivity of between 68.8% and 91% and an overall speciﬁcity of 71.9% 
and 100% (76). 
 
Investigation of new approaches to screening for CRC with non-invasive 
tests is promising in terms of sensitivity and specificity for CRC: however, 
these recent developments do not have the same programmatic and 
longitudinal data that supports the gFOBT as a screening modality. 
 
1.13 Conclusions 
 
CRC is an important cause of morbidity and mortality. There is a significant 
evidence base for the primary role of screening for CRC as it provides an 
opportunity to detect disease at an earlier stage. Individuals have a poorer 
prognosis if disease is detected at a later stage and where there have been 
metastases to other organs. Use of gFOBT as a screening modality has a 
sound evidence base from RCT performed in the 1990s in which significant 
reductions in disease specific mortality were demonstrated.  
 
The RCT outlined in this Chapter all used gFOBT as the screening test. 
However, there were differences in study protocols such as screening 
interval, (annual or biennial), sensitivity (testing dry or rehydrated gFOBT) 
and whether dietary restriction preceded sample collection. In the 
Minnesota study, the group offered annual screening with a rehydrated test 
card and undertook dietary restriction. This study had the greatest positivity 
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and referrals for colonoscopy and the most involved interactions for 
participants. However, this study reported a 33% decline in mortality at 13 
years (33).  
 
The initial mortality reductions seen in the Nottingham gFOBT study of 1996 
have been followed up for 20 years and found to have been sustained (35). 
With each subsequent round of screening, the number of CRC in the 
screened population is reduced and a cumulative protective effect is seen 
(46). As mentioned earlier, there is also the potential to reduce incidence of 
CRC when repeated gFOBT is used as a screening modality as polyps are 
removed from the screened population. A continuing reduction in incidence 
of CRC has been shown at the 18 and 30 year follow-up of participants in 
the Minnesota trial (6) (77). 
 
Screening with colonoscopy as the first-line test has high sensitivity and 
specificity for CRC. However, endoscopic examination of patients is 
expensive, has some risks and not all individuals wish to undertake this 
procedure. This means that improvements to other non-invasive tests 
should continue to be pursued alongside those in endoscopy.  
 
Individuals who present to primary care often have later stage CRC than 
those detected by screening: gFOBT are no longer recommended for use 
in primary care, and current guidelines recommend urgent referral for bowel 
visualisation for abdominal symptoms, rectal bleeding and IDA of unknown 
cause (19). However, the burden on endoscopy services is increasing as 
more people in primary care are referred for non-specific abdominal 
symptoms, as well as those referred for colonoscopy through participating 
in a screening programme and also surveillance. This is a significant burden 
on endoscopy departments. The development of a test that is more 
sensitive for CRC in all these groups is therefore a priority. 
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There is no one test or algorithm to detect CRC that can be recommended 
for all countries and clinical settings. Each health provider must consider the 
benefits and drawbacks of available detection modalities and devise a 
strategy that serves the needs of the population most appropriately while 
considering the needs of the individual.  
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CHAPTER 2: Why Change from gFOBT to 
Faecal Immunochemical Tests (FIT) for Hb 
Detection? 
 
2.1 Introduction 
 
As discussed in the previous Chapter, there is sound evidence that using 
gFOBT in screening programmes can identify those who would benefit from 
bowel visualisation to detect CRC. The reference gFOBT method for these 
studies was the Hemoccult test. However, since the introduction of the 
guaiac method for detection of Hb in faeces, other methods of detection 
have been developed that utilise the antibody-antigen reaction. These 
determine the presence of human globin, a component of Hb, in faeces and 
are referred to as immunochemical faecal occult blood tests (iFOBT) or 
more correctly as Faecal Immunochemical Tests (FIT) for Hb. 
 
A number of approaches have been taken to delivery of FIT methods. One 
of the earliest used on a large scale was the reversed passive 
haemagglutinin antibody reaction (RPHA). This method relies on the 
reaction between chicken erythrocytes coated with rabbit anti-Hb A and Hb 
in the sample (78). The Magstream® (Fujirebio, Tokyo, Japan) represents 
another approach using magnetic particle agglutination to measure Hb (79). 
However, in more common use now are lateral flow immunoassay 
cassettes. This particular technology is widely used in pregnancy test kits 
and detection of drugs of abuse.  
 
In order to understand why it would be beneficial to move from the gFOBT 
to the FIT modality an understanding of the principles underlying the 
methods is necessary. Focussing on the three methods to be used within 
the work described in this thesis, namely; gFOBT, lateral flow immunoassay 
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and latex immunoturbidimetry assay (80) the advantages and drawbacks 
that each method brings to the detection of Hb in faeces will be explored.  
2.2 Principle of gFOBT and FIT 
 
FOBT have been defined as ‘Tests for faecal occult blood, detect blood in 
the stool that is not visible on gross inspection, usually less than 50 mg of 
Hb per gram of stool’ (81). This definition is obsolete with the development 
of newer, more analytically sensitive tests as we shall see in this chapter. 
The gFOBT method has been the first line method of choice for the current 
Scottish Bowel Screening service. gFOBT rely on a pseudo-peroxidase  
mediated chemical reaction as shown in Figure 2. Guaiac resin extracted 
from the Guaiacum officinale tree is used to manufacture alpha guaiaconic 
acid. In the presence of haem and oxygen, the alpha guaiaconic acid is 
converted to a quinone compound - it is the pseudo-peroxidase activity of 
haem that enables the reaction. The addition of hydrogen peroxide to haem 
and alpha guaiaconic acid increases oxygen availability, speeding up the 
reaction and, due to the concentration of guaiac, produces a visible blue 
colour. The appearance of blue colour is considered a positive test result. 
The blue colour has a very short half-life and results must be read within 30 
– 60 seconds following the addition of hydrogen peroxide (82).  
 
Figure 2 Guaiac reaction 
 
Image from Ostrow JD, Clinical Methods (81) 
 
Commercially produced gFOBT cards consist of a cardboard housing 
around filter paper that is impregnated with sufficient alpha guaiaconic acid 
to give the manufacturer set analytical detection limit. Also included are 
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negative and positive control materials - the positive must turn blue when 
the hydrogen peroxide is added to validate the test result (82). An example 
of the test card and a positive test result can be seen in Figure 3.  
 
Figure 2 Single slide guaiac faecal occult blood test (gFOBT) and positive test result 
 
 
Image courtesy of the Scottish Bowel Screening Laboratory (2014) 
 
There are many commercial suppliers of gFOBT cards and therefore many 
opportunities when procuring the gFOBT product for a national screening 
programme. The analytical detection limit of the hema-screen gFOBT 
(Immunostics, Ocean, New Jersey, USA) used in the Scottish Bowel 
Screening Programme (SBoSP) is 600 µg Hb/g faeces. This test format was 
developed over time to align with early work that advocated sampling three 
consecutive faecal samples to increase sensitivity (83). The requirement for 
two samples of faeces from each of three faeces in screening is the same 
regimen used in the algorithms in the RCT described in Chapter 1 (43).  
 
A review of the presence of FIT in the worldwide market prepared by the 
Expert Working Group (EWG) on FIT for Screening of the Colorectal Cancer 
Screening Committee (CRCSC) of the World Endoscopy Organisation 
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(WEO) described 39 suppliers of qualitative FIT and 13 quantitative FIT 
platforms (84). The most common qualitative method used was lateral flow 
immunoassay. This method consists of an immunochromatographic assay 
strip housed inside small plastic cassette, as seen in Figure 4 (85). 
 
Figure 4 Lateral flow immunoassay 
 
Image from Cytodiagnostics product information (85). 
 
Faecal samples are collected in a DEVEL-A-TAB card (Immunostics, 
Ocean, New Jersey, USA). This is used to deliver a controlled amount of 
faeces into a buffer tube. The faecal suspension is delivered into the test 
cassette directly from the buffer tube. The test strip within the cassette has 
three different zones. When the liquid phase, containing the faecal sample 
(potentially containing human globin from Hb), is added to the well at the left 
hand side of the strip, it is pulled through the zones by capillary action. 
Primary antibodies are located in the first zone. These are mouse 
monoclonal antibodies directed to human globin and have gold 
nanoparticles are conjugated to them. Where there is human globin present 
in the sample an antibody antigen complex is formed here. 
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The next zone on the test strip has the capture antibody which is usually a 
polyclonal goat or sheep anti-human globin antibody. In a positive test the 
antibody antigen complex binds here and the gold conjugate is concentrated 
in this zone and a pink line appears. The final zone is the control zone which 
contains anti mouse immunoglobulin. This binds any free primary antibody 
gold conjugate. A pink line must appear in this zone to indicate the test strip 
is working correctly. Results are read five minutes after the addition of the 
faecal suspension (85). An example of positive and negative test result are 
shown in Figure 5. 
 
Figure 5 Positive and negative qualitative faecal immunochemical test (FIT) results 
Image courtesy of the Scottish Bowel Screening Laboratory (2014) 
 
The DEVEL-A-TAB collection device and hema-screen SPECIFIC cassette 
((Fig 4.) Immunostics, Ocean, New Jersey, USA) are currently used as the 
second line test in the SBoSP. This system is quoted by the manufacturer 
to have a detection limit of 50 ng Hb/ml buffer (10 µg Hb/g faeces).  
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The OC Diana works on the basis of latex agglutination immuno-
turbidimetry. The reagent is a latex polystyrene particle using anti HbA IgG 
polyclonal rabbit antibodies. (Figure 6).  
Figure 6 Latex particles have antibodies directed toward globin moiety of human Hb 
 
 
The instrument measures the latex agglutination in the presence of human 
Hb in the sample. This is shown in Figure 7. 
Figure 7 Latex particles come into contact with globin in the faecal sample causing agglutination 
antibody 
latex 
human globin 
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When human Hb is present, particle agglutination occurs thus causing 
turbidity. The variation in this turbidity is measured photometrically at 660nm 
and considered as absorbed energy, is directly proportional to the Hb 
concentration. The immunoturbidimetric FIT method has been developed 
by manufacturers in Japan, where automated quantitative analysers have 
been used in their population based screening programmes for many years 
(86).  
 
2.3 Constraints of gFOBT 
 
The gFOBT tests have a proven track record in CRC screening programmes 
and have been demonstrated to be affordable. However, the methodology 
is problematic in that it has characteristics that will impact on the screening 
efficiency. Table 5 highlights potential for both false positive and false 
negative test results using this technology.   
 
Table 5 Factors affecting the results of gFOBT 
False-positive results. 
1.  Non-human haemoglobins: red meat (myoglobin). 
2.  Intake of foods that contain peroxidase activity (uncooked fruits and 
vegetables). 
3.  Drugs: Topical iodine, aspirin, NSAIDs. 
4.  Rehydration of the test kit. 
 
False-negative results. 
1.  Vitamin C (ascorbic acid) intake. 
2.  Storage of cards: sunlight and heat give false positive test results. 
3. Improper sampling or development. 
4.  Lesion not bleeding at time of faecal collection. 
5. Haem degradation by colonic bacteria. 
Adapted from Beg (87). 
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A high number of false positive test results would lead to unnecessary 
colonoscopies being carried out and healthy individuals being exposed to 
unnecessary risk. A test failure, or false negative means that a case will be 
missed.  The main considerations are discussed below: 
 
Dietary components may cause false positive results 
 
False positive test results may be found with excessive amounts of non-
human haem found in animal proteins if they are consumed in large 
amounts (88). These effects may be related to regional diet, in particular 
high levels of black pudding consumption may cause false positive test 
results (89). Some raw vegetables, such as dark green leafy vegetables, 
horseradish and turnips, have high levels of peroxidase activity and 
consumption of a diet rich these foodstuffs may cause false positive test 
results.  
 
A study carried out in Australia examined this effect on gFOBT and 
performing the development of cards at 24, 48 and 72 hours. They found 
that the plant peroxidase interference decreased as the sample dried but 
did not decrease in rehydrated tests. They concluded that, given sufficient 
drying time after the application of the faecal sample, (48 hours) there is no 
requirement for dietary restriction in screening programmes using un-
rehydrated gFOBT, but that this would not work where the test is rehydrated 
before analysis (90). 
 
When gFOBT were introduced, it was recommended that dietary restrictions 
were observed prior to the sampling of faeces. These included measures 
such as advising that, up to three days before the collection of samples the 
participant must not consume red meat because of the presence of haem 
compounds and that  no dark green vegetables, cucumber, cauliflower or 
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horseradish were to be consumed to avoid artefactually increased 
peroxidase activity.  
 
However, asking a participant undertaking screening to follow a strict dietary 
regime may adversely affect compliance (91). Sinatra et al. demonstrated 
that drying of the sample card prior to development reduces this interference 
(90) and the way many screening programmes are set up, with invitation 
sent through the mail and samples returned to a large central laboratory for 
analysis, again via the mail system this recommendation almost fulfils itself 
by the nature of the infrastructure of the programme. 
 
A meta-analysis and systematic review of dietary restrictions have been 
conducted, Pignone et al. (92) analysed four RCTs and Konrad et al. (93) 
reviewed 10 case series (where the effects of challenge or restriction diets 
were reported), five non randomised cohort studies and five RCTs. The 
meta-analysis found that moderate dietary restriction would not adversely 
impact uptake. Both studies suggest it is reasonable to disregard previous 
advice to perform dietary restriction and that outcomes in large nationally 
organised screening programmes would not be affected. Each programme 
provider must look at their own situation when deciding whether to 
implement dietary restriction (94). 
 
Medication can elevate positivity 
 
Anticoagulants, such as warfarin and heparin, can cause increased 
bleeding in the gut and these may increase the presence of Hb in faeces. 
NSAIDs, such as aspirin and cyclo-oxygenase-2 enzyme (COX-2) 
inhibitors, may also, through irritation or changes to the intestinal 
microenvironment, increase the amount of Hb in the gut which may cause 
false positive test results. In the Scottish arm of the UK CRC screening pilot 
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participants taking regular anticoagulant therapy at the time of testing had 
an increased likelihood of a false positive FOBT result of 10%. This 
suggests that this group have an increased exposure to colonoscopy, a 
procedure with associated risks, with a negative outcome and no significant 
clinical findings. It was recommended by this group that, where possible 
medication was stopped three days before starting the gFOBT (95).  
 
However, evidence of false positives due to taking medication was varied in 
a later systematic review conducted by Konrad et al., who observed that the 
standard of these studies did not allow for the evaluation of sensitivity and 
specificity of gFOBT for those taking anticoagulants and NSAIDs (96). A US 
study of 193 veterans reported no association between regular aspirin or 
NSAIDs use and false positive gFOBT results (97) Therefore, it appears 
that, there is no good evidence that long-term use of aspirin and NSAIDs 
would be linked to false positive gFOBT results. The pragmatic approach 
would be to not ask participants to stop taking medication which could 
potentially lessen uptake (uptake being one of the key factors in the 
effectiveness of a screening programme (94)) and this approach has been 
adopted in the SBoSP.  
 
An early study in England reported that prescription of more than 5 years of 
aspirin or NSAIDs was strongly associated with reduced incidence of 
advanced adenomas (98). This has been replicated in a 20 year follow up 
of five large trials of aspirin use. Rothwell et al. reported, in a meta-analysis 
of these studies, a reduction in the incidence and mortality of CRC where 
doses of greater than 75 mg aspirin per day were being taken and it is likely 
that the causes of the reductions is the protective effect of long-term aspirin 
use rather than falsely elevated gFOBT results (99).  
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Rehydration affects outcome 
 
If samples are rehydrated before testing, a higher number of positive test 
results without the commensurate increase in disease detection decreases 
specificity for CRC (28). Although, in the Minnesota RCT, rehydration of the 
gFOBT was associated with a reduction in long term CRC mortality (34), to 
avoid large numbers of referrals for colonoscopy, it has been recommended 
that a sample should be dried at least 48 hours on the gFOBT card before 
the developer is applied – this also minimises interference from plant 
peroxidases (90).  
 
A consideration not highlighted by Beg (87) (Table 5) is improper storage of 
test cards prior to development. Improper storage conditions including 
exposure to excessive heat and light which renders alpha guaiaconic acid 
unstable. This increases the likelihood of the number of positive test results 
seen is increased with no increase in disease detection (82).  
 
A false negative test result is a missed opportunity to visualise the bowel 
and detect underlying pathology. The most common factors leading to false 
negatives are: 
 
High levels of vitamin C reduce positivity 
 
Vitamin C (ascorbic acid) reduces the pseudo-peroxidase activity of haem 
and excessive amounts in the diet can cause false negative test results 
since the antioxidant action inhibits the production of the blue colour that 
indicates a positive result (87). With a number of studies reporting the 
inhibitory effect of doses of vitamin C in the range 1000 – 1500 mg per day, 
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it may be recommended that those wishing to participate in screening using 
a gFBOT refrain from taking vitamin C before collecting samples (93).  
 
Improper sampling or development of gFOBT 
 
In many screening programmes, the participant is responsible for taking the 
samples and returning the sample to the testing laboratory (56). The 
participant is required to smear two samples from three different faeces on 
the test card and date all of these correctly. Where the test card is not dated 
a decision cannot be made about the age of the samples and they must be 
as out-with the 21 day period of sample integrity. Analysis of gFOBT 
requires considerable training and expertise. It is subject to variations in the 
interpretation of subtle colour changes. Difficulty in interpretation of colour 
change, inexperience at point of care, incorrect sampling technique and 
insufficient time left for the sample to dry before development, can all lead 
to incorrect result interpretation (100). 
 
Lesion does not bleed at time of faecal collection 
 
The usual gFOBT test format requires the participant to apply faeces from 
one bowel motion to two sample windows on the card and do this for three 
consecutive bowel motions. This multiple sampling increases the probability 
that lesions that bleed intermittently or at low levels are detected. However, 
no screening method that detects Hb in the faeces as a marker of neoplasia 
will detect CRC that do not bleed. This group of CRC are not amenable to 
screening with faecal tests for Hb of any kind. There is a potential role for 
methods other than FOBT in screening for CRC as discussed in Chapter 1 
(101). 
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Hb in faeces may be below the analytical detection limit of the test method 
 
The gFOBT method does not give a positive result in all cases where there 
is Hb in faeces. The performance characteristics of a gFOBT are 
determined by the manufacturer. In the case of the hema-screen gFOBT a 
concentration of 600 µg Hb/g faeces is the analytical detection limit reported 
by the manufacturer. This means that some people who perform the test will 
receive a negative test result even when they do have Hb in their faeces 
that is related to CRC.  
 
When advising participants about the sample collection procedure, it must 
be mentioned that the faecal samples are small enough (about the size of a 
pea) to dry on the gFOBT card prior to analysis; this acts as a bacteriostatic 
measure in the faeces. If this does not happen, false negative test results 
may be reported where the amount of Hb in the faeces has been near the 
analytical detection limit of the method and the action of faecal bacteria 
degrades haem to a concentration below the analytical detection limit of the 
gFOBT (87). That false negative test results occur with the gFOBT is 
evidenced by the high number of IC: 30 - 60 % of all CRC diagnosed in the 
screened population, in the Scottish Pilot rounds, were present in those who 
had had a negative gFOBT. These figures increased as more incidence 
rounds were completed (33).  
 
Ultimately, the effectiveness a screening programme using gFOBT as the 
first-line test is in part determined by the number of participants who take 
part in screening and the number referred for colonoscopy; this in turn is 
dependent on the performance characteristics of gFOBT and minimisation 
of sources variation in the pre-analytical, analytical and post analytical 
phases. 
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2.4 Benefits and Disadvantages of Qualitative FIT  
 
Qualitative FIT utilise the principle of the antibody-antigen reaction to 
directly detect human globin in faeces, thereby avoiding dietary sources of 
interference. This leads to a removal of one of the sources of false positives 
test results that compromised the effectiveness of the gFOBT. In addition 
FIT is more specific for lower GI bleeding than gFOBT as globin is more 
amenable to digestion by bacterial enzymes than haem. Globin is quickly 
degraded by bacteria in the intestine and so FIT are more sensitive for 
bleeding from the large bowel, rather than further up the gut. The location 
of bleeding may impact upon the concentration of Hb as bacteria degrade 
the intact Hb and a longer transit time potentially increases Hb degradation. 
This issue also appears to be sex related, with women often having a lower 
f-Hb than their male counterparts (14). Without a bacteriostatic preservative 
in the FIT sample collection device, microflora from the faeces may continue 
to degrade the globin, in some cases so much so that globin is not 
detectable (82). This issue is discussed further in Chapter 3. 
 
Qualitative FIT are easy to use and the test can be performed by healthcare 
practitioners in the context of point of care testing (POCT). This type of 
screening model could provide fast turnaround of results and potentially 
avoid the additional costs of centrally organised screening. Qualitative FIT 
have overall improved performance characteristics than gFOBT, including 
better detection of adenomas, but like gFOBT  offer only a positive or 
negative outcome. The analytical detection limits of the most commonly 
available qualitative FIT are more sensitive for Hb than gFOBT. This would 
result in more referrals for colonoscopy but only a slight increase in the 
number of CRC detected, thus the sensitivity is increased but with a loss of 
specificity. 
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Qualitative FIT are produced by many different manufacturers who, due to 
a lack of consensus, set different analytical detection limits. A recent study 
compared six qualitative FIT performed on patients who all had undergone 
colonoscopy (102). Here, the FIT performed better than a single gFOBT in 
all categories assessed: location, number of adenomas and size. However, 
a great deal of variation was found in the diagnostic performance of the 
different qualitative FIT and this suggests caution must be used when 
selecting a qualitative FIT method since different analytical detection limits 
impact on clinical outcomes when used in a screening context. 
 
Further evaluation of the six different qualitative FIT methods gave positivity 
ranging from 6.4 – 46.8%, sensitivity 29.8 – 73.4% and specificity 58.8 – 
96.7% (103). It can be seen from these results that different qualitative FIT 
methods do not give the same positivity, sensitivity or specificity when 
assessed against each other. Qualitative FIT give fewer false positives than 
gFOBT but they also have the potential to give different performance 
characteristics within the same test modality when applied to a screening 
setting and these are not within the control of the programme organisers.  
 
The issue of apparent different performance in different manufacturers’ 
products can be addressed by adopting standardised units relating to the 
mass of Hb in the mass of faeces. This requires a conversion factor from 
the concentration of Hb in the volume of buffer (ng Hb/mL buffer), for each 
manufacturer to micrograms of Hb per gram of faeces (µg Hb/g faeces) 
(104). Adoption of these units has been recommended by the Expert 
Working Group on FIT for Screening of the Colorectal Cancer Screening 
Committee of the World Endoscopy Organization (105) and would give 
programme organisers a better indication of performance across analytical 
methods (106). 
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2.5 Positivity when using gFOBT and Qualitative FIT in the 
Scottish Bowel Screening Programme (SBoSP) 
 
Within the context of the UK, Scotland has the highest crude rate (number 
of new cases over a year per 100,000 of the population at risk) of CRC 
incidence - exceeding the four nations’ average, which is shown in Figure 8 
(2).  
Figure 8 Incidence of CRC in UK 
 
Cancer Research UK, Bowel cancer incidence statistics (2) 
 
The Scottish Colorectal Cancer Screening pilot of screening was based on 
the Nottingham RCT of the 1990s. The pilot rounds of CRC screening 
invited men and women in three NHS Boards in Scotland from the age of 
60 – 69 years to test using a gFOBT only algorithm (96). The results of the 
RCT (25) were mirrored in Scotland (46) and England (107). In addition, in 
2013, a reduction in disease specific mortality of 10% (27% when corrected 
for participation) was reported from Scottish data using a matched cohort 
study comparing screened and unscreened areas during the pilot rounds of 
screening (5). The gFOBT used in Scotland is seen in Figure 9. 
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As a result of the pilot studies, programmes of CRC screening have been 
rolled out across the UK. The SBoSP currently invites all men and women 
between the age of 50 and 74 years (with the option to opt-in over the age 
of 75 years) to participate in screening using a two-tier reflex algorithm (66). 
Each eligible person is offered a gFOBT at invitation.  
Figure 9 Scottish Bowel Screening Programme (SBoSP) gFOBT 
 
Image courtesy of the Scottish Bowel Screening Laboratory (2014) 
 
Any participant testing positive in 5 or 6 windows is immediately referred for 
colonoscopy in their local NHS Board (0.4%) and their GP notified. Those 
testing positive in 1 – 4 windows, i.e. any weak positive results (8.0%), are 
offered a qualitative FIT to complete. In this group approximately 20% have 
a positive test outcome. These participants are also referred for 
colonoscopy. The qualitative FIT used in Scotland is seen in Figure 10.  
 
This algorithm has been in place since June 2007. Over that timeframe, the 
positivity and hence the referral rate, has been approximately 2.4% (set 
against a projected positivity of 2.1%). Uptake within the SBoSP has 
consistently been 53 – 54%. Participants are eligible for invitation once 
every two years irrespective of previous outcomes. Participants are 
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excluded when their GP confirms they have no colon or if they wish to opt 
out of screening. 
 
Figure 10 SBoSP qualitative FIT 
 
Image courtesy of the Scottish Bowel Screening Laboratory (2014) 
 
Clinical outcomes are captured nationally in the Key Performance Indicators 
(KPI) published by Information Services Division Scotland (ISD). The most 
recent publication (108) shows that more women than men participate in the 
SBoSP and that uptake decreases with increasing deprivation. The overall 
referral for colonoscopy is 2.4% and, of those referred, the crude CRC 
detection rate is 0.20% for men and 0.10% for women. The adenoma 
detection rate is 1.08% and 0.42% for men and women respectively. The 
overall positive predictive value (PPV) for polyp CRC or invasive CRC in 
those who have had a positive screening result and proceeded to have a 
colonoscopy is 6.4%. 
 
2.6 Defining a Quantitative FIT Algorithm 
 
The Expert Working Group (EWG) on FIT for Screening, on behalf of the 
Colorectal Cancer Screening Committee (CRCSC) of the World Endoscopy 
Organisation (WEO), determined that there were 13 automated quantitative 
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FIT analytical platforms that could provide an estimate of quantitative f-Hb 
(84). It is of note that in this group there was one manufacturer that supplied 
four different analytical platforms to suit a range of healthcare settings, from 
point-of-care to large centrally organised laboratories. 
 
The majority of automated quantitative FIT available utilise a small 
specimen collection device which collects faeces in a serrated or spooned 
probe attached to the cap of the device. These collect between 2 and 10 mg 
of faeces into the body of the device which contains between 1 and 2 ml of 
buffer and matched bench-top analyser to provide the testing system. 
Sample collection devices and analysers are not generally interchangeable. 
Such systems are currently being trialled or are in use in many European 
countries. Despite it appearing that FIT could be used as a direct 
replacement of the gFOBT as a test for FOB in faeces, there are many 
variables that need to be considered before the introduction of FIT in a 
screening programme. These include, but are not limited to – number of 
samples used, screening interval and f-Hb cut-off: each is examined in 
further detail below. 
A FIT approach requiring a single sample might well be associated with a 
higher uptake than the two-tier approach currently used in Scotland which 
requires three samples for the gFOBT and two for the qualitative FIT (109). 
Concerns regarding the reduction of the number of samples used in 
screening are that, of the CRC that bleed, some may bleed intermittently or 
the blood may not be distributed evenly across the faeces passed. This 
issue has been addressed in a number of studies which are described 
below.  
 
In The Netherlands, a study of 1,096 participants who collected two faeces 
samples and had colonoscopy based on three possible outcomes 
(positive/negative, negative/positive) (positive/positive) (mean of both FIT) 
at increasing f-Hb cut-off. These concentrations were compared to disease 
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severity. This study strongly suggested that double FIT sampling does not 
provide a superior combination of sensitivity and specificity compared to 
single FIT sampling. On the other hand, it indicated that an increase in 
sensitivity could be achieved by lowering the f-Hb cut-off for reporting of a 
positive test result rather than increasing the number of samples required 
(110). 
 
In another study, 1,682 patients with either normal or slightly elevated risk 
of CRC, attending one of three clinics for colonoscopy in Israel, provided 
further information regarding cut-off and number of samples to use. Each 
participant completed samples from three different faeces and returned 
them to a central laboratory for analysis. It was shown that, using the lowest 
f-Hb cut-off, that using ‘any sample as positive’ as the criteria gave 100% 
sensitivity for CRC. The sensitivity with one FIT at the same f-Hb cut-off was 
75%. Further analysis showed that the gain in sensitivity to CRC and 
advanced adenomas comes at the cost of specificity; the low f-Hb cut-off 
meant that the numbers sent for colonoscopy increased (111).  
 
Another important study calculated sensitivity and specificity of the OC-
Sensor Diana analyser (Eiken Chemical Co., Tokyo, Japan) in a mixed 
cohort (screening, surveillance and symptomatic) at six increasing cut-off 
from 50 - 200 ng Hb/ml buffer (112). At the lowest cut-off (50 ng Hb/ml) the 
test detected 84.2% of early CRC and at the highest cut-off (200 ng Hb/ml) 
78.9%, but there was a larger decrease in detection of all screen relevant 
neoplasia, from 47.1% to 37.2%. The number of positive test results 
dropped from 16.5% at 50 ng Hb/ml buffer to 10.2% at 200 ng Hb/ml buffer. 
The authors propose that cut-off can be adapted to suit resources, 
suggesting that, in the prevalent round, a high cut-off could be used as most 
prevalent CRC will be detected and that as more incident and less advanced 
CRC form in the population, the cut-off can be reduced making the test more 
sensitive for early disease than using the cut-off of the prevalent round. 
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There has been concern that Hb is not stable enough in native faeces to be 
used as part of a screening programme in which sampling devices are 
posted to a central laboratory for processing (113). Drying faeces, as 
described in the gFOBT method, reduces this effect and card based FIT 
sample collection systems are available (90). Many FIT technologies use a 
liquid-based sample collection system and so the buffer must contain 
preservatives and stabilisers that will not interfere with the test.  
 
Recent studies have investigated the stability of Hb in buffer over time and 
at different temperatures. Dutch studies describe the average return time 
for one FIT in their screening trials as three days. They tested 71 positive 
FIT every three to four days for a further three weeks and plotted the Hb 
concentration. They conclude that none of the positive test results suffered 
from Hb degradation to such an extent that the test results changed from 
positive to negative within 10 days and that delays in returning samples to 
the laboratory of up to one week would not necessitate repeat sampling. 
Over this time, however, Hb concentration may be reduced in the FIT 
sample collection device which may have a clinical impact (114). This is in 
line with the Dutch findings (115) that delays in testing may cause false 
negative test results.  
 
A study in the Florence district of Italy (116) determined f-Hb from the 
screening programme and aggregated them into four seasons – spring, 
which had a mean temperature 27.60C (95% CI 26.2 to 29.1); summer 
25.20C (95%CI 23.1 to 27.3); autumn 29.20C (95% CI 27.7 to 30.6); winter 
29.50C (95% CI 27.9 to 31.1). These data were analysed to determine the 
impact of temperature on FIT positivity. They found that there was a 
decrease in positivity during the warmer months and proposed that this 
might affect the use of FIT, particularly in countries with high ambient 
temperatures. These issues must be addressed by manufacturers and 
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newer generations of FIT buffers should be developed to render Hb more 
stable and more suitable for use in population screening. 
 
Many studies investigated development of an evidence base for the use FIT 
algorithms have used one, two or three sampling devices at varying f-Hb 
cut-off and with varying intervals. Currently, there are no firm 
recommendations within the literature regarding which is the best strategy 
to adopt. However, it is clear from these studies that the automated, 
quantitative FIT algorithm used in a national screening programme would 
be adaptable according to the constraints of available resources. 
 
2.7 Comparisons of gFOBT and FIT  
 
The diagnostic accuracy of one gFOBT, the Stool Occult Blood Test Kit 
(Cenogenics Corporation, Morganville, New Jersey) and two FIT analytical 
systems, the OC-Sensor µ (Eiken Chemical Co., Ltd, Tokyo, Japan) and 
FOB Gold (Sentinel Diagnostics, Milan, Italy) have also been assessed 
(117). In this study, three faecal samples were initially assessed by gFOBT 
and FIT to determine that they tested as negative for f-Hb. One sample was 
retained as a negative result and two lysates prepared from heparinised 
human blood samples were used to give f-Hb of 2.5 mg Hb/g faeces (weak 
positive test result) and 4.5 mg Hb/g faeces (strong positive test result). 
They asked nine experienced ward staff to prepare and test one sample 
from each of the faecal samples on gFOBT cards and tested them on two 
quantitative FIT systems with the cut-off at 100 ng Hb/ml buffer. The ward 
staff gave a correct reading for the negative sample in eight out of nine tests; 
they reported a correct reading in five of nine samples in the weak positive 
sample and seven out of nine in the strong positive sample. The FIT 
determined all of the negative faeces as negative and all of the spiked 
samples as positive. Overall, the analytical sensitivity and specificity of the 
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gFOBT were 67% and 89% respectively, the quantitative FIT outcomes 
were both 100%.  
 
Evidence relating to the clinical advantages of using FIT compared with 
gFOBT in the detection of CRC derive from a number of studies, the most 
compelling of which comes from The Netherlands where gFOBT and an 
automated, qualitative FIT (OC-Sensor µ) were compared in a randomised 
population-based trial (118). The FIT yielded a significantly higher PPV for 
both CRC and advanced neoplasia, a significantly lower false positive test 
percentage and a higher uptake.  
 
These results are not directly applicable to the SBoSP since, using the 
manufacturer’s recommended f-Hb cut-off the positivity for the FIT was 
5.5%, too high for the existing colonoscopy capacity in Scotland. However, 
this study did demonstrate unequivocally that gFOBT significantly 
underestimates the prevalence of CRC and adenoma in a screening 
population when compared with FIT under the conditions adopted in the 
study. Further work from France, in which participants carried out both a 
gFOBT and a FIT simultaneously, produced a similar endorsement of FIT 
as the better test (119). 
 
2.8 Benefits of Automated Quantitative FIT 
 
Earlier in this Chapter, the disadvantages of gFOBT when screening for 
CRC were examined and how qualitative FIT addresses some of these was 
discussed. This section outlines how many of the remaining disadvantages 
of qualitative FIT are addressed by the quantitative FIT option (100).  
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In 2012, the FIT Guidelines Expert Panel in Ontario, Canada (120), 
published a comprehensive review of published literature detailing most 
relevant gFOBT/FIT comparisons, i.e. those systems that are approved for 
processing in laboratories in Canada. It concluded that the ideal FIT would 
have the characteristics described in Table 7. 
 
Table 6 Characteristics of the ideal FIT 
1 Provide a numerical result (so the f-Hb cut-off can be set by end user) 
2 Be readily automated in the laboratory 
3 Require one faecal sample 
4 Have specimen stability across a wide variation in temperatures 
5 Have sample stability of at least 7 days from date of collection to date of analysis 
FIT Guidelines Expert Panel Rabeneck et al (120) 
 
A number of evaluations of automated quantitative FIT platforms have been 
undertaken. Vilkin et al. undertook an evaluation offering a three FIT sample 
regime, tested on the OC-Sensor analyser, to a symptomatic cohort of 
patients presenting in primary care. It evaluated test reproducibility, Hb 
degradation, intra-patient variability of f-Hb, sensitivity and specificity for 
significant neoplasia (121). This study found that five prepared faecal 
sample collection devices tested five times did not produce significantly 
different results. When 30 samples were stored at 40C, 200C and 28 – 300C 
for three weeks, those stored at 40C did not have f-Hb that was significantly 
lower than their original concentration, but those stored at 28 – 300C did 
demonstrate a significant drop in f-Hb. In each category of disease, f-Hb 
increased with disease severity. The study reported an additive clinical 
value of repeated FIT with a sensitivity of 76.5% and speciﬁcity of 95.3% at 
100 ng Hb/ml buffer. In this study, even though the FIT was more sensitive 
than the gFOBT for significant neoplasia, because of the f-Hb cut-off and 
the high number of referrals for colonoscopy, they did not ﬁnd it more 
sensitive than a cheaper gFOBT. 
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Generally one sample is required 
 
It has historically been that gFOBT used in screening programmes have 
been performed on three consecutive samples. Two studies have 
investigated the effectiveness of one v two FIT sampling regimes. In the 
Dutch study all invitees for colonoscopy, were asked to complete one or two 
FIT samples (Eiken OC Sensor). Results were analysed in three ways; one 
of two FIT positive, two of two FIT positive and where the mean of two FITs 
exceeds the positive cut-off. This was performed across a range of cut-off 
values 50, 75, 100, 150 and 200 ng Hb/ml buffer. The second study was 
conducted on a screening population across four areas of Italy. Participants 
with at least one result >79 ng Hb/ml buffer were referred for colonoscopy, 
those with a result < 80 ng Hb/ml buffer received a negative result letter. In 
both studies the authors found that using two FIT over one FIT at different 
cut-offs did not improve the sensitivity and sensitivity of the test and that if 
sensitivity, for CRC or advanced adenomas was the main concern this could 
be improved by using one FIT with a low cut-off (110) (122). There is 
considerable evidence that this approach with FIT is associated with higher 
participation than the current gFOBT approach (118) (123). 
 
Screening interval can be extended  
 
Current evidence suggests a 10 year development process from adenoma 
to carcinoma. This is supported by histopathological data from adenomas 
left in situ (11) and more recent genetic and cytogenetic evidence (8). Based 
on this, biennial screening should detect early CRC and adenomas before 
symptoms appear. The RCT described in the previous Chapter where the 
decision was taken to use two year (and in the case of the Minnesota RCT 
one year) screening intervals demonstrated a significant reduction in CRC 
mortality (25). However, the introduction of quantitative FIT set at a lower f-
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Hb cut-off could provide an opportunity for extending the interval between 
screening rounds without reducing the PPV for CRC. 
 
A Dutch study, inviting over 10,000 screening naïve people, to undertake 
one FIT test at one, two or three year intervals over two screening rounds, 
as compared to a reference group who were offered once only FIT, reported 
interesting outcomes. It was determined that the uptake of a second 
invitation was higher in the two and three year interval groups than those 
invited annually. In addition, the number of individuals with advanced 
neoplasia was not influenced detrimentally by the length of time between 
FIT. The implication is that screening intervals up to three years could be 
used to tailor referral rate for colonoscopy without any detriment to 
neoplasia detection and that uptake may improve with longer screening 
intervals (124). 
 
f-Hb cut-off can be set by the user, dependent on resources 
 
The use of automated quantitative FIT is becoming widespread and seen 
by many as the current method of choice (27) (31). However, one major 
drawback is that manufacturers often recommend f-Hb cut-off that causes 
referral to colonoscopy to be 10 – 16%. This would be too high for UK 
countries to cope with at the present time. The approach of using one f-Hb 
cut-off uses the quantitative FIT simply as a qualitative investigation, i.e., 
dividing the participants into two classes, those who do not and those do 
warrant further investigation, usually colonoscopy. As numbers referred 
increase, sensitivity for neoplasia increases but specificity decreases as 
more people have to undertake colonoscopy to find neoplasia (125). Where 
colonoscopy capacity is a major consideration, it would be a benefit for the 
programme to be able to adjust the f-Hb cut-off in line with local colonoscopy 
resources, decreasing the f-Hb cut-off in successive rounds of screening.  
 
59 
  
Aspirin use can be beneficial 
 
There is evidence that, when undertaking screening with the newer FIT 
modality, the use of low-dose aspirin is associated with a markedly higher 
sensitivity for detecting significant neoplasia (126) (127). This was seen in 
two different automated quantitative FIT systems evaluated and was not 
seen with gFOBT. It may be that, in people with smaller lesions, taking 
aspirin causes increases in gastrointestinal blood loss that would be 
undetectable using gFOBT, have detectable f-Hb using FIT. A further study 
found that aspirin use was not a risk factor for causing false positive test 
results (128). 
 
FIT cost more than gFOBT at the point of invitation to screen, but, there are 
very few direct evaluations of the cost benefits of gFOBT and FIT. The 
Centre for Reviews and Dissemination reported on seven economic 
evaluations: the extra cost of FIT is likely to be cost-neutral or cost-saving 
to the potential for an increase in the detection of significant lesions and 
reduction in chemotherapy and treatment costs further on in the care 
pathway (129) (130). 
 
With automated quantitative FIT there now exists the technology to 
determine f-Hb. There is growing evidence to support the utility of this 
approach in determining not just the presence of CRC, but adenoma 
detection within screening programmes. 
2.9 Conclusion and Aims of This Work 
 
Automated quantitative FIT technology has now become widely accessible?   
FIT have many advantages and some disadvantages when compared to 
gFOBT as an examination to be used in CRC screening programmes.  
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There are a number of areas that would benefit from further study and these 
form the main questions put forward in this thesis:  
 can FIT be successfully introduced into the current SBoSP,  
 does FIT outcome have a relationship with demographic variables, 
and  
 can FIT be used to triage symptomatic patients?  
Since FIT are highly specific for Hb and its early degradation products, they 
offer the possibility of reducing false positive test rates in bowel screening 
programmes leading to fewer unnecessary colonoscopies. This provides 
opportunities for optimising demand on colonoscopy services and delivery 
improved population outcomes. The availability of quantitative data allows 
the programme organiser, not the manufacturer, to set the f-Hb that divides 
positive from negative test results [cut-off] and thereby enables adjustment 
of the positivity to suit endoscopy capacity.  
 
Colonoscopy is a scarce resource. Any test that can prioritise those who 
need urgent referral for colonoscopy would be of great benefit to the patient 
and the health care system. The FIT could be performed on a symptomatic 
patient presenting in primary care and the f-Hb be used to decide the 
appropriate care pathway. The algorithm developed for the triage of 
symptomatic patients would differ from that used in a screening setting since 
sensitivity would ideally have to approach 100% if used as a rule-out 
diagnostic test. Evidence must be gathered in order to demonstrate that 
very few patients with CRC would be missed by this strategy. 
 
This Chapter has set out the growing evidence that detection of CRC would 
be best performed by automated quantitative FIT using immunoturbidimetric 
analysis. The next Chapter details the verification of the FIT analyser used 
for the work described in this thesis.  
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CHAPTER 3: Evaluation of a Quantitative FIT 
Analytical System  
 
3.1 Introduction 
 
Currently there are several automated analytical systems that can provide 
f-Hb measurement. Automation enables movement from manual processes 
and subjective result interpretation which cast limitations on both gFOBT 
and qualitative FIT as described in Chapter 2. This Chapter outlines the 
validation and verification of the quantitative FIT analyser used in this work 
and the methods used to confirm or refute the manufacturers stated 
performance characteristics. 
 
Manufacturers provide information regarding the specification of their 
product. Details will vary but should include: linear range, number and 
concentration of control materials, reported range of measurement, 
analytical detection limit, imprecision and Hb stability. A number of these 
characteristics are explored further in this Chapter. 
 
The current interest in automated FIT analysers prompted an evaluation of 
the four most widely used analytical systems considered suitable for use in 
the NHS Bowel Cancer Screening Programme, and by implication SBoSP, 
by the Guildford Medical Device Evaluation Centre (GMEC) (131). Detailed 
analysis of the technical performance and suitable specimen collection 
systems contained in the report helped inform the choice of analyser. 
 
3.2 Characteristics of the Analytical System Adopted 
 
The OC-Sensor Diana analyser is a bench-top (630 mm x 560 mm x 560 
mm and 60 kg), automated quantitative analytical system that replaces the 
smaller OC-Sensor µ. The O-C Sensor Diana was reported to have the 
capacity to test 280 samples an hour and be able to continuously accept 
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new samples. It is able to hold two bottles, each containing 200 ‘shots’, of 
latex; these can be replenished during analysis.  
 
The OC-Sensor Diana was the only analyser to be CE-marked for use in 
the UK at the time of the work described here: use of such certified methods 
is essential for the maintenance of external accreditation (the SBoSL 
currently holds unconditional accreditation with Clinical Pathology 
Accreditation UK Ltd (CPA)) (132). It is one of the Quality Improvement 
Scotland standards that the SBoSL hold accreditation to ISO 15189 
standards (133).  
 
The OC-Sensor Diana is the analyser from which much of the evidence on 
the merits of FIT have been determined in Europe. 
 
As described already, during periods of this work two OC-Sensor Diana 
analysers were used, this was to provide a backup should one fail during 
the evaluation of FIT in the SBoSP. The positioning of the analysers is 
shown in Figure 11. A representative from MAST Group Ltd (MAST House, 
Bootle, Merseyside, UK) was assigned to support the laboratory and 
maintain the analysers.  
 
Figure 11 Set up of two OC-Sensor analysers 
 
Image courtesy of the Scottish Bowel Screening Laboratory (2014) 
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At the time of this work there was no World Health Organization (WHO) 
reference standard suitable for demonstrating metrological traceability for 
immunochemical tests with low analytical detection limit for f-Hb. OC-
Sensor standards and controls are calibrated using  an internal standard 
which is calibrated to hemoglobincyanide 98/708 National Institute for 
Biological Standards and Control (NIBSC) (134). This was still the case after 
the work was completed. 
 
3.2.1 Verification of the Method 
 
Introduction of any new analytical system within the SBoSL requires 
demonstration that the method is suitable for its intended use (135). This 
includes evaluation of the pre-analytical process, analysis of samples and 
post-analytical steps. In addition there must be evaluation of the analyser in 
situ forming a comparison with the manufacturer’s stated analytical 
performance characteristics where available. All these facets were 
investigated during the validation and verification of the analyser. This 
followed the Department of Biochemical Medicine, Ninewells Hospital and 
Medical School, Standard Operating Procedure (SOP) - Evaluation of a new 
method and are included in the SOP SBSL 31 How to operate the OC-
Sensor analyser (Appendix 1) written before the work commenced.  
 
The study undertaken within the symptomatic setting commenced February 
2010 and ended March 2012. The period of study involving participants in 
the SBoSP started July 2010 and ended April 2011. It was only during the 
period when testing samples for the SBoSP that two analysers were used. 
During this part of the work, each analyser was set up on alternate days: if 
the chosen analyser was out-with the control limits set for acceptance of the 
run, the alternate analyser was set up and run. 
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3.2.2 Analysis of Intra-run and Inter-run Imprecision 
 
The imprecision of a method (dispersion) is usually measured using 
standard deviation (SD), whilst the magnitude of dispersion is interpreted by 
using the coefficient of variation (CV). Intra-run variation is determined by 
testing the same sample/control material repeatedly on the same day. Inter-
run imprecision is determined by testing freshly prepared samples/control 
material over a number of days. The ideal minimum number of replicates for 
the determination of standard deviation is 20 and it is also useful to use a 
variety of sample types. In this instance there was no opportunity to use 
patient samples as the analyser was not in use anywhere else in Scotland 
and so high and low control materials were used alongside ‘spiked’ faecal 
samples.  
 
The high and low control material was supplied by the manufacturer as 
lyophilised powder in vials and required the addition of 1.0 ml of purified 
water and to be allowed to stand for 15 minutes before use. The 
manufacturers high and low control ranges were LOT specific. The other 
type of material used in the assessment of imprecision was native faeces 
‘spiked’ with human whole blood lysate which had been diluted to a 
concentration that was within the analytical range of the analyser. The 
manufacturer provided all the other components required for testing, 
including latex, calibrator, buffer, diluent and bleach. 
 
Initially only one analyser was in-situ. High and low control material and four 
‘spiked’ samples were used to determine intra-run variation. To prepare 
these, fresh specimens of faeces from four apparently healthy volunteers 
were tested for haemoglobin with hema-screen SPECIFIC. They were all 
negative. After thorough mixing, one portion of each was saved; the rest 
were supplemented with Hb lysate from a redundant pack of SNBTS blood. 
This was prepared by freezing 1 ml aliquots and thawing for use. Four 
different concentrations of Hb lysate were used, giving five sets of results. 
The range of concentrations used reflects clinically relevant concentrations 
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of Hb. Due to the heterogeneous nature of faecal material, distribution of 
the lysate was difficult, accurate sampling into the collection tube also 
proved to be difficult as the serrated end of the sampling stick is small. Given 
these factors, the initial Hb concentrations show variation within the four 
spiked groups. Due to the difficulty of preparing faeces and Hb lysate at this 
early stage the spiked samples all have low levels of Hb present.  
 
However, given the constraints, the analyser was shown to have similar 
imprecision to that stated by the manufacturer within the linear range 40 – 
1000 ng Hb/ml buffer. The raw data is shown in Table 7. In the case of 
Sample 1, it is usual for measurements near the analytical detection limit of 
a method to have greater dispersion and higher coefficient of variation. 
During the course of the evaluation samples with concentrations greater 
than the upper limit were not diluted and re-assayed. 
 
Table 7 OC-Sensor spiked samples run on one analyser over one day 
4 spiked (Hb lysate) faecal samples 
High control material (mean) 630ng Hb/ml buffer,  
Low control material (mean) 155 ng Hb/ml buffer 
 
REPEAT SAMPLE 1 SAMPLE 2 SAMPLE 3 SAMPLE 4 LOW HIGH 
1 16 32 64 74 162 669 
2 21 37 70 76 165 685 
3 29 44 77 78 164 688 
4 15 43 74 84 171 701 
5 26 44 69 81 176 758 
6 30 49 77 88 176 701 
7 33 53 76 81 173 713 
8 25 54 73 86 175 713 
9 24 48 73 94 173 716 
10 35 59 71 89 167 698 
11 30 55 72 88 169 706 
12         174 702 
13         175 724 
14         182 728 
15         180 724 
n 11 11 11 11 15 15 
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Low 15 32 64 74 162 669 
High 35 59 77 94 182 728 
MEAN 25.8 47.1 72.4 83.5 172.1 708.4 
SD 6.5 8.1 3.9 6.1 5.8 21.1 
CV (%) 25.2 17.2 5.4 7.3 3.4 3.0 
 
When the second analyser was validated the imprecision studies were 
revisited and further high and low control material were run fifteen times on 
one day on both analysers named OC-Sensor 1 and OC-Sensor 2 (new 
analyser). The raw data concerning intra-run imprecision on two analysers 
are contained in Table 8.  
 
Table 8 OC-Sensor intra-run imprecision 
High control material (range) 144 - 168 ng Hb/ml buffer,  
Low control material (range) 573 - 681 ng Hb/ml buffer 
 
 OC 1   OC 2   
REPEAT LOW HIGH LOW HIGH 
1 147 628 143 594 
2 149 637 145 599 
3 148 633 144 603 
4 149 625 142 605 
5 151 629 145 608 
6 150 634 142 572 
7 142 595 142 596 
8 148 612 142 596 
9 149 610 142 597 
10 148 621 146 603 
11 150 633 149 605 
12 152 641 149 607 
13 151 627 151 588 
14 154 700 153 610 
15 155 647 153 625 
n 15 15 15 15 
Low 142 595 142 572 
High 155 700 153 625 
MEAN 151 631 146 601 
SD 3.1 23 4.1 12 
CV (%) 2.0 3.6 2.8 1.9 
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Limited variability in reported results is expected in these intra-run data and 
this is reflected in the low coefficient of variation (CV): no further statistical 
tests were performed on these data. 
 
Assessment of inter-run imprecision required that the shut-down, restart and 
daily maintenance was performed according the SOP between each set of 
controls being tested. These data are shown in Table 9. 
 
Table 9 OC-Sensor inter-run imprecision 
High control material (range) 144 - 168 ng Hb/ml buffer 
Low control material (range) 573 - 681 ng Hb/ml buffer 
OC 1     OC 2   
Day LOW HIGH   Day LOW HIGH 
1 140 623   1 158 671 
2 145 621   2 163 616 
3 168 700   3 164 615 
4 145 596   4 154 597 
5 142 598   5 154 605 
6 150 622   6 149 603 
7 148 618   7 149 608 
8 150 620   8 150 610 
9 151 625   9 146 600 
10 148 616   10 152 644 
n 10 10   n 10 10 
MEAN 148.7 623.9   MEAN 153.9 616.9 
SD 7.7 28.6   SD 6.1 23.1 
CV (%) 5.2 4.6   CV (%) 3.9 3.7 
 
There are two statistical tests that could be used to assess the data from 
two analysers. The t-test was used in a non-parametric, comparison of two 
groups of continuous variables to assess the difference of the two means 
for the high and low control values across the two analysers. For the low 
control the P-Value equals 0.1100 which is not significant at p < .05 and the 
high control material, the P-Value is 0.5548, this is not significant at p < .05.  
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These results indicate that the high and low control values are not 
significantly different between the two analysers. 
 
The F test allows comparison of the variance of two systems. Analysis of 
the low control material, gave F as 1.594: the critical value of F for P < 0.05 
with 9 degrees of freedom [n-1] is 3.18 and for P < 0.01, the critical value is 
5.35. So, F is less than the critical value, therefore, the imprecision of the 
two analysers at the low concentrations are not statistically different.  
For the high control material, F was 1.778: the same critical values apply, 
so again there is no difference. Therefore, the data collected over 10 days 
show that statistically the analysers do not have different analytical 
imprecision. 
 
Preparation of the samples for Hb degradation studies provided a small 
number of real faecal samples spiked with Hb lysate which could be 
analysed. These samples were used to set up a comparison across the two 
machines. These samples were run once on each analyser and the results 
are shown in Table 10 as raw data and a comparison table. This data shows 
greater parity in repeat tests with lower Hb concentrations than high faecal 
Hb concentrations.  
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Table 10 Real faecal samples measured on OC 1 and OC 2 
 
SAMPLE OC1 OC2 
1 155 149 
2 37 44 
3 46 49 
4 0 7 
5 355 267 
6 37 47 
7 693 707 
8 67 67 
9 43 31 
10 446 334 
11 54 59 
12 26 28 
13 17 24 
14 510 448 
15 425 384 
n 15 15 
low 0 7 
high 510 448 
 
There is again an issue here regarding the heterogeneity of faecal samples 
and dispersion of faecal material and Hb. During the preparation of samples 
this is addressed by thorough mixing but may still be causing an artefact in 
the results. 
 
3.2.3 Internal Quality Control Data  
 
High and low control material was supplied by the manufacturer and run 
with participant samples at a rate of one high and one low control material 
for every 100 participant samples, or where there were fewer than 100 
participant samples one set of high and low controls were analysed. This is 
similar to the internal quality control (IQC) process already used in the 
SBoSL with gFOBT and qualitative FIT. These data were checked to be 
0
100
200
300
400
500
600
700
800
OC Sensor 1             OC Sensor 2
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within limits and each run signed off as acceptable by Health and Care 
Professions Council (HCPC) registered Biomedical Scientist staff. Over the 
course of this work these data were collected and analysed. The 
imprecision, taking account of both analysers, during use in the evaluation 
period was less than 3.8%. These results reflect the manufacturer’s claims 
and so were accepted for this method. These data are shown in Table 11. 
Table 11 OC-Sensor 1 and 2 imprecision during evaluation period July 2010 – January 2011 
   Low Control  High Control 
Date  LOT OC n Mean*  SD  CV % n Mean*  SD  CV % 
06/07 01001 1 38 154.7 8.35 5.41 38 637.1 31.81 4.99 
30/08 01001 1 74 150.7 5.87 3.90 74 620.9 23.06 3.71 
01/11 08001 1 10 147.9 2.47 1.67 10 642.3 19.32 3.01 
13/11 08001 1 22 153.6 5.23 3.41 21 640.9 20.73 3.23 
03/12 08001 1 23 146.0 5.01 3.43 23 598.8 22.29 3.72 
24/12 09013 1 5 162.2 5.85 3.61 5 682.8 13.21 1.94 
06/01 09013 1 7 155.7 3.15 2.02 8 676.0 24.17 3.58 
12/01 09013 1 53 158.8 13.43 8.46 54 672.1 35.61 5.33 
12/07 01001 2 61 153.0 15.21 9.94 61 622.3 27.49 4.42 
31/08 01001 2 72 153.2 4.73 3.09 72 614.5 20.36 3.31 
01/11 08001 2 9 151.2 3.53 2.33 9 610.8 24.49 4.01 
09/11 08001 2 21 155.8 4.83 3.01 20 619.4 21.90 3.54 
03/12 08001 2 26 152.0 5.36 3.53 26 636.7 37.33 5.86 
24/12 09013 2 3 155.7 19.63 12.31 3 658.3 70.50 10.51 
06/01 09013 2 7 160.7 3.95 2.46 7 702.6 11.90 1.56 
12/01 09013 2 59 158.7 15.95 9.98 59 653.8 25.99 3.89 
 
Date  LOT OC n Mean*  SD  CV % n Mean*  SD  CV % 
06/07 01001 1 106 152.4 6.5 4.3 106 627.7 25.9 4.1 
01/11 08001 1 48 150.7 5.6 3.7 47 630.9 26.2 4.2 
24/12 09013 1 52 160.5 5.1 3.2 62 672.5 24.4 3.6 
12/07 01001 2 130 152.4 4.6 3.0 130 617.9 20.0 3.2 
01/11 08001 2 54 153.6 4.8 3.2 54 625.5 27.5 4.4 
24/12 09013 2 54 162.6 6.0 3.7 53 697.3 20.8 3.0 
Assigned 01001   156 6   627 27  
Assigned 08001   154 5   626 25  
Assigned 09013   161 7   685 20  
Overall   1 206   3.9 215   4.0 
Overall   2 238   3.2 237   3.5 
Overall   1+2 444   3.5 452   3.8 
*mean is reported as ng Hb/ml buffer **weighted for each LOT 
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The analysers were calibrated every month, or each time the latex LOT 
changed, whichever occurred first. This was followed by a period of 
accepting internal quality control values based on the manufacturers 
acceptance criteria. After 10 replicate analyses a local multirule acceptance 
criteria was calculated based on results being within two standard 
deviations of the mean (12s). This rule was used to determine acceptance 
or rejection of subsequent analytical runs. 
 
3.2.4 External Quality Assessment Scheme Data 
 
It is a requirement of the ISO 15189 standards that laboratories must 
participate in an External Quality Assessment Scheme (EQAS), where it is 
available, for each measurand that is examined in that laboratory. There is 
currently no EQAS scheme within the UK for FIT testing. However, the 
manufacturer of the OC-Sensor Diana analyser do organise a Japanese-
based worldwide EQAS.  
 
During the period of the work in which two analysers were in use there was 
one opportunity for the SBoSL to participate in this scheme. The 
manufacturer provided Sample A and Sample B, pre-prepared as liquid 
controls, ready to be placed in a control cup for analysis – this is similar to 
testing control material rather than patient samples.  
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Figure 12 Eiken external quality assessment report OC-Diana 1 (reproduced with kind permission 
from Mast Group) 
 
When testing Sample A, the mean attained by the 805 participating 
laboratories was 135.5 ng Hb/ml buffer. The result generated by OC-Sensor 
1 was 131 ng Hb/ml buffer and by OC-Sensor 2 138 ng Hb/ml buffer. For 
Sample B, OC-Sensor 1 returned a result of 421 ng Hb/ml buffer and OC-
Sensor 2 a result of 434 ng Hb/ml buffer, the mean for the group was 445.5 
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ng Hb/ml buffer. Analyser 1 gave a low result >1 SD away from the mean of 
the group and a high result < 1 SD from the mean. Analyser 2 gave results 
< 1SD away from the mean.  
Figure 13 Eiken external quality assessment report OC-Diana 2 (reproduced with kind permission 
from Mast Group) 
 
Overall the results from the two analysers were low compared to the group. 
However, all returned results were within 2 SD of the mean. This confirms 
the results seen in the SBoSL evaluation of imprecision between the two 
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analysers and manufacturers claims. The Eiken reports are shown in 
Figures 12 and 13. 
 
3.3 Hb stability 
 
There is evidence that, when faeces are collected with no preservative 
present, degradation of Hb continues after collection (113). Manufacturers 
are unable to offer definitive guidelines regarding the stability of Hb in their 
sample collection devices due to a number of factors, namely each 
individual’s faecal flora affects Hb degradation, increased transit time is 
likely to reduce the amount of detectable Hb and delays before testing may 
also contribute to a reduction in f-Hb. These issues cannot be replicated by 
the manufacturer. Manufacturers have suggested that users investigate 
local conditions.  
 
The storage temperature and time taken to transport participant samples 
cannot be controlled. In order to investigate the effect of different 
temperatures and varying lengths of time before testing on f-Hb, 55 faecal 
samples were set up to mimic possible pre-analytic conditions.  
 
Fresh specimens of faeces from four apparently healthy volunteers were 
tested for the presence of Hb with hema-screen SPECIFIC (Immunostics, 
Ocean, New Jersey, USA). They were all confirmed to have no detectable 
f-Hb by analysis using the OC-Sensor Diana. After thorough mixing, one 
portion of each was saved. Hb lysate was prepared by freezing and thawing 
a specimen of venous blood from a redundant pack of blood supplied by 
Scottish National Blood Transfusion Service (SNBTS). Four different 
concentrations (using doubling dilutions) of Hb lysate were used with the 
portion that tested negative, giving five sets of f-Hb. The range of 
concentrations prepared reflected clinically relevant concentrations of Hb in 
faeces. Due to the heterogeneous nature of faecal material, incorporation 
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of the lysate was difficult. Reproducible sampling into the collection device 
also proved to be difficult since the serrated end of the sampling probe is 
small. Due to these factors, the initial Hb concentrations show variation 
within the four spiked groups. These samples were stored in the collection 
tubes at ~ 40C, ~ 200C, and ~ 260C. These were re-assayed daily, for 12 
days. 
 
The initial concentrations of Hb in the spiked faecal samples were in the 
range 85–635 ng Hb/ml buffer. Five samples with undetectable f-Hb were 
included in the study. The results from the study showed that Hb 
concentration fell in all groups of samples over 12 days, as documented in 
Figure 14.  
 
The rate of decrease was slightly different in each sample. This may be in 
part due to the difficulties in preparing the samples and/or different faecal 
flora present in each sample device. Overall, lower Hb was detected at each 
analysis as temperature increased. In samples stored at 40C there was a 
16% decrease in f-Hb concentration, 31% at 200C and 61% at 260C. The 
four spiked samples were denoted as W, X, Y and Z, with W containing high 
Hb, X medium, Y the least and Z the highest of the group. The percentages 
of Hb degradation according to initial concentration are 32%, 40%, 36% and 
37% respectively. The study indicated that the rate of decrease was not 
proportional to the original f-Hb. 
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Figure 14 Hb stability study data at 4, 20 and 26 oC  
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This study demonstrated that the concentration of Hb detected by 
automated immunochemical testing using OC-Sensor sample collection 
devices does decrease over time. The results also show that higher storage 
temperatures produce a greater reduction in the f-Hb detected. This is in 
contrast to gFOBT which does not suffer from this issue once the faeces 
has dried out (80). The rate of reduction seen was not proportional to the 
original f-Hb.  
 
The outcomes from this work informed the decision to set the maximum time 
between sample collection and analysis as 10 days where temperatures 
tend to be under 200C: after this it was considered that the result would not 
be accurate since f-Hb may have degraded too far to give a meaningful 
result.  
 
The data presented here were used to extend sample acceptance beyond 
the manufacturer’s claims of 3 days at room temperature, 7 days at 2-10°C, 
10/14 days at –20°C. These data are shown in Figure 15. Despite the desire 
to further extend acceptance, the decision taken must take into 
consideration the modality of returning samples and not attempt to include 
as many returned samples as possible which may not provide a meaningful 
result. 
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Figure 15 Eiken Hb stability data 
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3.4 Results and Reporting  
 
The OC-Sensor analyser requires a complimentary specimen collection 
device. This contains 2.0 ml of buffer (± 0.13 ml) into which are suspended 
10.5 mg of faeces (± 2.0 mg). The mass of faeces is standardized by use of 
a grooved sampling device which is passed through the neck of the buffer 
tube, acting as a collar to remove excess faeces, this is shown in Figure 16.  
 
Figure 16 Diana OC-Sensor sample collection device 
                         
Image courtesy of the Scottish Bowel Screening Laboratory  
An analysed concentration of 100 ng Hb/ml buffer corresponds to a quantity 
of Hb equal to 200 ng Hb in the bottle (that is in 10 mg of faeces). Thus, a 
conversion to µg Hb/g of faeces can be made, as shown in Table 12. These 
characteristics provide a reproducible way to convert ng Hb/ml buffer to µg 
Hb/g of faeces.  
 
Table 12 Conversion of faecal haemoglobin concentrations (f-Hb) 
ng Hb/ml buffer    µg Hb/g faeces 
10  2 
50  10 
100  20 
250  50 
400  80 
1000  200 
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The EWG on FIT for Screening of the CRCSC of the WEO recommend that 
units of μg Hb/g faeces be used and the conversion for this particular 
analyte (105). As the majority of the work undertaken in this thesis was 
carried out before this recommendation all results are reported as ng Hb/ml 
buffer. 
 
3.5 Summary 
 
Outcomes for the intra and inter-run imprecision in the linear range of the 
analyser, 40 – 1000 ng Hb/ml buffer, had a CV < 20. Where samples had f-
Hb lower than the bottom of the linear range imprecision increased to CV > 
20. Analysis of IQC material used on for the two analysers over the course 
of the study was CV <3.8% at both low (155 ng Hb/ml buffer) and high (650 
ng Hb/ml buffer) control levels. The variation in results produced between 
the analysers was not significant. These outcomes are similar to the 
performance claims made by the manufacturer and were accepted as 
suitable for the purposes of the evaluation of FIT in the SBoSP and 
symptomatic study. 
 
Measurement of the degradation of f-Hb in the sample devices at three 
temperatures produced results that were closely aligned to the 
manufacturer’s data and the decision was taken to allow 10 days after the 
application of faeces before declaring the sample untestable. 
 
This important, preliminary, work provided an opportunity to SBoSP team to 
use the OC-Sensor Diana. Staff were able to familiarize themselves with 
reagent usage, calibration, sample handling and minor operational issues. 
Despite the overwhelming evidence that automated qualitative FIT is the 
modality of choice for detection of FOB in faeces, it is a requirement of the 
ISO 15189:2012 accreditation standard to validate the manufacturer’s 
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analytical specifications whilst an analyser is in situ in the laboratory and 
before any participant samples are tested.  
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CHAPTER 4: Using FIT in Asymptomatic 
Population Screening 
 
4.1 Introduction 
 
It has been previously discussed in this thesis that, although gFOBT have 
advantages for use in structured screening programmes, they also have 
major disadvantages. The major disadvantages are poor sensitivity and 
specificity, and that the cut-off concentration between gFOBT negative and 
positive results is set by the manufacturer. Thus, the positivity and the 
clinical characteristics cannot be adjusted by the end-user. One way around 
this would be to develop a specialised algorithm locally e.g., one based on 
the results of initial testing with gFOBT and repeat testing with qualitative 
FIT as the second line test (66). This is the approach used in Scotland, 
resulting in a 2.1% positivity which gives the number of referrals that can be 
handled satisfactorily within current colonoscopy resources. However, this 
can tend to make programme organisation and execution complex as 
shown in Figure 17. 
 
Most published studies using FIT have been performed using the cut-off as 
recommended by the manufacturer. This results in a higher positivity and 
greater sensitivity, albeit with lower specificity than a gFOBT-based 
programme. However, a significant consideration in Scotland, where 
colonoscopy capacity is limited, is that increasing the cut-off concentration 
reduces the positivity, in effect lowering sensitivity but with the benefit of 
higher specificity and fewer colonoscopies (122) (137). The use of a low 
referral rate for colonoscopy is necessitated by resource constraints: 
however, these outcomes may be relevant to other nations as healthcare 
resources become scarcer. 
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Figure 3 SBoSP algorithm, July 2010 
 
 
 
4.2 Aims of the Evaluation 
 
Although the suitability of FIT as a first-line test (FFLT) in Scotland could be 
inferred from other research studies and small scale screening 
programmes, there has never been a direct comparison between a fully 
rolled out national screening programme using gFOBT and results obtained 
with an automated FIT system.  
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The primary aim of this study was to evaluate the feasibility of using the 
FFLT algorithm over a six month period in two evaluation NHS Boards in 
Scotland with the f-Hb cut-off set to give the same positivity as seen in the 
SBoSP. 
 
The secondary aims were to: 
 
 compare the clinical outcomes with those obtained 1 year before and 
1 year after in the evaluation NHS Boards, 
 make a comparison with contemporaneous data in another two 
similar (control) NHS Boards,  
 assess the effect of the single sample quantitative FIT collection 
device on uptake by sex, age and deprivation, as determined by 
Scottish Index of Multiple Deprivation (SIMD), and 
 analyse clinical outcomes at 2.1% referral for colonoscopy. 
 
4.3 Benchmarking 
 
In Scotland, the performance of many healthcare services are reviewed 
through internal benchmarking. In this study the Key Performance Indicators 
(KPI) already being collected and published by Information Statistics 
Department (ISD) of NHS National Services Scotland were used as a basis 
for evaluation (108).  
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Table 13 Relevant Key Performance Indicators (KPI) for the Scottish Bowel Screening Programme 
(SBoSP) and expected direction of change 
Benchmark Current 
Outcome 
Expected direction 
of change 
1.Overall uptake of screening 53.7 ↑ 
3.Positive screening test result rate 2.3 ↔ 
8.Crude cancer detection rate 0.14 ↑ 
9.Percentage of people with screen detected CRC that 
are Dukes' Stage A 
10.Percentage of people with screen detected CRC 
that are Dukes' Stage B 
11.Percentage of people with screen detected CRC 
that are Dukes' Stage C1 
12.Percentage of people with screen detected CRC 
that are Dukes' Stage C2 
13.Percentage of people with screen detected CRC 
that are Dukes' Stage D 
27.7 
 
24.1 
 
21.8 
 
1.6 
 
2.5 
↔ 
 
↔ 
 
↔ 
 
↔ 
 
↔ 
17.Polyp CRC detection rate 
18.Percentage of polyp CRC 
0.04 
28.0 
↑ 
↑ 
19.Overall adenoma detection rate 
20.High risk adenoma detection rate 
0.71 
0.11 
↑ 
↑ 
21.PPV to CRC 
22.PPV of all adenomas where adenoma is the most 
serious diagnosis 
23.PPV to high risk adenoma 
24.PPV to high risk adenoma or CRC 
25.PPV to any adenoma or CRC diagnosis 
7.3 
38.1 
5.8 
13.1 
45.4 
↑ 
↑ 
↑ 
↑ 
↑ 
Based on KPI Report Invitations between 1st Nov 2008 and 31st October 2010 (98) 
 
Effectiveness of the screening programme is a result, inter alia, of 
participation and sensitivity of the test for neoplasia. Those KPI pertaining 
to measuring effectiveness were selected for review and it was 
hypothesised in which direction they would change, as shown in Table 13. 
The outcomes of the study and impact on the KPI are discussed in the 
Results section of this Chapter. 
 
4.4 Methods 
 
The study was carried out in three phases: 
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Phase 1 – collection of training data 
Planning assumptions for the rollout of the SBoSP included positivity at 
2.1%. This was based on the outcomes of the first three pilot rounds (46). 
The positivity in the SBoSP at the time of planning the study was 2.3% (108). 
Data from Dutch quantitative FIT studies (discussion with Leo Van Rossum) 
was used to convert this positivity back to f-Hb cut-off (118). The analyser 
cut-off was set at 400 ng Hb/ml buffer (equivalent to 80 µg Hb/g faeces). 
This would become the ‘training’ data and would be reviewed after one 
month. The resulting data would: 
 reveal the actual positivity in the evaluation group compared to that 
in the SBoSP 
 allow adjustment of the f-Hb cut-off to give a 2.1% positivity. 
 
Phase 2 – remaining study period 
At this point, if it was required, an adjustment would be made to the cut-off 
based on the training data. For the remainder of the study period, individuals 
with a test result above the revised threshold would be defined as positive. 
 
Phase 3 - conclusion 
At the end of the six month period, the NHS Boards in the evaluation 
reverted to using gFOBT/FIT two tier reflex algorithm. Full analysis of the 
evaluation data was performed at this point. 
 
The initial planning for the SBoSP was based on Health Boards agreeing to 
resource colonoscopies on a 2.1% referral rate. The challenge in planning 
for this study was to determine a suitable f-Hb cut-off to give a positivity in 
the study boards that was similar to that in the programme. Dutch 
researchers had been very active in FIT research and van Rossum 
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performed analysis of FIT data from an average risk screening population 
tested on the OC-Sensor (137). These calculations are shown in Table 14. 
These data provide evidence that using one FIT sampling device with a cut-
off set to ensure a similar number of referrals for colonoscopy as the current 
programme, should detect similar numbers of cancer and adenomas to the 
current gFOBT/FIT algorithm in Scotland. This data was used to inform the 
cut-off for the training data set in the SBoSP. The 400 ng Hb/ml buffer cut-
off was retained for the entire study period.  
 
TABLE 14 Calculation of cut-off based on data from The Netherlands (FIT is reported as ng Hb/ml buffer) 
 gFBOT FIT 50 FIT 400 FIT 500 
Positive (N) 103 428 122 104 
Scoped positives (%) 1.7% 7.0% 2.0% 1.7% 
CRC 11 28 16 16 
Advanced Adenomas 46 1.6 53 46 
Extra CRC compared to gFOBT  2.5 1.5 1.5 
Number needed to scope     
CRC 9.4 15.3 7.6 6.5 
CRC + Advanced Adenomas 1.8 2.3 1.8 1.7 
 
 
The cut-off f-Hb was designed to give a positivity that could be managed by 
the available colonoscopy resources. Positive screening referrals would 
continue at 2.4% of the population that returned the collection devices, 
thereby picking up those with the highest concentration of Hb in their faeces. 
These are the group who have the highest probability of significant 
neoplasia. (140). 
 
Analyses were carried out in the SBoSL by trained staff whose major 
function is to perform faecal test analyses: the SBoSL has a comprehensive 
total quality management system and is accredited to ISO 15189 based 
standards by CPA (UK) Ltd. The analytical strategy and performance 
achieved have been detailed previously in Chapter 3. Briefly, the analysers 
88 
  
were calibrated once per month, or when the latex LOT changed, with the 
calibrators provided. Each analytical run was preceded by analysis of two 
quality control materials at different Hb concentrations. The target values for 
the lots of materials used were set a priori by 20 replicate analyses and a 
12s rule (where the mean plus or minus two standard deviations are used 
as the control limits) used for acceptance or rejection of analytical runs.  
 
Chapter 3 also reported that high temperatures and delayed testing may 
contribute to a reduction in the concentration of Hb detected at analysis. 
Because this effect is known, any samples returned more than 10 days after 
the date of sampling were deemed ‘expired’. Since this preliminary work 
was undertaken further studies have been published that examine the 
stability of f-Hb in sample device tubes that reinforce our findings, and 
endorse the use of 14 days as the point of expiry in next generation sample 
devices. Lower storage temperatures reduce f-Hb degradation (141) (142). 
 
Faecal samples that have Hb concentration near the cut-off would be likely 
to fall below the cutoff if subjected to high temperatures and a prolonged 
delay in testing. From the experience gained in this study the ‘instruction for 
use’ and invitation letter sent to the participant extols them to return the 
sample device soon as possible. The protocol within the SBoSL was to test 
samples on the day of arrival. If this was not possible, the sample would be 
stored at 40 C for testing within 24 hours. As far a possible this reduced the 
potential for the concentration of f-Hb to be further reduced after arrival in 
the SBoSL. 
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4.4.1. Population and Evaluation Period 
 
There are 14 territorial NHS Health Boards in Scotland. For this FFLT study, 
all individuals in the NHS Tayside and NHS Ayrshire & Arran areas of 
residence from 01 July 2010 to 12 January 2011 were sent a study invitation 
pack. NHS Tayside was in the fifth round of screening and so prevalent CRC 
have been detected and mainly incident CRC emerging. NHS Ayrshire and 
Arran were part way through their prevalence round of screening and so it 
was anticipated that would be more neoplasia detected in this group in the 
study.  
 
Instructions for use 
All those eligible to participate in the SBoSP receive a letter of invitation, a 
‘know the facts’ leaflet, instructions for use (IfU), a test kit, initially a gFOBT, 
cardboard applicators and a freepost foil return envelope.  
Figure 18 Information for Users (IfU) for FIT as a First-Line Test (FFLT) Evaluation 
 
 
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The IfU that are sent out to eligible SBoSP participants would not be 
applicable to those in the study. The Senior Management Team, a 
multidisciplinary group including clinical and management staff, at the 
Scottish Bowel Screening Centre (SBoSC) developed new IfU (adapted 
from the manufacturers’ literature) and these were sent to participants in the 
study (Figure 18). 
 
Helpline activity 
The SBoSC also hosts the helpline for the service. The staff are specifically 
trained to deal with bowel screening queries but do not offer medical advice. 
Training sessions were organised to pre-empt questions that might arise 
during the study and template answers devised to ensure equity of service. 
During the study calls regarding the FFLT study were monitored and 
recorded.  
 
4.4.2. Invitation to the Study 
 
Each person in NHS Tayside and NHS Ayrshire& Arran eligible to 
participate in screening during the study period was sent a FFLT invitation 
pack. The invitation pack was based on the current SBoSP pack and 
contained an invitation letter, a booklet on CRC and a thin card wallet with 
printed written and pictorial instructions, Figure 16, for sample collection.  
Inside the wallet was a single faecal sample collection device, a small zip-
lock plastic bag with integral absorbent material and a foil mailing pouch for 
device return.  
The invitation letter contained an integral SBoSP identification label which 
was removed by the participant and attached to the outside of the zip-lock 
bag before return of the sample. Participants were guided through the 
sampling process by the pictorial instructions which had been devised 
specifically for the study. All study material was developed in the SBoSC 
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and approved by Health Scotland. Further advice about completing the 
sampling process could be gained by contacting the SBoSP helpline by 
telephone. 
 
Invitees were allocated a compliance period of 90 days from the date of 
invitation to return their specimen collection device. A reminder letter was 
sent out at 6 weeks as per the SBoSP algorithm. Invitees who contacted the 
helpline to opt out or where post was undelivered were treated as per the 
usual practices of the SBoSP. The algorithm used for the study is set out in 
Figure 19.  
Figure 49 SBoSP algorithm, 1 July 2011 – 12 January 2012 
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4.4.3. Sample Handling  
 
The unique SBoSP label documented the name of the participant, CHI and 
accession number. The CHI number is a unique 10-digit identifier used 
ubiquitously in NHS Scotland to access healthcare; it identifies the date of 
birth, sex and area of residence of the individual. The label also had a 10-
digit accession number generated by the BoSS IT system. The participant 
was required to write the date of sample collection on this label and to return 
the sample back to the SBoSL without delay. The foil mailing pouches, with 
completed sample collection devices in the zip-lock bags, were returned 
through the normal UK Post Office mail system by business class freepost. 
 
On return to the SBoSL, the foil mailing pouches were opened and the label 
on the zip-lock bag replicated using in-house software. This secondary label 
was fixed to the sample collection device and the receipt of a sample 
captured electronically by BoSS during the ‘book-in’ process which gave 
confirmation of the name, CHI number and kit number via scanning of the 
barcode. Samples that were received >10 days from date of sample 
collection were termed “expired” and not tested further. This decision was 
based on in-house validation studies of Hb stability performed during the 
commissioning of the analysers as described in Chapter 3.  
 
Analyses were carried out in the SBoSL by trained staff whose major 
function is to perform faecal test analyses. The SBoSL has a 
comprehensive total quality management system and is accredited to ISO 
15189 based standards by CPA (UK) Ltd. The analytical strategy and 
performance achieved have been detailed in Chapter 3. 
 
Once in the SBoSL 93.3% of returned samples were tested on the day of 
receipt; where this did not happen samples were stored at 4oC. During the 
course of the evaluation, the maximum storage at 4oC was 8 days (owing to 
delays shipping reagents during adverse weather). These samples were 
allowed to return to room temperature before analysis. 
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4.4.4. Reporting of Participant Results  
 
The OC-Sensor Diana uses a Windows® based operating system controlled 
by a touch screen interface. It has sufficient software to construct and 
display calibration curves and collect control data, allowing the user to 
review retrospective control data and examine these for imprecision and 
bias. Unfortunately, the test result data can only be printed via a ticker tape 
set up or be imported into a comma-separated values (.csv) file. As part of 
the work up for using this analyser, representatives from MAST Group 
undertook construction of an interface programme that allowed the 
conversion of quantitative results into qualitative data which was produced 
in a format allowing results to be printed out linked to the participant’s unique 
test request number. This gave positive/negative test results that could be 
printed onto a worksheet and entered manually by two members of staff into 
the bespoke Bowel Screening System (BoSS) IT interface each day 
(Appendix 2). These printed records where retained as per all patient 
records (136). 
 
All participants with f-Hb <400 ng Hb/ml buffer were considered negative 
and sent an explanatory letter. Those who sent an untestable device were 
sent another FIT kit pack. All participants with a f-Hb ≥ 400 ng Hb/ml buffer 
were considered positive and also letter informing them of this. The relevant 
GP was notified and the individual referred to the NHS Board of residence 
for colonoscopy.  
 
4.4.5. Study Groups  
 
Individuals with f-Hb ≥ 400 ng Hb/ml buffer were referred for colonoscopy. 
Data on colonoscopy outcomes and any subsequent pathology in the 
participants with positive results were downloaded from the appropriate 
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NHS Tayside and NHS Ayrshire & Arran clinical IT systems for colonoscopy 
and pathology (Group 1).  
 
Data on clinical outcomes for NHS Fife and NHS Forth Valley were provided 
by Information Services, NHS National Services Scotland (Group 2). Data 
on clinical outcomes for an identical period of time, at the same time of year, 
before the study (01 July 2009 to 12 January 2010) were collected as 
described above for NHS Tayside and NHS Ayrshire & Arran (Group 3). 
Similarly, data on clinical outcomes for an identical period, immediately after 
the study, (13 January 2011 to 27 July 2011) were collected for NHS 
Tayside and NHS Ayrshire & Arran (Group 4). The makeup of the groups is 
shown in Table 15. 
 
Table 15 Identification of Groups used for analysis of clinical outcomes (in chronological order) 
showing time periods, NHS Boards and screening algorithms in use 
 
01 July 2009 - 12 January 2010 
Group 3 
 NHS Tayside – three pilot rounds and into 2nd round of SBoSP 
 NHS Ayrshire & Arran - 2 months into prevalence round of screening, 4½ months 1st  
incidence round of SBoSP 
 gFOBT/FIT two-tier reflex algorithm 
01 July 2010 – 12 January 2011 
Group 1* 
 NHS Tayside – three pilot rounds and into 2nd round of SBoSP 
 NHS Ayrshire & Arran – 1st incidence round of SBoSP 
 FFLT algorithm 
Group 2 
 NHS Fife – three pilot rounds and into 2nd round of SBoSP 
 NHS Forth Valley – 1st incidence round of SBoSP 
 gFOBT/FIT two-tier reflex algorithm 
13 January 2011 - 27 July 2011 
Group 4 
 NHS Tayside  - three pilot rounds and into 2nd/3rd round of SBoSP 
 NHS Ayrshire & Arran - 1st incidence round of SBoSP 
 gFOBT/FIT two-tier reflex algorithm 
* Evaluation Group 
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4.4.6. Statistical Analysis  
 
Data on sex and age were determined from the CHI number. Number, size 
and location of CRC and adenomas were recorded. Assignment to outcome 
groups was as recommended by the British Society of Gastroenterology 
(BSG) (48), but also in accordance with the protocol for patient follow-up 
used in Scotland in that the higher (high and Intermediate) risk adenoma 
(HRA) group was based on combining the intermediate and high-risk groups 
identified by the BSG. 
 
Assuming a 60% uptake, the participants in this study were expected to 
generate 840 colonoscopies at 2.1% positivity. With the current algorithm, 
this would be expected to detect about 80 CRC and 300 adenoma cases. 
Overall, these numbers were sufficient to detect, with 85% power, an 
increase in uptake from 55% to 60%, an increase in CRC detection rate 
from 0.07% to 0.17% and an increase in PPV from 7.5% to 10.0%. 
 
Statistical analysis of uptake was undertaken by comparing those invited 
during the FIT study period and the corresponding six month time periods 
from previous and subsequent years in the comparator NHS Boards. Chi-
squared tests were used to assess the change in uptake during the FIT 
study period compared with uptake in the other time periods combined and 
weighted. MedCalc (MedCalc Software, Mariakerke, Belgium) statistical 
software was used for all calculations. Probability of p<0.05 was considered 
significant. 
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4.5 Results 
 
The results recorded reflected the programme KPI’s discussed earlier in the 
Chapter. 
 
4.5.1 Number of Invitations Sent Out and Sample Devices 
Returned  
 
Study kits were mailed to participants from 1 July 2010 and ceased to be 
sent to participants on 12 January 2011. The number of packs [flow-pack 
with sample collection device, return envelope and zip-lock bag, IfU and the 
Know the Facts leaflet] sent out from the SBoSC as initial invitations was 
66,225 of those 40,125 were returned.  
 
Uptake  
Uptake, defined as the percentage of invitees (66,225) who completed their 
cycle with a positive or negative test result (38,720), was 58.5%. In 99.2% 
of cases the sample was analysed three or fewer days after receipt of 
sample: 93.3% were analysed on the day of receipt. 
 
Before and after the study period uptake in the four NHS Boards was 
recorded for periods of six calendar months. Data for the Study Boards has 
been truncated to 31 December 2010 to match the rest of the data 
presented. This gave uptake for three different periods as shown in Table 
16. The p-values demonstrate that the uptake was significantly higher 
during the FFLT evaluation period in NHS Tayside and NHS Ayrshire & 
Arran than during the time periods before and after. 
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Table 16 Uptake (%) in four NHS Boards for three six-month periods. (FIT Study group in bold.) 
 Tayside Ayrshire & Arran Fife Forth Valley 
01 Jul 2009 – 31 Dec 2009     
Invited 37275 31713 30685 21972 
Accepted (%) 20764 (55.7) 16491 (52.0) 16311 (53.2) 11640 (53.0) 
01 Jul 2010 – 31 Dec 2010     
Invited 32195 30570 29397 22881 
Accepted (%) 19600 (60.9) 17742 (58.0) 15425 (52.5) 11626 (50.8) 
01 Jul 2011 - 31 Dec 2011     
Invited 37153 32450 30938 22898 
Accepted (%) 20274 (54.6) 16790 (51.7) 16044 (51.9) 11848 (51.7) 
p-value <0.0001 <0.0001 0.102 0.036 
 
NHS Tayside and NHS Fife were compared since both NHS Boards participated 
in the screening pilots, they are of a similar size and have similar population 
demographics. NHS Ayrshire & Arran and NHS Forth Valley did not participate 
in the early pilot rounds of screening and have similar populations (144). Figure 
20 and 21 show comparisons of uptake in each of the two NHS Board groups. 
 
Figure 20 Comparison of uptake (%) in NHS Tayside and NHS Fife before, during and after the study 
period 
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Figure 21 Comparison of uptake (%) in NHS Ayrshire & Arran and NHS Forth Valley before, during 
and after the study period 
 
This is the first time that it has been shown that uptake rates fall back to previous 
levels with the reintroduction of the gFOBT/FIT algorithm. 
 
Untestable Samples 
Participants who return samples to the SBoSL may return samples that are 
untestable. These fall into the following categories: spoiled, expired, 
unused, incomplete and technical fail. The return rate for repeat samples 
was more than 80% in each category, as shown in Table 17. This is higher 
than the uptake of the initial screening tests, irrespective of whether gFOBT 
or quantitative FIT.  
 
Experience in the SBoSP indicates that the return rate of the reflex 
qualitative FIT is approximately 95%, which again is higher than uptake for 
the initial screening test. 
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Table 17 Return of repeat ‘untestable’ sample devices 
Expired     Non-Technical Fail    Spoiled    
Condition Number % Condition Number % Condition Number % 
Returned 1134 86.1 Returned 34 94.0 Returned 41 83.0 
Not returned 171 13.0 Not returned 2 5.6 Not returned 8 16.3 
Total 1305   Total 36   Total 49   
Negative 1051 80.2 Negative 34 94.4 Negative 31 63.3 
Positive 32 2.4 Positive 0 0.0 Positive 3 6.1 
Expired 40 3.1 Expired 0 0.0 Expired 1 2.0 
Spoiled 4 0.3 Spoiled 0 0.0 Spoiled 6 12.2 
Closed 167 12.7 Closed 2 5.6 Closed 8 16.3 
Returned 0 0.0 Returned 0 0.0 Returned 0 0.0 
Not Returned 3 0.2 Not Returned 0 0.0 Not Returned 0 0.0 
Others 8 0.6 Others 0 0.0 Others  0 0.0 
Total 1305   Total 36   Total 49   
 
 
Further Outcomes 
A major rationale for the study was to evaluate whether FFLT could be 
delivered within the context of the SBoSL. Aspects of service delivery that 
were tested during the study were staff training, set-up and maintenance of 
analysers and turnaround times for results. Overall, the planning and 
delivery of the evaluation went smoothly with no major problems. Over 99% 
of results were reported within three days of receipt in the Laboratory.  
 
The vast majority of participants received an unequivocal result in less than 
two weeks from sample collection. 98% of SFIT were returned within 10 
days of the sampling date. This would have been higher if not for the 
extreme adverse weather in November 2010. A detailed report regarding all 
laboratory outcomes is included in Appendix 3.  
 
There were very few calls to the Helpline regarding SFIT and its use: 205 
calls from the 66 225 invitations issued (0.3% compared to 6% with the 
current gFOBT/FIT algorithm). Focus group work found that the pictorial and 
written instructions for use were very clear. Participants seemed to find the 
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single stool sampling method and sampling process straightforward. The 
analysis of helpline activity is shown in Appendix 4. 
 
 
4.5.2 Characteristics of Those Who Returned a Sample 
Device 
 
The number and percentages of participants with a positive test result 
stratified into 5-year age groups are shown in Table 18 for Groups 1, 3 and 
4: similar data for Group 2 were unavailable. As expected, the proportion of 
participants receiving a positive test result increased with increasing age 
and was higher in males than in females when the non-stratified totals are 
compared. 
Table 18 Number (%) of participants with a positive test result by sex and age. * indicates the 
evaluation Group 
 Group 1* Group 2 Group 3 Group 4 
Total 943  736 732 626 
Males 532 (56.4) 401 (54.5) 443 (60.5) 376 (60.1) 
Females 411 (45.6) 335 (45.5) 289 (39.5) 250 (39.9) 
50-54 years 151 (16.0) n/a 99 (13.5) 88 (14.1) 
55-59 years 189 (20.0) n/a 139 (19.0) 129 (20.6) 
60-64 years 173 (18.3) n/a 131 (17.9) 129 (20.6) 
65-69 years 206 (21.8) n/a 168 (23.0) 136 (21.7) 
70-74 years 224 (23.6) n/a 195 (26.6) 144 (23.0) 
n/a data were unavailable from Information Services Division, NHS National Services Scotland 
 
The effects of deprivation and sex on Group 1 are illustrated below, Figure 
22. As expected from SBoSP data, uptake fell with increasing deprivation 
and was greater in women than in men. Uptake ranged from 45.8% in the 
most deprived males up to 69.9% in the least deprived females.  
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Figure 5 Uptake and Scottish Index of Multiple Deprivation (SIMD) quintile of Group 1 
 
 
A higher percentage of males had a positive result than females in every 
deprivation quintile and positivity was at its lowest in the least deprived and 
highest in the most deprived as shown in Figure 23. The least deprived 
females, therefore, had the lowest positivity, at 1.6%, which was less than 
half of that of the highest positivity which was found amongst the most 
deprived males, at 3.5%. 
 
Figure 23 SIMD Quintile of participants who received a positive test result 
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Interestingly, however, there was no effect of deprivation on pathology, 
Figure 24, whereas a negative association with increasing deprivation has 
been demonstrated with gFOBT (145). It can be seen that uptake was 
higher in both sexes and all deprivation categories than has been observed 
with gFOBT in either of the evaluation NHS Boards.  
 
Figure 24 SIMD quintile showing colonoscopy outcome in evaluation group 
 
 
 
4.5.3 Clinical Outcomes of Those with a Positive Test Result 
 
A complete data set was collected for those patients with a positive test 
result and this is shown in Table 19. This demonstrates that the clinical 
outcomes of those who participated in the evaluation (Group 1) was 
essentially the same as in the three other Groups. It is worth noting that the 
PPV for CRC was lower for Group 1 participants (4.8%) than Group 3 
participants (7.7%) – p = 0.0291 – this is because in newly  screened 
populations areas there is a higher prevalence of disease than in a screened 
and treated population. Screening followed by action reduces the 
prevalence of the disease in the target population. 
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There were 943 participants with a positive test result in Group 1, 453 
(48.0%) from participants in NHS Tayside and 490 (52.0%) from participants 
in NHS Ayrshire & Arran, For Group 2, there were 736 positive results, 383 
(52.0%) from NHS Fife and 353 (48.0%) from participants in NHS Forth 
Valley. For Group 3, there were 732 positive results, 374 (51.1%) from NHS 
Tayside and 358 (48.9%) participants from NHS Ayrshire & Arran. For 
Group 4, there were 626 positive results, 280 (44.7%) from participants in 
NHS Tayside and 346 (55.3%) from participants in NHS Ayrshire & Arran in 
the prevalent screening round.  
 
Essentially, the quantitative FIT performed as expected when taking into 
account the effect of participants completing various rounds screening in 
the Groups. The prevalent screening round encompasses 100% of 
individuals who have never undertaken screening. Incident rounds are the 
subsequent screening rounds: in such rounds a small number, 50 year olds 
and others new to screening will be in a prevalent round for them. 
Table 19 Clinical outcomes in participants with a positive test result 
    Group 1 Group 2 
   Total Males Females Total Males Females 
   n (%) n (%) n (%) n (%) n (%) n (%) 
Participants with 
positive result 
943  532  411  736  401  335  
No investigations 
/incomplete 
investigations/outcome 
unknown/excluded 
129 (13.7) 73 (13.7) 56 (13.6) 130 (17.7) 65 (16.2) 65 (19.4) 
Investigations 
completed 
814 (86.7) 459 (86.6) 355 (86.8) 606 (82.3) 336 (83.8) 270 (80.6) 
Clinical Outcomes n PPV n PPV n PPV n PPV n PPV n PPV 
       CRC 39 4.8 23 5.0 16 4.5 33 5.4 19 5.7 14 5.2 
  High-risk adenoma 
(HRA) 
190 23.3 127 27.7 63 17.7 115 19.0 80 23.8 35 13.0 
  CRC + HRA 229 28.1 150 32.7 79 22.3 148 24.4 99 29.5 49 18.1 
  All adenoma 311 38.2 205 44.7 106 29.9 217 35.8 139 41.4 78 28.9 
  
Total neoplasia 
(CRC + all 
adenoma) 
350 43.0 228 49.7 122 34.4 250 41.3 158 47.0 92 34.1 
  Hyperplastic polyps 64 7.9 40 8.7 24 6.8 - - - - - - 
  
Normal/Other 
pathology (IBD, 
DD, 
angiodysplasia, 
haemorrhoids etc,) 
400 49.1 191 41.6 209 58.9 - - - - - - 
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    Group 3 Group 4 
   Total Males Females Total Males Females 
   n % n % n % n % n % n % 
Participants with 
positive result 
732  443  289  626  376  250  
No investigations 
/incomplete 
investigations/outcome 
unknown/excluded 
80 (10.9) 45 (10.2) 35 (12.1) 84 (13.4) 58 (15.4) 26 (10.4) 
Investigations 
completed 
652 (89.8) 398 (90.5) 254 (88.8) 542 (86.6) 318 (84.6) 224 (89.6) 
Clinical Outcomes n PPV n PPV n PPV n PPV n PPV n PPV 
  CRC 50 7.7 35 8.8 15 5.9 38 7.0 26 8.2 12 5.4 
  High-risk adenoma 
(HRA) 157 24.1 114 28.6 43 16.9 120 22.1 88 27.7 32 14.3 
  CRC + HRA 207 31.7 149 37.4 58 22.8 158 29.2 114 35.8 44 19.6 
  All adenoma 252 38.7 181 45.5 71 28.0 190 35.1 130 40.9 60 26.8 
  
Total neoplasia 
(CRC + all 
adenoma) 
302 46.3 216 54.3 86 33.9 228 42.1 156 49.1 72 32.1 
  Hyperplastic polyps 58 8.9 40 10.1 18 7.1 32 5.9 19 6.0 13 5.8 
  
Normal/other 
pathology (IBD, 
DD, 
angiodysplasia, 
haemorrhoids etc,) 
292 44.8 142 35.7 160 63.0 284 52.4 143 45.0 141 62.9 
-   these data were unavailable from Information Services Division, NHS National Services Scotland 
 
 
This affects the amount of disease detected, Figure 25 shows disease 
detection was greatest in the historic NHS Tayside and NHS Ayrshire & 
Arran gFOBT/FIT group and least in the same NHS Boards after the study 
period. The Group 1 lie between these two groups in chronology and 
magnitude. 
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Figure 25 Percentage of participants in each clinical outcome group 
 
 
4.5.4 Clinical Outcomes at 2.1% Positivity 
 
Having complete data for the 2.4% of Group 1 referred for colonoscopy 
means these are available to analyse the outcomes if the positivity was set 
at 2.1% as per the SBoSP planning assumptions. In this scenario, 775 of 
the 943 actually referred would have positive results. Taking the 775 
participants with the highest f-Hb in the FFLT evaluation and looking at F-
Hb would mean changing the f-Hb cut-off to 526 ng Hb/ml buffer. Clinical 
outcomes of the 168 participants who were positive in the FFLT evaluation 
with f-Hb above 400 ng Hb/ml buffer but below 526 ng Hb/ml buffer, are 
shown in Table 20. Table 21 shows the clinical outcomes of the 775 
participants who would be deemed positive using the 526 ng Hb/ml buffer 
cut-off and Table 22 shows, for comparison, the overall outcomes seen with 
the actual Group 1 participants with the cut-off at 400 ng Hb/ml buffer 
(positivity: 2.4%). 
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Table 20 Outcomes where f-Hb is 400 – 526 ng Hb/ml buffer 
 
Table 21 Outcomes where f-Hb is ≥ 526 ng Hb/ml buffer 
 
Table 22 Outcomes where f-Hb is ≥ 400 ng Hb/ml buffer 
 
PPV for CRC and HRA are lower in the group with f-Hb 400 – 526 ng Hb/ml 
buffer than in the group with f-Hb above 526 ng Hb/ml buffer that would give 
the 2.1% positivity (2.0% and 15.2% compared with 4.8% and 23.3%, 
respectively), although raising the f-Hb cut-off would mean three CRC and 
  Males Females Both sexes 
  n % n % n % 
Positive test result 90  78  168  
No investigations/ Outcome unknown /Excluded 5 5.6 12 15.4 17 13.7 
Investigations completed 85 94.4 66 84.6 151 89.9 
Clinical Outcomes       
Total neoplasia 41 48.2 21 31.8 62 41.1 
All adenoma 38 44.7 21 31.8 59 39.1 
Higher risk adenoma (HRA) 17 20.0 6 7.7 23 15.2 
CRC + HRA 20 23.5 6 7.7 26 17.2 
CRC 3 3.5 0 0 3 2.0 
   Males Females Both sexes 
   n % n % n % 
Positive test result 442  333  775  
No investigations/ Outcome unknown/Excluded 68 15.4 44 13.2 112 14.5 
Investigations completed 374 84.6 289 86.8 663 85.5 
Clinical Outcomes       
Total neoplasia 187 50.0 101 34.9 288 43.4 
All adenoma 167 44.7 85 29.4 252 38.0 
Higher risk adenoma (HRA) 110 29.4 57 19.7 167 25.2 
CRC + HRA 130 34.8 73 25.3 203 30.6 
CRC 20 5.3 16 5.5 36 5.4 
   Males Females Both sexes 
   n % n % n % 
Positive test result 532  411  943  
No investigations/ Outcome unknown/Excluded 73 13.7 56 13.6 129 13.7 
Investigations completed 459 86.3 355 86.4 814 86.3 
Clinical Outcomes       
Total neoplasia 228 49.7 122 34.4 350 43.0 
All adenoma 205 44.7 106 29.9 311 38.2 
Higher risk adenoma (HRA) 127 27.7 63 17.7 190 23.3 
CRC + HRA 150 32.7 79 22.3 229 28.7 
CRC 23 5.0 16 4.5 39 4.8 
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23 HRA would have been missed in this group. The three CRC that would 
not have been detected were one rectal cancer with Dukes’ stage C1, one 
Dukes’ B rectal cancer and one 7 mm diameter polyp CRC located in the 
sigmoid colon. 
 
4.6 Discussion and Conclusions 
 
The overall uptake of the FIT (58.5%) was greater than that achieved 
throughout the three pilot screening rounds undertaken in Scotland, which 
used gFOBT only (46). The KPIs for the SBoSP, which uses the two-tier 
gFOBT/FIT algorithm, provide benchmarking for uptake and clinical 
outcomes of screened individuals. The data available for the period 01 
November 2008 to 31 October 2010 show uptake was 53.7% overall in 
Scotland and 53.1% in NHS Ayrshire & Arran and 58% in NHS Tayside 
(108). Uptake during the FFLT study rose by 5.2% and 6.0% in the NHS 
Boards, respectively. Attainment of this increase meets one of the goals of 
the evaluation in assessing introduction of a new test modality on the 
effectiveness of a fully rolled out SBoSP. In addition, the data gathered 
showed that, when the study ended, uptake fell to similar values to those 
previously seen with the current algorithm. The two NHS Boards in which 
FIT was not used had small changes in uptake over time but did not have 
the important rise in participation seen with use of the quantitative FIT.  
 
It is not surprising that uptake with a single sample collection device is 
higher than that in the SBoSP which uses gFOBT as an initial test since 
gFOBT require two samples from each of three faeces and, although, those 
with five or six windows positive are referred directly for colonoscopy, 
whereas those with one to four windows positive are required to undertake 
another test. This finding is similar to the results found in other studies 
comparing uptake with gFOBT and FIT (146). 
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Development of the study materials necessitated making changes to the 
information sent to participants. This presented an opportunity to develop a 
different style of communication and a pictogram was devised to be 
displayed on the A5 sized wallet containing the sample collection device. 
This new packaging style may have seemed modern and appealing and 
may well have contributed to the increase in uptake. The number of 
participants who were unable to complete their test kit was lower in the study 
group than in the SBoSP as were the number of calls to the helpline. 
Unfortunately, it was not possible to evaluate the psycho-social aspects of 
the information for users during the study: however, these very positive 
findings provide support for the widely-held view that more user-friendly 
faecal collection devices and sampling regimes encourage participation in 
screening programmes. Further analysis of sample return rates showed a 
significant increase in uptake in the most deprived groups and particularly 
in deprived males. Although, Symonds et al state that ‘It is concerning that 
the lowest participation rates for FIT screening occur in males and those 
who are more socio-economically deprived’, increased uptake in these 
groups may be considered a benefit from moving to FIT (141). 
 
In line with previous findings in bowel screening pilots and programmes 
using faecal tests, males accounted for a higher percentage of positive test 
results than females in all four Groups. The percentages of positive test 
results in each five year age group for Groups 1, 3 and 4 are shown in 17. 
In the three study groups, the highest proportion of positive results was in 
the 70-74 years of age quintile and, in general, positivity increased with age 
in both sexes. It is also known that incidence of CRC is affected by sex and 
age and the potential consequences of these relationships have been 
published in detail (1) (2). It may be that different f-Hb cut-off or different 
screening intervals should be applied for the different sexes and ages: this 
is discussed in more detail in Chapter 5. 
 
109 
  
Since this evaluation was performed in the context of a fully rolled-out 
operational screening programme, those participants who had results below 
the chosen f-Hb cut-off (400 ng Hb/ml buffer) were not investigated further. 
This is in contrast to the two randomised controlled trials performed in The 
Netherlands (118) (147) (148) and in some other studies (149) (150). Such 
studies have shown that, at the lower f-Hb cut-off used, positivity for FIT 
were higher than for gFOBT and, when reported, sensitivity was higher for 
FIT than gFOBT, although the specificity was lower. Thus, the gain in 
disease detected was offset by the number of false positive test results. It 
has been well documented that the sensitivity increases and the specificity 
decreases as the f-Hb cut-off concentration is lowered: the gain is mainly in 
detection of advanced neoplasia (122) (137) (147). 
 
The PPV of the screening strategy is a vital characteristic of any 
programme. PPV has been shown to increase and positivity decreases as 
the cut-off f-Hb is increased (148) (149). The results in Table 18 
demonstrate that there is very little difference between the four Groups and 
that the pathology found with the evaluation Group was similar to that 
achieved with the gFOBT/FIT two-tier reflex screening algorithm.  
 
This finding was not unexpected since the f-Hb cut-off selected was 
designed to give the same positivity for both approaches. If the benefits of 
FIT for detection of adenomas in particular (120) are to be achieved, then a 
lower cut-off would be required, a greater colonoscopy resource would have 
to be available and the programme would have to be prepared to deal with 
lower specificity with a greater number of false positive test results, as 
shown by the decrease in PPV that occurs as f-Hb cut-off is lowered (151). 
 
Progression through rounds of screening should reduce the likelihood of 
finding disease as it is detected and treated, round by round. Therefore, the 
differences in stage of screening between the Groups means that 
comparison of PPV between the Groups comes with some caveats. Group 
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3 included some NHS Ayrshire & Arran participants in prevalence screening 
and, upon further examination of this group, the PPV was found to be 
statistically significantly higher (p < 0.05) for those in the two months in 
prevalence screening than those in the 4½ months of incidence screening 
for CRC + HRA (50.0% and 31.4%), HRA (41.7% and 23.5%), and total 
neoplasia (60.4% and 53.6%).  
 
Those invited within the prevalence round accounted for 20.6% of the NHS 
Ayrshire & Arran participants in Group 3 but had 35.0% of the CRC and 
34.2% of the HRA detected. This may explain the higher PPV for all clinical 
outcomes in Group 3 compared to Group 1 participants: however, this does 
not explain the high PPV for CRC in Group 4. It is of note that Group 1 
compares favourably with regard to adenoma detection and Groups 3 and 
4 with regard to normal/other pathology outcomes. These data show that 
the clinical outcomes using quantitative FIT with a high f-Hb cut-off are 
similar to those gained with gFOBT and gFOBT/FIT approaches. 
 
One of the constraints of the study is that it was performed in 2 of the 14 
NHS Boards in Scotland. Data presented in this Chapter suggest that 
screening round affects clinical outcomes, but there is the further 
consideration of social and geographical factors, particularly deprivation as 
determined by postcode and Scottish Index of Multiple Deprivation (SIMD). 
Across Scotland there is variation in SIMD, and the NHS Boards 
participating in this study may be considered to represent a general picture 
(144). However there is a variation in the SIMD, diet and health choices in 
each board area. Geographical variation has been reported in a comparison 
of f-Hb in Scotland, Taiwan and Italy (151). 
 
Chaing et al. (152) investigated whether there are differences in the 
performance characteristics of different analytical platforms. Data from the 
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Taiwanese Nationwide CRC Screening and Taiwan Cancer Registry was 
used to evaluate the short-term and long-term performance characteristics 
of two FIT analysers used in a screening setting, OC-Sensor (Eiken 
Chemical Co, Tokyo, Japan) and HM-Jack ( Kyowa Medex Co Ltd, Tokyo, 
Japan).The f-Hb cut-off were set to give a positive result at 20 µg Hb/g 
faeces. When measuring the short term indicators, including, PPV for CRC, 
cancer detection rate and the interval cancer rate the OC-Sensor performed 
better than the HM-Jack. PPV was 6.8% and 5.2% in each analytical system 
and cancer detection rate was 0.21% and 0.17% respectively. The interval 
cancer rate, was 30.7 v 40.6 per 100,000 person years.  
 
The study used data from 2004 to 2009, this provided an opportunity to 
calculate mortality, a long term indicator of the effectiveness of a screening 
programme. The hazard ratio for crude rates was 1.21 (95% CI, 0.91 – 1.61) 
for the whole cohort and reduction in mortality of 11% (95% CI, 6 – 16%) 
when comparing participants and nonparticipants. These outcomes were 
not significantly different between the two analysers. The difference in 
outcomes in the short-term and lack of difference in long-term indicators is 
not what would be expected and it may be that given more time any 
difference in long term outcomes will increase in magnitude. 
 
Another of the limits of the evaluation of FFLT in the context of the SBoSP 
was that data were not available to determine the effects of variables other 
than age, gender and deprivation on screening outcomes. A recent 
retrospective analysis of screening and surveillance FIT results by Symonds 
et al. (141) found that f-Hb was higher in men and increased with age and 
deprivation. In addition, this group also investigated the effect of previous 
screening participation, seasonal variation in ambient temperature and time 
from sample to test. The study found that during summer months (when 
temperatures in Australia were on average 280C), test positivity and f-Hb 
were significantly lower than during the cooler months. This did not affect 
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the detection of significant neoplasia, but did affect the detection rates of 
LRA as the f-Hb associated with these is near the cut-off. A further finding 
was a significant relationship between previous participation in screening 
and lower f-Hb and positivity. If screening programme providers are to fully 
realise the effectiveness of population screening further analysis of 
environmental, health and social factors is required. 
 
In conclusion, uptake was higher than with the current screening algorithm 
and returned to usual levels when participants in the NHS Boards were 
invited with FIT were switched back to the current gFOBT/FIT algorithm. 
Untestable FIT due to spoiled, unlabelled and undated collection devices 
were lower than with the gFOBT/FIT algorithm. Calls to the helpline were 
lower. The quantitative nature of the analyses allows consistency of testing 
and permits modification of the f-Hb cut-off used - perhaps to allow for 
colonoscopy capacity. The increased uptake, ease of use for participants 
and favourable clinical outcomes of this feasibility study all support the 
introduction of FFLT in the SBoSP. 
 
There is now evidence that FIT perform better than gFOBT (143) and an 
ever-growing number of countries are employing FIT as the screening 
modality. The European Group on Tumour Markers (EGTM) presented an 
updated paper detailing the current position in screening for CRC (27). 
There are nine different organisations that recommend national screening. 
However amongst this group there are a wide variety of modalities 
suggested. Furthermore, the International Agency for Research into Cancer 
(IARC) has recently published new guidelines for quality assurance in CRC 
screening, and these recommend the use of a quantitative FIT as the 
screening test of choice (31). 
 
 
113 
  
CHAPTER 5: f-Hb Partitioned by Sex and Age 
 
5.1 Introduction 
 
Screening the asymptomatic population for significant colorectal neoplasia, 
that is, CRC and HRA, has generated much interest over recent years. 
There are differences in approaches between countries (29), but the use of 
faecal tests is widespread, based on the findings of population-based RCT 
using gFOBT which demonstrated reductions in disease-specific mortality 
(43). 
 
It has been documented in Scottish (46) (145), English (107) (153) and 
French (154) screening programmes that sex and age affect key 
performance indicators, including positivity. Although significant neoplasia 
is more common in men and older people, analysis of quantitative FIT data 
could be used to determine how f-Hb changes when certain important 
population characteristics are studied.  
 
5.2 Aim of the Study 
 
Current evidence supports the view that quantification of f-Hb in 
individuals is warranted (155). Laboratories commonly use sex and age 
partitioned reference values which describe 95% of the selected 
population, facilitating clinical interpretation of results. Guidance on how to 
do this is set out by the Clinical Laboratory Standards Institute (CLSI) in 
guidelines on how to define and determine reference intervals (156) (157).  
Similarly, it may be that different cut-off or decision making tools using f-Hb 
could be used as the criteria for further investigation for different groups. In 
this study f-Hb, in a large cohort of individuals aged 50-74 years, the age 
group invited to take part in the SBoSP, were investigated. Potential 
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reference values were devised using the most recent international CLSI 
guidelines. The likely implications for CRC screening programmes of using 
decision limits based on different f-Hb in men and women and in different 
age quintiles were examined. 
 
Estimation of f-Hb in a large group of ostensibly asymptomatic people 
prompted analysis of the data to see if patterns in sex, age and uptake of 
screening were present. The aim of this analysis was to investigate potential 
reference values. Those who returned a testable faecal sample were 
defined as the reference population. The usual SBoSP exclusion criteria 
were applied. 
 
5.3 Methods 
 
In order to determine whether the new FIT method would benefit a 
screening population a study of feasibility was undertaken in a selected 
group already eligible for the current SBoSP. Scotland has been offering 
screening to men and women between the ages 50 – 74 years since June 
2007. The rollout proceeded as NHS Boards were able to meet the 
additional colonoscopy demand. The algorithm used consists of inviting 
participants with a gFOBT kit when potential participants reach 50 years of 
age or are in the target age range and become eligible on receiving a 
Community Health Index (CHI) number (Appendix 5). When the gFOBT kit 
is returned to the SBoSL and the test result is returned as positive the 
participant is offered colonoscopy. Where a weak positive or spoiled result 
is obtained the participant is sent a qualitative FIT test. If this is positive, the 
participant is referred for colonoscopy (Appendix 6). Where there is a 
negative test result, the participant is informed by letter and re-invited in two 
years. 
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5.3.1 Statistical Analysis  
 
Potential reference intervals were calculated for men and women and for 
both sexes in quintiles according to the CLSI Approved Guideline C28-A3c 
(157). The percentage of positive test results that would be obtained at a 
number of f-Hb were calculated from the cumulative percentage 
distributions. The number and percentages of individuals who would fall into 
the risk categories of Chen et al (158), namely, low, intermediate, high, and 
extremely high risk groups were defined using faecal concentrations of 1–
19, 20–39, 40–79 and 80–99 ng Hb/ml buffer, respectively, were estimated 
from the distributions. MedCalc (MedCalc Software, Mariakerke Belgium) 
statistical software was used for all calculations.  
 
5.4 Results 
 
The number of people invited to participate in the study was 66,225: 48.8% 
were men and 51.2% women. Some participants returned a sample that 
was untestable due to being received more than 10 days after collection of 
faeces or spoiled in some way. Participants who returned such a sample 
were offered the chance to participate again with a further kit sent to them. 
The total number of specimen collection kits sent out during the study period 
was 68,041; this includes requests for repeat samples. The number who 
responded by returning a kit was 40,125 and thus the uptake was 60.6%. 
Of these, the reference sample group comprised 38,720 in total: 18058 men 
(46.6%) and 20,662 women (53.4%) who returned a testable sample and 
therefore received a negative or positive test result. Final uptake for the 
study group was therefore 58.5%. Figure 26 shows the distribution of Hb for 
men and women. 
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Figure 26 Distribution of f-Hb in 40,000 screening participants 
 
 
It is usual practice in CRC screening to divide the population into quintiles. 
For men and women and for each of the age quintiles, none of the 
distributions of data were Gaussian (D’Agostino-Pearson test, P < 0.0001) 
and, in all cases, the coefficients of skewness and kurtosis were significantly 
greater than 1.00 (P < 0.0001). Tables 23 and 24 show that more females 
returned a kit than males (53.4%:46.6%). They also tabulate the 
distributions of f-Hb for men and women in five age groups with the 
conventional 95% CI. The 97.5% percentile represents the potential non-
parametric upper reference limit of the 0.95 inter-fractile reference interval 
and 90% CI are given as recommended in Clinical and Laboratory 
Standards Institute (CLSI). 
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Table 23 Percentiles (with 95% CI) of f-Hb (ng Hb/ ml buffer) in men and potential upper reference 
limits (with 90% CI) 
Age 
range 
(years) 
N (%) 25.0% 50.0% 75.0% 90.0% 95.0% 
97.5% 
URL 
50-75 18058 
0  
(0-0) 
1  
(1-1) 
12  
(12-13) 
67  
(61-73) 
184  
(175-213) 
519  
(468-575) 
50-54 
4075 
(21.9) 
0  
(0-0) 
0  
(0-0) 
7  
(7-8) 
35  
(29-41) 
104  
(91-127) 
281  
(234-368) 
55-59 
4160 
(23.0) 
0  
(0-0) 
0  
(0-0) 
9  
(9-10) 
48  
(41-57) 
154  
(127-18t) 
415  
(340-478) 
60-64 
3489 
(19.3) 
0  
(0-0) 
1  
(0-1) 
12  
(11-13) 
62  
(50-73) 
185  
(159-226) 
520  
(411-663) 
65-69 
3497 
(19.4) 
0 
(0-0) 
2  
(2-3) 
17  
(15-20) 
98  
(87-112) 
253  
(298-319) 
713  
(526-999) 
70-75 
2837 
(15.7) 
0  
(0-0) 
3  
(3-4) 
21 
(19-24) 
125  
(104-149) 
347 ( 
632-979) 
737  
(647-927) 
 
Table 24 Percentiles (95% CI) of f-Hb (ng Hb/ ml buffer) in women and potential upper reference 
limits (with 90% CI) 
Age 
range 
(years) 
N (%) 25.0% 50.0% 75.0% 90.0% 95.0% 97.5% URL 
50-75  20662 
0  
(0-0) 
0  
(0-0) 
9  
(8-9) 
38  
(35-41) 
114 
(106-121) 
283  
(257-316) 
50-54  
4543 
(22.0) 
0  
(0-0) 
0  
(0-0) 
6 
(6-7) 
23  
(20-26) 
68  
(53-80) 
170 
(142-248) 
55-59  
4730 
(22.9) 
0 
(0-0) 
0  
(0-0) 
7  
(6-8) 
31 
(27-34) 
92  
(76-115) 
244  
(191-310) 
60-64  
4058 
(19.6) 
0  
(0-0) 
0  
(0-0) 
8  
(7-9) 
34 
(30-38) 
101  
(87-117) 
235  
(184-313) 
65-69  
3985 
(19.3) 
0  
(0-0) 
0 
(0-0) 
10  
(10-11) 
45 
 (40-53) 
129  
(112-151) 
317  
(254-418) 
70-75  
3346 
(16.2) 
0  
(0-0) 
0  
(0-0) 
15  
(14-17) 
80  
(67-95) 
190 
(157-243) 
533  
(409-675) 
 
 
Table 25 shows the positivity for men and women in the age quintiles at 
commonly used f-Hb cut-off (ng Hb/ml buffer) and the f-Hb cut-off to attain 
2.0% positivity. More males than females were reported as having a positive 
test result using a 400 ng Hb/ml buffer cut-off (56.4%:43.6%). 
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Table 25 Positivity (%) at commonly used f-Hb (ng Hb/ml buffer) and cut-off to attain 2.0% positivity 
for men and women 
Sex 
Age range  
(years) 
50  
 
75 
 
100 
 
200 
 
400 
 
Cut-off to give 
2.0%  
positivity  
 
Men 50-75  11.6 9.3 7.8 4.8 3.0 680 
 50-54  7.9 6.4 5,2 3.2 1.9 390 
 55-59  9.7 6.7 6,6 4.0 2.6 525 
 60-64  11.0 8.7 7.6 4.7 3.0 670 
 65-69  15.0 11.8 9.7 6.0 4.5 950 
 70-75  16.4 13.8 11.3 9.3 4.5 950 
Women 50-75  8.4 6.7 5.5 3.1 2.0 400 
 50-54  5.9 4.7 3.9 2.7 1.4 270 
 55-59  7.2 5.7 4.8 2.8 1.9 350 
 60-64  7.8 6.3 5.0 2.7 1.8 340 
 65-69  9.4 7.4 6.3 3.3 2.2 430 
 70-75  13.0 10.4 8.6 4.9 3.0 680 
 
The number of individuals who would fall into the risk categories of Chen et 
al (158) namely, low, intermediate, high, and extremely high risk groups 
defined using faecal concentrations of 0–19, 20–39, 40–79 and 80–99 ng 
Hb/ml buffer, respectively are shown in Table 26. 
 
Table 26 Percentage of individuals in low, intermediate, high, and extremely high risk groups (ng 
Hb/ml buffer) 
Sex Age 
range 
(years) 
Low risk 
0-19 
Intermediate risk 
20–39 
High risk 
40–79 
Very high risk 
80–99 
Men 50-75  80.3 6.3 4.3 1.2 
 50-54  85.6 5.1 3.1 1.0 
 55-59  83.5 5.4 3.6 0.9 
 60-64  80.2 6.9 4.4 0.9 
 65-69  76.1 6.8 5.6 1.6 
 70-75  73.9 7.9 5.4 3.1 
Women 50-75  84.6 6.9 3.3 0.8 
 50-54  88.9 4.3 2.4 0.5 
 55-59  86.2 5.2 3.1 0.6 
 60-64  85.6 5.6 2.8 1.0 
 65-69  82.6 6.4 3.9 0.5 
 70-75  77.9 7.1 4.9 1.4 
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5.5 Discussion and Conclusions 
 
This study examined the f-Hb in a large group of ostensibly asymptomatic 
people aged 50-75 years. Table 24 shows that men have higher f-Hb than 
women in all age quintiles. This is already known, but the reason for this sex 
difference is not known. Brenner et al (159) have documented some 
possibilities. Men have higher blood Hb than women but the population of 
women here is likely to be mainly post-menopausal when such sex 
differences are not so apparent; in addition, use of aspirin and non-steroidal 
anti-inflammatory drugs might be more common in men than women. A 
plausible explanation is that colonic transit time is faster in men than in 
women. As a result, more degradation of f-Hb passed into the gut before 
passing of faeces takes place may occur in women since f-Hb is very 
unstable (14). In addition, f-Hb increases with age in both men and women 
but the reasons for this are unclear.  
 
The question arises whether this large database should be used to create 
sex and age partitioned reference values for f-Hb. The non-parametric 
upper reference limits of the 0.95 inter-fractile reference interval were 
determined and, with 90% CI, are given in Table 22 and 23. The partitioned 
data was not able to be assessed against colonoscopy outcome in this study 
as it was not practicable within the constraints of the resources available.   
 
In this study, the reference sample group is large and represents men and 
women generally regarded as asymptomatic. Although f-Hb is related to 
stage of neoplastic disease, (140) (160) (161) a number of individuals with 
high f-Hb had no abnormalities on colonoscopy and no evidence of disease. 
However, it is known that adenoma and early CRC are associated with few 
if any symptoms. Moreover, the fact that FIT are of considerable value in 
screening and that much early neoplastic disease is detected in individuals 
who participate in screening programmes makes it likely that our reference 
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sample group does contain a mix of healthy individuals, some taking drugs 
which stimulate bleeding into the gut or inhibit clotting and those with 
neoplastic disease and a number with other bowel conditions such as non-
neoplastic polyps, inflammatory bowel disease, diverticular disease and 
haemorrhoids, all of which may cause bleeding into the gut. So, the question 
is – can population based reference values be set for f-Hb?  
 
Inspection of the distributions of data shown in Table 22 and 23 suggest 
that, for both men and women, at least 90% have f-Hb less than 100 ng 
Hb/ml buffer, the manufacturer’s recommended and most usual cut-off 
concentration used to refer individuals for the further investigation of bowel 
visualisation, usually colonoscopy. Indeed, more than half of the overall 
population screened have no detectable f-Hb. Thus, in spite of the accepted 
view that everyone has some blood in their faeces (162). It is postulated that 
the healthy individual has no detectable f-Hb and that any Hb present is not 
usual. In consequence, it is considered that population-based reference 
intervals for f-Hb, however established, would be of very limited value and 
that numerical decision limits should be applied in the screening setting and 
the data available here will be invaluable in setting these. 
 
The positivity that would be found for men and women in the age quintiles 
at f-Hb cut-off commonly used in screening programmes are shown in Table 
24. As expected, at any one concentration, the positivity found was higher 
for men than for women and was higher in older people than in younger 
people. This data can be used to predict positivity, the data given in Table 
20 shows the f-Hb projected to gain a positivity of 2.1%, the ideal for the 
SBoSP since colonoscopy is a scarce resource in Scotland. Thus, although 
it is well known that men have more colorectal disease than women and 
such disease is much more common in the elderly, the use of a single f-Hb 
cut-off, as is current practice, in all screening programmes, is far from 
optimal. At any one cut-off, the distributions of f-Hb mean that more men 
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and older people will be referred for further investigation. The evidence 
presented here supports the recently stated view that there is a need for 
more tailored screening strategies (163).  
 
Diagnostic laboratories commonly use sex and age partitioned reference 
values for other investigations. Similarly, it might be that different f-Hb cut-
off should be used as the criteria for further investigation for men and 
women and different age quintiles. Because these data were generated in 
an ongoing national screening programme, colonoscopy was not performed 
in our entire reference sample group. However, what is needed to take this 
proposal forward is detailed evidence on the burden of disease in the groups 
labelled as positive and negative so as to examine objectively the use of 
sex partitioned decision limits in bowel screening programmes based on f-
Hb.   
 
An important study by Chen et al (158) investigated f-Hb below the usual 
cut-off concentration of 100 ng Hb/ml buffer as a predictor of incident 
colorectal neoplasia. f-Hb at first screening did predict subsequent risk of 
incident colorectal neoplasia. Table 25 shows the percentage of men and 
women in the age quintiles the population according to the low, 
intermediate, high and extremely high risk groups. As expected from the 
distributions of f-Hb, the percentage of men in each of the risk groups was 
higher than those of women and both sexes moved with increasing age 
towards a higher risk. These data could be used with advantage in 
screening programme planning: since the majority of individuals are in the 
low risk group, if screening was offered every three or four years for 
instance rather than every two years as is currently commonly done, 
resources would be saved. Even if, in addition, the high risk and very high 
risk individuals were invited annually rather than every two years, the 
overall number of positive screening test results, and thereby 
colonoscopies, would be lower than the usual current approach. 
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Risk scoring strategies exist for asymptomatic individuals which include sex 
and age (164), and for the symptomatic, risk scoring may include signs and 
symptoms, laboratory data, weight loss, diabetes and obesity (165). Now 
that automated quantitative FIT analyses are available, the evidence 
supports the concept that f-Hb could, be included in such scoring systems. 
This should prove a fruitful field of research for the future and is explored 
further in the conclusion. The statement made recently by Fraser (155) that, 
‘with modern information technology, flair and imagination, risk adapted 
strategies could be adopted in future bowel screening programmes’ seems 
appropriate. The data presented here on associations between f-Hb and 
demographic characteristics should assist those involved in programme 
design.  
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CHAPTER 6: Using FIT in the Assessment of 
the Symptomatic Population 
 
6.1 Introduction 
 
Deciding which patients seen in primary care with symptoms suggestive of 
lower abdominal disease who will benefit from referral for investigation is 
difficult. As discussed recently by Manz et al (166), this is partly because 
the symptoms reported for colorectal diseases overlap considerably. 
Moreover, of such referred patients, only 22% to 37% actually have an 
important colorectal disease (23). There is growing evidence that faecal 
calprotectin is potentially useful for stratification of patients with lower 
abdominal symptoms, particularly as a rule-out test for inflammatory bowel 
disease (IBD), and an undetectable calprotectin concentration in a low-risk 
patient supports discharge of the patient without further investigation (76). 
There is little evidence to support guaiac-based faecal occult blood testing 
(gFOBT) in this decision-making context. Indeed, certain authoritative 
guidelines did state that these tests have no place in investigation of 
symptoms (19) (20). For these and other reasons, laboratories in the UK 
are very actively eliminating gFOBT from their repertoire and their use has 
been discouraged in other clinical settings (167).  
 
In contrast gFOBT, has been demonstrated to reduce CRC mortality in 
randomised controlled trials of asymptomatic population screening (25). 
These results have been mirrored in bowel screening programmes (47) (66) 
that have been established following successful pilot studies. However, 
although gFOBT has some merit for use in structured population screening 
programmes, it also has major disadvantages (100) and many consider that 
gFOBT is now obsolete for use even in screening (168).  
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Newer tests for Hb detection have many advantages, are recommended for 
screening in current guidelines (31) and are being widely adopted. 
Quantitative FIT allow the measurement of f-Hb and have many benefits 
over qualitative FIT including the ability to vary the f-Hb cut-off used to refer 
for further investigation. As recently summarised by Rabeneck et al (120), 
there are many studies that document clinical outcomes in screening for 
colorectal neoplasia, which show that quantitative FIT are superior to 
gFOBT, particularly for adenoma detection. With regard to the use of these 
newer FIT in the assessment of patients with symptoms, a recent systematic 
review and meta-analysis on the value of the symptoms and additional 
diagnostic tests for CRC in primary care stated that, although results for 
qualitative FIT showed good diagnostic performance for CRC screening, 
evidence from primary care was lacking. It was suggested that high quality 
studies on their role in the diagnostic investigation in primary care are 
urgently needed (16).  
 
6.2 Aim of the Study 
 
The aim in this study was to examine the utility of f-Hb measurements, 
determined by a quantitative FIT, in deciding who of those that present in 
primary care with symptoms of lower abdominal disease would benefit from 
referral for endoscopy.  
 
6.3 Methods 
 
The performance characteristics of the OC-Sensor analyser are outlined in 
Chapter 3, briefly, the analysers were calibrated once per month, or when 
the latex LOT changed, with the calibrators provided. Each analytical run 
was preceded by analysis of two quality control materials at different Hb 
concentrations. The target values for the lots of materials used were set a 
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priori by 20 replicate analyses and a 12s rule used for acceptance or 
rejection of analytical runs.   
 
This study was performed according to the STARD (Standards for the 
Reporting of Diagnostic accuracy studies) checklist as far as possible (138). 
This set of 25 reportable items is designed to improve quality and 
comparability across studies and is particularly useful for comparing 
analytical methods. 
 
6.3.1. Evaluation Period 
 
Patients who had been referred from primary care for endoscopic 
examination of the lower gastrointestinal tract in NHS Tayside from 01 
February, 2010, to March 31, 2012, were invited to participate in this study. 
Reasons for referral were symptoms including rectal bleeding, change in 
bowel habit, IDA, abdominal pain, bloating, polyp/colorectal CRC 
surveillance, family history and assessment of inflammatory bowel disease 
(IBD). Patients who were under 16 years of age, unable to understand 
instructions or unable to consent were excluded. Those referred for 
investigation of a positive test result from the SBoSP were also excluded.  
 
6.3.2. Participants and Sample Collection  
 
Participants were recruited in the order that they appeared on the 
endoscopy appointment list, no intervention was made based on the f-Hb. 
A short letter of invitation to the study was included with their appointment 
letter (Appendix 7), along with a concise description of the rationale and 
aims of the study (Appendix 8). A research nurse followed up the invitation 
with a telephone call. If a patient was willing to take part, a sample collection 
device, written and pictorial instructions for collection of a faecal sample, 
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see Figure 27, a small labelled zip-lock plastic bag with integral absorbent 
material and a foil return mailing pouch were then mailed to the participant. 
The single faecal sample collection device is designed to collect ca. 10 mg 
freshly passed faeces using a serrated probe integral to the device cap into 
2.0 ml of buffer in a tube. The label documented the participants unique 
study number numerically and in a barcode. The participant wrote the date 
of sample collection on the sample collection device and the information 
provided emphasised the need to post the sample back to the SBoSL 
immediately. The foil mailing pouches, with completed sample collection 
devices, were returned through the normal UK Post Office mail system by 
first class freepost. 
 
Figure 27 Instructions for Use in the FIT in the symptomatic study 
 
 
 
4   Put the date on the tube. 
Insert the tube into the zip-lock 
bag and close it. 
 
5   Put it into the return 
mailing envelope. 
 
6   Review the check list - seal 
the envelope and post without 
delay. 
 
                                                             
How to collect your sample 
 Place layers of toilet paper in the toilet bowl to catch your sample.  
 It doesn’t matter if your sample touches the toilet water. 
 
                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Please repeat this process for both sample collection devices given to you.  
1   Twist open the 
green cap of the tube 
and pull it out 
2   Collect a sample by scraping the green 
stick on the bowel motion until the 
grooved end of the stick is covered. 
3   Insert the stick back into 
the tube. Push closed. Wash 
your hands. 
Please check   
Have you completed your 
test? 
Have you dated 
your kit? 
 
Now post immediately 
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The single faecal sample collection device was distributed, and the label 
documented the participant’s unique study number numerically and in a 
barcode format. The participant wrote the date of sample collection on the 
specimen collection device and the information provided emphasised the 
need to post the device back to the SBoSL immediately. The foil mailing 
pouches, with completed sample collection devices, were returned through 
the normal UK Post Office mail system by first class freepost. 
 
 
6.3.3. Sample Handling 
 
On return to the SBoSL the foil mailing pouches were opened, the barcode 
detailing the study number was used for analysis. Samples that were 
greater than 10 days from date of sample collection were termed expired 
and not tested further. 
 
6.3.4. Measurement of f-Hb 
 
The returned samples were analysed for f-Hb using one of two OC-Sensor 
Diana automated immunoturbidimetric analysers. Analyses were carried out 
in the SBoSL by trained staff whose major function is to perform faecal test 
analyses; the SBoSL has a comprehensive total quality management 
system and is accredited to ISO 15189 based standards by Clinical 
Pathology Accreditation (UK) Ltd. The analytical strategy and performance 
achieved have been detailed in chapter 3. The analysers were calibrated 
once per month with the calibrators provided. Each analytical run was 
preceded by analysis of two quality control materials at different Hb 
concentrations. The target values for the lots of materials used were set a 
priori by 20 replicate analyses and a 12s rule used for acceptance or 
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rejection of analytical runs. The combined imprecision obtained for the two 
analysers over the course of the study was CV < 3.8 %. 
 
 
6.3.5. Reference Standard 
 
Colonoscopy and FS were performed in the Endoscopy Unit, Ninewells 
Hospital and Medical School, Dundee, Scotland. Located within NHS 
Tayside, the Unit performs ca 1,000 procedures a year, and participates in 
the accreditation scheme of the Joint Accreditation Group on GI Endoscopy 
(JAG). 
 
Data for endoscopy outcome and any subsequent pathology were 
downloaded from the appropriate NHS Tayside clinical IT systems. Data 
were collected on the quality of the investigation (quality of preparation, 
completeness) and on the results including number, size and localization of 
CRC, high-risk adenoma (HRA) and low-risk adenoma (LRA), and whether 
biopsy was performed. Full pathological data were collected on all excised 
and biopsy specimens including polyp type, presence or absence of 
malignancy, stage of any CRC and the characteristics of all adenomas. 
Following this, f-Hb from participants were collated into clinical outcome 
groups according to their most serious diagnosis. Assignment to the HRA 
group was dependent on the participant having three or more adenomas, or 
any adenoma with a maximum diameter of 1 cm or greater, as 
recommended by the BSG (as modified for general use in Scotland) (48). 
Finally, the reasons for referral for endoscopy were documented. The 
median f-Hb in all those who had a particular reason for referral were 
compared with the remainder of the patients in the overall study group. 
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6.3.6. Statistical Analysis  
 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was 
used for all calculations. Data analyses after inclusion of 280 evaluable 
patients providing a maximum margin of error of 5% at 90% probability. Age 
and sex in the different groups were compared using the chi-squared test. 
PPV, NPV, sensitivity and specificity were calculated with 95% CI.  
 
CRC, adenoma, particularly HRA, and IBD were defined as those conditions 
for which endoscopy was of particular benefit. Hyperplastic polyps (HPP), 
diverticular disease (DD), haemorrhoids and prolapse were considered as 
those conditions for which endoscopy was not of major clinical value, along 
with the finding of a normal large bowel. Analyses of the diagnostic accuracy 
of f-Hb were performed with participants grouped in four different 
combinations of these clinical outcomes as positive: Group 1 - all neoplasia 
plus IBD (CRC + HRA + LRA + IBD), Group 2 - significant neoplasia plus 
IBD (CRC + HRA + IBD), Group 3 - all neoplasia (CRC + HRA + LRA) and 
Group 4 – significant neoplasia (CRC + HRA). The remaining, with all other 
clinical endpoints and normal endoscopy (Group 5), were considered 
negative. f-Hb in various classes of symptoms were compared with the chi 
squared test. Probability of p<0.05 was considered significant.  
 
Receiver operator characteristics (ROC) were used to determine the area 
under the curve (AUC) and analyse suitability as a diagnostic test (139). 
 
6.4 Results 
 
Ethical approval was granted by Tayside Research Ethics Committee 
(09/S1401/52, 04 June, 2009) and informed consent to participate was 
implied if a sample for FIT analysis was provided. In addition, the work was 
approved by the SBoSP Board and had Caldicott Guardian approval from 
NHS Tayside. 739 participants were invited to participate in the study, with 
474 accepting and 265 declining. Although 291 completed both the FIT and 
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endoscopy, 11 of these were excluded either due to the FIT sample being 
completed after endoscopy or the sample not being dated and having 
arrived in the laboratory later than the endoscopy appointment date. Figure 
28 shows the study flow with the number of patients invited, accepting, 
declining, undertaking both investigations, endoscopy, FIT, neither 
investigation and excluded.  
 
 
Figure 28 Flow diagram showing number of participants completing FIT and colonoscopy following 
study invitation. 
 
 
 
Table 27 shows the breakdown, of participants invited, accepting, declining 
and completing both, one of, or neither of the investigations, by sex and with 
median age compared with those excluded.  
 
 
 
 
 
 
 
INVITED 
n = 739 
DECLINED 
n = 265 
(35.9%) 
ACCEPTED 
n = 474 
(64.1%) 
COMPLETED FIT 
ONLY 
n = 15 (2.0%) 
COMPLETED 
ENDOSCOPY ONLY 
n = 138 (18.7%) 
COMPLETED FIT 
AND ENDOSCOPY 
n = 280 (37.9%) 
DID NOT COMPLETE 
FIT OR ENDOSCOPY 
n = 30 (4.1%) 
EXCLUDED 
n = 11 (1.5%) 
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Table 27 Breakdown of number of participants completing FIT and colonoscopy following study 
invitation by sex and median age 
 n % of n % of Invited Median age (years) 
Invited 739 100 100 59 
Male 331 44.8 100 60 
Female 408 55.2 100 59 
Declined 265 100 35.9 57 
Male 120 45.3 36.3 59 
Female 145 54.7 35.5 56 
Accepted 474 100 64.1 61 
Male 211 44.5 63.7 60 
Female 263 55.5 64.5 61 
Completed neither 
investigation 
30 100 4.1 58 
Male 15 50.0 4.5 56 
Female 15 50.0 3.7 58 
Completed FIT only 15 100 2.0 70 
Male 7 46.7 2.1 57 
Female 8 53.3 2.0 70 
Completed endoscopy 
only 
138 100 18.7 57 
Male 71 51.4 21.5 55 
Female 67 48.6 16.4 58 
Completed both 
investigations 
280 100 37.9 63 
Male 113 40.4 34.1 64 
Female 167 59.6 40.9 63 
 
 
There were no statistically significant differences between the proportions 
of men and women when comparing those accepting and declining 
invitation. The ages of those invited ranged from 16 to 89 years. 
Comparison of the median age between groups showed that those who 
declined invitation were significantly younger than those who accepted (p = 
0.008), and those who accepted and went on to complete both tests (p < 
0.0001). In addition, those who underwent endoscopy only were younger 
than those who underwent both investigations (p < 0.0001). All of those who 
accepted the invitation but did not go on to complete the FIT were younger 
than all of those completing a FIT (p < 0.0001).  
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The number of days between the participant completing the FIT and date of 
endoscopy was investigated due to a possibility of change in disease status 
over time. Only two of the 280 patients included in those completing both 
investigations did not date their sample collection device, but the samples 
were received by the SBoSL four days and nine days prior to their 
endoscopy appointment date, and these were therefore included. The 
remaining 278 participants completed and dated their sample device prior 
to undergoing endoscopy within a range of 1 - 112 days: the median was 
nine days and inter-quartile range 4 - 20 days. The results of endoscopy for 
the 280 participants in the group who completed both investigations are 
documented in Table 28. 250 underwent colonoscopy and 30 flexible 
sigmoidoscopy. There were no adverse effects during this study.  
 
Table 28 Clinical outcomes of participants completing both FIT and endoscopy 
 n % 
CRC 6 2.1 
All adenoma 54 19.3 
High-risk adenoma (HRA) 23 8.2 
Low-risk adenoma (LRA) 31 11.1 
Hyperplastic polyps 12 4.3 
Inflammatory bowel disease 26 9.3 
Diverticular disease 68 24.3 
Proctitis 2 0.7 
Haemorrhoids 27 9.6 
Prolapse 1 0.4 
Normal 84 30.0 
Total 280 100 
 
To assess the relationship between f-Hb and severity of disease, ROC 
curve analysis was undertaken for those designated as positive in Groups 
1 to 4 against all other data, defined as negative. Figures 29 - 32 show the 
ROC curves generated for each of the Groups.  
 
The AUC for all Groups with the more important diseases classified as 
positive ranged from 0.734 to 0.671, suggesting only a “fair” to “poor” 
diagnostic test. The sensitivity and specificity were 62.1% or less and 88.1% 
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or less respectively at the optimum f-Hb cut-off. The overall optimum f-Hb 
for detection of significant disease was 51 ng Hb/ml buffer. 
 
Figure 29 Receiver Operating Characteristic 
(ROC) curve with all neoplasia plus 
inflammatory bowel disease classed as disease 
 
Figure 30 ROC curve with significant neoplasia 
plus inflammatory bowel disease classed as 
disease 
 
 
 
Figure 31 ROC curve with all neoplasia classed 
as disease 
 
Figure 32 ROC curve with significant neoplasia 
classed as disease 
 
 
The optimum f-Hb cut-off in the different clinical outcome groups are also 
shown together with 95% CI in Table 29. Each of the four groups described 
above to differently classify disease as positive (Groups 1 to 4) had 
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significantly higher optimum f-Hb cut-off than those in the Group (Group 5) 
classed as without significant disease, that is, classed as negative.  
 
 
Table 29 Results of Receiver Operator Curve (ROC) analysis 
Disease 
classification 
Area under 
curve  
(95% CI) 
Optimum f-Hb 
cut-off (ng Hb 
/ml buffer) 
Percentage 
sensitivity  
(95% CI) 
Percentage 
specificity 
(95% CI)  
All neoplasia  plus 
IBD 
0.734  
(0.678 - 0.785) 
> 54 
55.1  
(44.7 – 66.5) 
88.1  
(82.7 – 92.3) 
Significant neoplasia 
plus IBD 
0.700  
(0.643 – 0.753) 
> 63 
54.6  
(40.6 – 68.0) 
84.4  
(79.0 – 88.9) 
All neoplasia 
 
0.702  
(0.644 – 0.755) 
> 41 
61.7  
(48.2 – 73.9) 
79.1  
(73.1 – 84.3) 
Significant  
neoplasia 
0.671  
(0.612 – 0.725) 
> 46 
62.1  
(42.3 – 79.3) 
75.3  
(69.5 – 80.5) 
Overall  51   
 
 
Set out in Table 30 are the diagnostic characteristics of FIT at a f-Hb cut-off 
50 ng Hb/ml buffer.  
 
Table 30 Positive Predictive Value (PPV), Negative Predictive Value (NPV), sensitivity and specificity 
for different clinical outcome groups with a f-Hb > 50 ng Hb/ml buffer 
Disease classification PPV (%) NPV (%) Sensitivity (%) Specificity (%) 
CRC 7.6 100.0 100.0 93.9 
All adenoma 36.7 87.6 53.7 98.5 
High-risk adenoma (HRA) 13.9 94.0 47.8 96.3 
Low-risk adenoma (LRA) 22.8 93.5 58.1 97.7 
Inflammatory Bowel Disease (IBD) 17.7 94.0 53.8 97.1 
All neoplasia + IBD 62.0 81.6 57.0 99.0 
Significant neoplasia + IBD 39.2 88.1 56.4 98.6 
All neoplasia 44.3 87.6 58.3 98.7 
Significant neoplasia 21.5 94.0 58.6 97.6 
Other/no pathology 38.0 18.4 15.5 93.4 
 
 
 
135 
  
6.5 Discussion and Conclusions 
 
This study is the first to evaluate the diagnostic accuracy of f-Hb 
measurements to discriminate between important colorectal disease and 
pathology of lesser clinical importance. Patients with CRC, HRA, LRA and 
IBD had significantly higher median f-Hb than those with findings considered 
to be of less clinical importance, namely HPP, DD, proctitis, haemorrhoids 
and prolapse. As expected, almost one-third of patients had no abnormality 
on endoscopy and these also had significantly lower f-Hb.  
 
The decision to use one sample device in this study was based on literature 
related to screening populations. A recent evaluation of the clinical utility of 
using either one or two samples for the detection of disease in a 
symptomatic cohort reported that the diagnostic yield obtained by using the 
higher of two FIT samples (FIT/max) could also be obtained by using one 
FIT with a very low cut off (f-Hb ≥10 µg Hb/g faeces). This supports the 
strategy and findings presented in this work (169). 
 
The data showed that all six patients with CRC had an elevated f-Hb with 
five having f-Hb greater than 1000 ng Hb/ ml buffer (the other having 346 
ng Hb/ml buffer), but those with HRA, LRA and IBD had lower median f-Hb 
concentrations with wide confidence intervals, which is in accord with the 
concept that f-Hb is related to severity of disease (155). The highest AUC 
using ROC analysis was when CRC + HRA +LRA + IBD were considered 
as positive. In consequence, it might be considered that f-Hb measurement 
could be used as a rule-in test for important colorectal disease. However, 
the AUC for all Groups with the more important diseases classified as 
positive ranged from 0.734 to 0.671; traditionally, such AUC would suggest 
only a “fair” to “poor” diagnostic test.  
 
Analysis of the ROC showed that the f-Hb cut-off that gave optimum 
sensitivity and specificity together was circa 50 ng Hb/ml buffer. At this 
concentration, sensitivity was 100% for CRC but only 47.8% to 58.6% for 
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other types of important colorectal disease. In consequence, f-Hb 
measurements may have limited value in the diagnosis of important 
colorectal disease in patients presenting in primary care with lower 
abdominal symptoms except for CRC. However, the NPV for CRC, HRA, 
LRA and IBD were 100.0%, 94.0%, 93.5% and 94.0% respectively. Thus, 
the important finding of this study was that f-Hb could be a very good “rule-
out” test for important colorectal disease in those presenting with symptoms 
in primary care. 
 
Endoscopy is a scarce resource and it is believed that f-Hb should be 
measured before referral from primary care: those with f-Hb ≥ 50 ng Hb/ml 
buffer could be referred for urgent investigation and those with f-Hb <50 ng 
Hb/ml buffer could be managed expectantly or referred for a specialist 
surgical or gastroenterology opinion. Since, in keeping with other studies 
(23) (166), 30% of those referred had no abnormality and also had a low f-
Hb, this strategy would free up considerable endoscopy capacity for those 
who would benefit and potentially reduce waiting times. Patients often had 
more than one symptom reported. Symptoms or indications for endoscopy 
had no clear relationship with median f-Hb other than that performed for 
documented rectal bleeding and for family history. Thus, although f-Hb 
concentrations are associated with the severity of colorectal disease found, 
they do not correlate well with reported clinical symptoms. 
 
Since the publication of the findings presented in this work, that low f-Hb 
could be used to rule out colonoscopy and help manage endoscopy 
resources, Rodriguez-Alonso et al. (170) reported on the effectiveness of 
CRC urgent referral guidelines (NICE and SIGN guidelines) compared to f-
Hb in triaging symptomatic patients for colonoscopy. This was a prospective 
study of 1003 patients, 665 from primary care and 338 from secondary and 
tertiary care and colonoscopy was used as the gold standard. Analysis of 
the data showed that the number needed to scope to detect one case of 
cancer using NICE, SIGN, f-Hb ≥10 µg Hb/g faeces, and ≥15 µg Hb/g faeces 
(50 and 75 ng Hb/ml buffer) were 21, 24, 8 and 7 respectively and the 
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numbers needed to scope to detect one case of significant neoplasia were 
6, 6, 3 and 3. Although this was a mixed primary, secondary and tertiary 
care cohort, these are encouraging results and add to the growing evidence 
base for using f-Hb in the triaging of symptomatic patients. 
 
The major strength of the study presented in this Chapter is that the patients 
were recruited before endoscopy after being assessed as requiring this 
investigation. The setting of this study in primary care is important.  Studies 
previously reported in secondary care do not deliver approaches and results 
that can be readily translated into a primary care setting. The approach 
adopted to testing in that setting needs to fulfill a number of requirements 
that have been addressed in this study.  The primary care setting requires 
that diagnostic testing process must be easy for patients to comply with and 
provide a stable sample that can be transported easily to the laboratory for 
analysis. In addition the test should have good analytical practicability and 
reliability and provide results that are easy to interpret (171). The testing 
process for f-Hb used in the study presented here undoubtedly fulfil these 
requirements (100) (120) (167). The f-Hb test has an additional advantage 
of being viewed as inexpensive (approximately £3.00 for the sample 
collection device and analysis).  
 
In Chapter 5 it is described that f-Hb is very dependent on sex and age in a 
screening population and suggested fixed decision-making limits be used 
based on sub sets of that group. On the basis of this study, two potential 
approaches to triaging patients in primary care could be developed. The use 
of centrally organised sample analysis or the use of simple POCT with an 
analytical detection limit stated to be 50 ng Hb/ml buffer (10 μg Hb/g faeces 
WEO recommended units) would appear to be viable approaches (172).  
 
There is a growing interest in risk scores for use in detection of colorectal 
neoplasia in asymptomatic populations and there have been a number of 
approaches which have calculated independent risk factors that impact on 
the development of neoplasia (173) (177). It has been suggested that the 
138 
  
evidence supports the idea that f-Hb could, with advantage, be included in 
such risk scoring systems (22): this could prove a fruitful field of research in 
CRC screening for the future and is discussed further in the final chapter of 
this thesis. There are also scoring systems for use in assessment of those 
with symptoms: the diagnostic performance to identify symptomatic CRC 
compared with current referral guidance was recently investigated by 
Marshall et al (165) and Rodriguez-Alonso et al. (170). A more recent 
development has led to the creation of an Internet calculator, the QCancer® 
(Colorectal) risk calculator (www.qcancer.org/colorectal/) (174): the 
performance of this has been recently validated (175). In spite of the fact 
that little relationship was found between f-Hb and symptoms, it might be 
that such risk scoring systems for the symptomatic would be enhanced by 
addition of f-Hb, and that, even without further detailed clinical information, 
the evidence supports the view that knowledge of f-Hb would assist in the 
evaluation of symptomatic patients.  
 
In conclusion, the study presented here indicates that f-Hb testing delivers 
a good rule-out test for clinically important colorectal disease. The outcome 
of the study would further suggest that application of f-Hb measurement to 
the symptomatic population in a primary care setting could enable delivery 
of a reduction in demand on endoscopy services. 
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CHAPTER 7: Highlights and Possible Future 
Work 
 
7.1 Introduction 
 
CRC is a significant cause of morbidity and mortality worldwide (2) (4). The 
presence of Hb in faeces can be used as a tumour marker, triggering further 
endoscopic investigation. A meta-analysis of four large RCT conducted in 
the 1990s was vital in providing evidence that a screening intervention, 
gFOBT, followed by colonoscopy for those who tested positive, significantly 
reduces disease specific mortality (43). However, these studies reported 
their findings decades ago and any test that performs better than gFOBT in 
terms of sensitivity and acceptability to the screened population should have 
a greater clinical impact than reported in these studies. Therefore the results 
achieved by the original RCT can be used to determine benchmarks 
whereby new screening modalities are investigated.  
 
The primary aims of this work were: 
 to determine if an automated quantitative FIT could improve 
outcomes for people who participate in the SBoSP  
 to examine f-Hb data by sex and age and assess the implications 
and applications of any differences, 
 to determine whether FIT can also be used to direct colonoscopy 
resources to those, referred from primary care, who will benefit most. 
 
7.2 FIT as a First-Line Test 
 
The effectiveness of a screening programme is influenced by a number of 
variables including the sensitivity of the test and it’s acceptability to 
participants. In Chapter 4, it was reported that during the feasibility 
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evaluation, FFLT, only one faecal sample was collected rather than the six 
required with the gFOBT. A combination of this, the single sample collection, 
the simple sample collection device and new instructions for use may have 
been the main factors that contributed to an overall increase in uptake of 
the test in the study cohort. It was shown that uptake returned to previous 
levels when the gFOBT/FIT algorithm resumed in the evaluation NHs 
Boards. Analysis of uptake by deprivation quintile showed the greatest 
increase in uptake in the most deprived quintiles, and a significant increase 
in the most deprived men. SBoSP outcomes such as number of spoiled kits, 
calls to the helpline and turnaround time for results were all reduced. 
Adopting a 400 ng Hb/ml buffer (80 µg Hb/g faeces) cut-off to achieve a 
referral rate similar to that of SBoSP resulted in clinical outcomes with only 
subtle differences which may have been linked to screening round. 
Reducing the cut off to deliver increased test sensitivity would have the 
effect of increasing the number of colonoscopies performed within the 
screening programme. 
 
The European Group on Tumour markers recommend the use of 
quantitative FIT with an adjustable cut-off for CRC screening. They 
identified that – ‘iFOBT is superior to gFOBT with respect to detection rate 
and PPV for adenomas and CRC’ (27). While there are many studies that 
document clinical outcomes that support the view that FIT are superior to 
gFOBT, non are in the context of national screening programmes. The 
studies used a low cut-off for FIT resulting in a higher positivity than could 
be resourced if adopted by the Scottish Bowels Screening programme (119) 
(143) (147). Findings presented in this thesis however demonstrate that use 
of FIT with a lower cut off could be adopted by the Scottish programme and 
deliver a number of benefits with a referral rate for colonoscopy comparable 
to that of the current gFOBT/FIT algorithm. Those benefits include improved 
outcomes in terms of screening uptake, compliance and turnaround time for 
results.  
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Further support for use of FIT as a frontline screening test comes from a 
prospective study undertaken in Saudi Arabia on 257 asymptomatic patients 
attending one of two tertiary hospitals (176). The authors reported on 
sensitivity and specificity of FOBT in screening for CRC. Each participant 
performed a once only gFOBT (Cologuard, Helena Laboratories, 
Beaumont, TX, USA) and qualitative FIT (RAPEPKT 313, DIAsource 
ImmunoAssays SA, Nivelles, Belgium 50 ng/ml buffer) and underwent a 
complete colonoscopy. The control group consisted of 20 cases of 
confirmed CRC who undertook the same regimen. What is interesting in this 
study is that patients were asymptomatic but everyone, with a positive and 
negative FOBT, was given a colonoscopy. In the asymptomatic cohort 37 
participants were positive with one or both of the gFOBT and FIT, the 
remaining 194 were negative with both tests. The gFOBT and FIT positivity 
for the screening and control groups were 22.6%, 12.1%, 65% and 80% 
respectively. The sensitivity of gFOBT and FIT for the detection of CRC 
among the screening group was 50.0% (95% CI =6.76–93.24) and 75.0% 
(95% CI =19.41–99.37), and the specificity of gFOBT and FIT was 77.9% 
(95% CI =72.24–82.83) and 90.1% (95% CI =85.76–93.50).  
 
This study adds to the growing evidence base indicating the effectiveness 
of FIT in screening for CRC. It is recognised that the Saudi Arabian study is 
relatively small in size with few cancers detected and wide confidence 
intervals bounding the reported sensitivities. Nevertheless the study lends 
some support to the case for using quantitative FIT in a screening 
programmes for CRC detection. 
 
7.3 f-Hb is Related to Sex and Age  
 
FIT measure f-Hb as continuous data variable and allow a cut-off to be 
chosen to give performance characteristics, such as screening test 
positivity, for objective assessment by screening programme organisers. In 
chapter 5, the investigation of the dispersions of f-Hb according to sex and 
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age was presented. It was shown, for the first time, that f-Hb increased with 
age in both men and women and that f-Hb was higher in men than in women 
in every age quintile. Differences amongst stratified data may prove useful 
in improving the efficiency of screening by enabling better targeted cut-off. 
Recent studies in Asia have suggested the possibilities of delivering 
individual-centred screening based on portioning of asymptomatic 
populations by age, gender, body mass index (BMI) (173) and the addition 
of further criteria such as, family history, smoking and presence or absence 
of diabetes mellitus (177). In the work undertaken here, the data gathered 
from all those who did attend colonoscopy demonstrated that, above the 
cut-off used increasing f-Hb is linked to increasing disease severity (178). It 
has now been shown, independently, that even below the conventional f-Hb 
cut-off can predict the risk of future significant neoplasia (158).  
 
New data published on the use of different FIT analytical systems from 
various manufacturers confirms the findings presented in this thesis that f-
Hb data can differ when partitioned according to age and gender (151). This 
holds true despite methods differing in terms of sample volumes, matrix 
effects and varying polyclonal antibody affinities for Hb and its degradation 
products. This is a consideration for programme organisers when procuring 
analytical equipment.  
 
7.4 FIT in the Assessment of a Symptomatic Population 
 
There is little evidence for the continued use of gFOBT in a spectrum of 
clinical settings. These tests have many serious disadvantages, should be 
considered obsolete and up until recently national guidelines have 
discouraged their use in primary care. In marked contrast, there is growing 
evidence that FIT would be useful, not only in screening for colorectal 
neoplasia, but also in the assessment of symptomatic patients.  
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The work described in Chapter 6 showed that f-Hb has very high NPV for 
significant colorectal disease (CRC, adenoma and IBD) in those patients 
who present in primary care with symptoms. FIT has the useful potential to 
be used as a rule-out test to help direct the available colonoscopy resource 
to those who would benefit most. In addition, data presented in this thesis 
showed all those patients with CRC had f-Hb above 50 ng Hb/ml faeces. A 
strategy of watch and wait for all those with f-Hb below this cut-off could 
potentially reduce endoscopy numbers by one third while ensuring that most 
disease would be picked up at colonoscopy.  
 
One of the limitations of the work presented in this thesis is the small 
numbers. A larger, well organised, multicentre, prospective study of the 
diagnostic accuracy of f-Hb, NICE and SIGN guidelines for detecting CRC 
in symptomatic patients has been reported by Cubiella et al (179). This 
study used the Spanish COLONPREDICT cohort to determine the most 
reliable tool for predicting CRC and other significant colorectal diseases in 
a cohort referred for diagnostic colonoscopy. A total of 787 subjects met the 
selection criteria, 17.5% of patients were referred from primary care, 75.3% 
were from primary to secondary care and 7.1% were referred from 
secondary care. Assessment was based on f-Hb >100 ng Hb/ml buffer (>20 
µg Hb/g faeces), NICE referral Criteria (20) and SIGN referral criteria (19). 
The diagnostic accuracy of the test for CRC, determined using AUC, 
showed FIT (0.88, 95% CI 0.84–0.92) was statistically higher than NICE 
(0.63, 95% CI 0.58–0.69) and SIGN (0.62, 95% CI 0.58–0.67) (P < 0.001) 
guidelines. In this study, use of FIT instead of NICE/SIGN referral criteria 
could reduce the number of colonoscopies required by 19.6% while 
increasing the number of CRC detected by 42.0%. This positive outcome 
supports the findings presented in this work. 
 
Further support of the use of FIT as a tool for triage of patients presenting 
with symptoms comes from another Spanish study of patients, two thirds in 
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primary care and one third secondary and tertiary care, referred for 
colonoscopy (170). NICE and SIGN guidelines are compared to FIT with a 
cut-off set at 10 µg Hb/g faeces (50 ng Hb/ml buffer) and 15 µg Hb/g faeces 
(75 ng Hb/ml buffer). The number needed to scope was 21 and 24 
respectively for the guidelines and 8 and 7 for the FIT. Using f-Hb above 10 
µg Hb/g faeces as the criteria for referral to colonoscopy would only miss 
0.1% of cancers and 5% of advanced adenomas. As suggested in this 
thesis, those people not referred could be placed under a system of ‘watch 
and wait’.  
 
In both the studies described above the use of SIGN and NICE guidelines 
improved the detection of significant neoplasia compared to no selection 
criteria, however the use of f-Hb further reduced the numbers needed to 
scope and increased the yield of significant neoplasia. 
 
7.5 Adjusting the f-Hb Cut-Off within a Screening Programme 
 
Three Scottish NHS Boards participated in the pilot rounds of screening (46) 
and from 2007 all NHS Boards are now participating in the SBoSP (66). In 
each pilot round the number of CRC detected and the PPV decreased. It is 
likely that this phenomenon is caused by screening out prevalent CRC and 
mainly finding incident CRC in the subsequent rounds and this still 
continues in the programme (108). If a screening strategy were to continue 
with the same f-Hb cut-off for many rounds, as the current programme does, 
the f-Hb within the screened population is likely to fall below the detection 
limit of the gFOBT and the number of CRC detected by this method will 
decrease. Introduction of a quantitative test where the end user sets the cut-
off could resolve this issue as the f-Hb cut-off could be reduced to maintain 
a constant positivity which would allow those with less and less f-Hb to be 
referred for colonoscopy. This strategy could lead to a reduction in IC as 
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participants with slightly less f-Hb (women and younger participants) are 
sent for colonoscopy.  
Examination of the three rounds of Scottish pilot data revealed the interval 
cancer rate increased with each round, from 31.2 to 58.9% (46). Data from 
Dutch studies show that using a low cut-off and referring high numbers of 
participants for colonoscopy increases the PPV for CRC (118). It was 
anticipated that a benefit of using a FIT strategy in the SBoSP would be a 
statistically significant increase in CRC detected; however, with the positivity 
set the same as the current gFOBT/FIT algorithm there was no significant 
increase in CRC detection. At this point it seems unlikely there will be a 
reduction in the number of IC in the evaluation group. Data regarding IC in 
the FFLT cohort will be very interesting when they are available. 
 
One of the most translatable findings of this work is that f-Hb is higher in 
men then in women and increases with age. This presents an opportunity 
to review how the current SBoSP is delivered. It is known that incidence of 
CRC is higher in men, that f-Hb is higher in men and, within the context of 
the pilot rounds, IC were higher in women than men (33).  
 
The quantitative nature of FIT allows for the f-Hb cut-off to be selected to 
give certain predesigned outcomes. If reduction of IC in women was an aim, 
the cut-off for women could be set lower than that used for men. If disease 
detection in younger ages was important the f-Hb cut-off for 50 – 60 years 
could be lowered or for over 75 years could be increased. Even though 
these changes could address inherent biases in the current dichotomous 
system, any changes would be dependent on not disadvantaging specific 
groups.  
Currently, many countries (including Scotland) are planning on using a 
single cut-off for referral for colonoscopy with the inherent sex biases, 
deprivation gradient and high IC rates. There is technology available already 
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that could allocate each individual a cut-off based on age and gender which 
are contained within each CHI number so individualising CRC screening 
and allowing monitoring of f-Hb with time. It would be gratifying to see more 
imaginative approaches being taken in the near future. 
 
7.6 Use of f-Hb in Risk Scoring 
 
It has been documented in this work that sex, age and deprivation are 
significant predictors of disease, and as such use of quantitative FIT as a 
dichotomous test does not fully utilise the benefits of f-Hb. Given that many 
inter-relationships in the development of CRC exist, there are opportunities 
to develop multivariate risk tools for screening and triage of symptomatic 
patients. This would allow an individualised approach to healthcare, and 
targeting of those who require endoscopy and reduce the pressure on this 
resource.  
 
A number of risk scoring models have been developed and published 
recently which demonstrate that stratifying risk, even without f-Hb, works 
well in asymptomatic populations. Since these studies are likely to inform 
programmatic effectiveness they are described in further detail here. Wells 
et al. (180) reported on the development of CRC-PRO in the USA. Case-
control data was used to populate and internally validate a risk prediction 
model. Interestingly the variables used for men and women differed and 
increased BMI affected men and women differently. The impact of different 
variables were ranked in two tables relating to men and women; the most 
important variable in men and women was age which also had the strongest 
affect over any other variable. This model demonstrates the importance of 
using more than just one variable such as age as the spread of risk within 
one age group is the result of many factors e.g., a 50 year old woman’s 10 
year risk of CRC may be between 0.2% and 2.0% dependent on the other 
variables included in this model. The ability to predict risk of developing 
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CRC could enable decisions to be made as to whether an individual may 
benefit from early endoscopic intervention or more frequent screening or 
longer screening intervals are adopted. The model gave good prediction 
accuracy. However, one of the underlying principles of a risk prediction 
model is that it should be simple enough to be used in clinical care. 
 
In 2015, Garcia et al. (180) published an analysis of f-Hb in relation to age, 
gender and clinical outcome in a Spanish screening cohort. Within Spain 
CRC screening is managed at a regional level and in 2010/2011 all regions 
operating a screening programme (12 out of 17 regions) switched to FIT, 
although they still report test results as positive or negative. This study 
reported on 1406 subjects who completed a colonoscopy after a positive 
(100 ng/ml buffer) screening test result. Similar to the findings presented in 
this thesis, increased f-Hb was associated with increased disease and f-Hb 
was significantly higher in men than in women. However, in this study 
increased age was not associated with increased f-Hb. Logistic regression, 
adjusted for age and sex, showed high-grade dysplasia, villous histology, 
distal location and increasing size were all associated with increasing f-Hb. 
All of this data was analysed with different cut-off to examine the effect of 
increasing the f-Hb cut-off on clinical outcomes. Increasing the f-Hb cut-off 
by 150 ng/ml buffer would reduce the positivity to 3%, but miss 15.9% CRC 
and 33.4% HRA. It was observed that as f-Hb cut-off is increased, PPV 
increased: however, there was more likelihood of missing lesions. 
 
Chen et al. (182) developed a risk scoring system for asymptomatic 
average-risk populations with Han nationality in the Jiangsu Province. A 
total of 905 cases met the study criteria. In this study multivariate analysis 
showed age, gender, coronary heart disease, egg intake and defecation 
frequency were independent variables associated with increased risk of 
neoplasia. These were used to populate the scoring system: patients were 
scored from 0 – 10 with 2.5 being the cut-off for referral colonoscopy. Using 
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this scoring system reduced the number of colonoscopies required by 
45.5% and missed three colorectal neoplasms, the NPV was 99.3%. 
In Singapore, Yeoh et al. (164) reviewed data from asymptomatic screening 
colonoscopies across Asia. One third of the cohort were used to develop 
the model and the remainder to validate it. The Asia Pacific Colorectal 
Screening (APCS) score used age, gender, family history and history of 
smoking. The scoring system had a range of 0-7 points and risk was 
stratified as average (0-1), moderate (2-3) and high (4-7). Advanced 
neoplasm was used as the end point as polypectomy gives secondary 
benefits within screening. No advanced neoplasms were found in the 
average risk group, who comprised 19.2% of the development cohort. 
However, in the validation cohort, average risk individuals comprised 29.5% 
of the cohort and had seven advanced neoplasms (12%). 
 
The APCS was tested with additional metabolic syndrome (MS) 
components (obesity, hyperlipidemia, hypertension and diabetes) by Wang 
(183). The additional MS components increased the amount of colorectal 
neoplasia that was detected, but this was not significant when compared to 
the APCS system. 
 
These examples of risk scoring systems for use in asymptomatic 
populations are valuable because they offer the opportunity to reduce the 
number of colonoscopies without a significant loss in sensitivity. Many 
studies used the Hosmer-Lemeshow goodness of fit statistic to determine 
the reliability of the risk model in validation cohorts. If the result is <0.05 the 
model is not good and should be rejected, above 0.5 and it is a good fit. For 
the studies that completed this test the results were 0.49 (164), 0.174 (182). 
Wells was not able to test the CRC-PRO model with a different cohort since 
adequate data had not been collected. However, there are a number of 
limitations in that there are many variables that affect the risk of developing 
CRC and deciding which to include and how many variables to include will 
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affect the ability of the system to determine risk. In order to manage data 
some continuous variables must be portioned e.g. age and this may reduce 
accuracy and these models relied on an element of self-reporting which is 
not always accurate. In addition, models are not likely to be transferable 
across geography and populations since race and ethnicity affect CRC risk. 
 
Addition of f-Hb in a scoring system should increase its ability to predict risk. 
This approach was taken by Rodreguiz-Alonso et al. (170) who used the 
data from a large cohort of symptom based referrals to construct a model to 
score risk of significant neoplasia and inform referral for colonoscopy. In this 
model age, gender and f-Hb were selected as they were linked to CRC in 
the analysis of the outcomes. The cohort were split into two groups, two-
thirds of the group were used to develop the risk scoring system and the 
other third were used to internally validate the system. Using this algorithm 
only 36.4% of the presenting population would need to be referred, all 
cancers would be detected and only 5.0% of advanced adenomas would be 
undetected.  
 
These studies demonstrate that reliable and accessible factors such as age, 
gender, BMI, smoking history and family history can be used to populate 
CRC risk models. However, the use of f-Hb should be included in any risk 
scoring model, in screening and symptomatic populations. In Scotland the 
screening programme has access to data on age and gender and so a risk 
scoring model could be developed with the existing data from the FFLT 
evaluation through the use of the CHI number and using established 
collaborative links developed with many with European countries, it would 
be possible to test it using similar screening data. Experience gained during 
the development of this work suggests that FIT is capable, within the context 
of risk scoring, of giving a result that has clinical characteristics similar to 
those seen in many diagnostic tests and evidence suggests that the number 
and frequency of colonoscopies could be reduced using this approach.  
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7.7 What Screening Interval should be used in a FIT Based 
Algorithm? 
 
Patients who undergo colonoscopy and have significant neoplasia detected 
are placed under surveillance, meaning further colonoscopy at 1, 3 or 5 year 
intervals. Family history may place a person in a ‘high risk’ category where 
frequent colonoscopy is recommended. This approach is laid out in the BSG 
Guidelines (48) and is a balance of benefits and risks as colonoscopy is a 
limited resource and may have complications.  
 
The FIT developments outlined in this work present an opportunity to 
rationalise and prioritise colonoscopy to those people who have evidence of 
need, decreasing waiting times and therefore improving outcomes. 
However, there is still very little research as to the interval that should be 
used between screening rounds. A recently published study investigated 
whether an offer of an annual, biennial or triannual single sample algorithm 
should be used and found that using an interval 1-3 years did not affect the 
detection of advanced neoplasia (124). Evidence is being gathered as to 
whether it is more beneficial to screen a small age group intensively with a 
low f-Hb cut-off or whether to screen for longer with a higher f-Hb cut-off. 
Early work indicates the benefits of an annual FIT strategy with a higher f-
Hb cut-off when colonoscopy resources are limited (125). However, it has 
also been found that lowering the f-Hb cut-off improves detection of 
advanced adenomas rather than CRC (122). 
 
Quantitative FIT results could be used to build a dataset to determine 
whether f-Hb at 50 years of age (index f-Hb) could be used indicate future 
risk of neoplasia, or a number of consecutive negative test results may 
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indicate the individual had less risk of developing significant neoplasia and 
that the screening/surveillance interval could be increased or if, following 
the index f-Hb there is an increase in f-Hb, a referral for bowel visualisation 
could be conducted.  
 
7.8 Conclusions 
 
There is significant potential for quantitative FIT to contribute to improved 
outcomes for people with undetected CRC in screening and symptomatic 
populations. The data presented in this work relate to the use of automated 
quantitative FIT in these two areas of interest; replacement of the 
gFOBT/FIT modality for early detection in the SBoSP and to triage those 
presenting in primary care.  
 
A significant part of the work in this thesis relates to the progression from a 
binary system of reporting analytical outcomes to development of risk 
scores underpinned by quantitative FIT results and weighted risk factors 
such as age and gender. It is hoped that outputs from this work are 
translated into clinical practice and that, in the near future, patients in 
Scotland, in all relevant clinical settings, have access to investigations 
based on level of risk to provide high quality evidence based, healthcare. 
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Clinical Relevance & Principle of Examination 
 
The aim of the Scottish Bowel Screening Programme is to screen persons between the 
ages 50-74, throughout Scotland, for faecal occult blood using a two-year recall. 
Quantitative FIT is being used as a trial in NHS Tayside and Ayrshire and Arran from July 
2010. All faecal occult blood test positive participants are referred to colonoscopy for 
further investigation. 
 
Measurement using the OC Sensor DIANA is based on latex agglutination. An antigen-
antibody reaction is a specific reaction that occurs between an antigenic determinant and 
the active group of an antibody. The amount of bonding depends on the concentration of 
antigen or antibody. 
 
A latex agglutination reaction is the clumping of antigen or antibody sensitized 
polystyrene latex particles through an antigen-antibody reaction. A light beam is passed 
through the reaction liquid to measure the changes in the intensity of the transmitted light 
beam (latex turbidimetry), and changes in the intensity of the scattered light beam (latex 
nephelometry). The OC Sensor DIANA uses latex turbidimetry to measure the amount of 
haemoglobin present in stool samples via the sampling device. 
 
References 
 
Refer to Instructions for Use 
 
Safety Data 
 
Biochemical Medicine Health and Safety Policy Health and Safety Codes of Practice 
TSAFE 10, NSAFE 52, and TSCRPU 25 
All staff must wear gloves and laboratory coats whilst testing due to potential biological 
and chemical hazards.  
 
Equipment and Specialist Supplies 
 
2 x OC Sensor DIANA, Eiken Chemical Co., Ltd 
 
Domestic bleach 
Purified water 
100-1000 µl pipette and tips 
Sample cups 
 
Zebra printer, labels 
 
Reagents, Standards or Calibrants, and Internal Quality Control Materials 
 
OC Diana Latex REF V-PZ01, Eiken Chemical Co., Ltd. Supplied ready to use, stored at 
2-10oC. These are kept in room CI-007, reagent store, in fridge 2. 
 
OC Diana Buffer REF V-PZ03, Eiken Chemical Co., Ltd. Supplied ready to use, stored at 
2-10oC. These are kept in room CI-007, reagent store, in fridge 2. 
 
Standards and Calibrants 
 
OC Standard REF V-IX50, Eiken Chemical Co., Ltd. This is stored at 2-10oC unopened 
for up to 1 year. These are kept in room CI-007 reagent store in fridge 2. 
 
The standard must be reconstituted by adding 1.0ml purified water and mixing gently by 
inversion several times and leave for a minimum of 15 minutes. The diluent is ready 
made. Using the pre programmed calibration rack, 2ml of diluent is placed in position 1 
and 250 µl of low control and 250 µl of high control in positions 9 and 10 respectively. 
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Internal Quality Control Materials  
 
There are two IQC OC-Control Low REF V-PH57 and OC-Control High REF V-PH58, 
Eiken Chemical Co., Ltd.  These are supplied freeze-dried and are stable at 2-10oC for 1 
year. These are kept in room CI-007, reagent store, in fridge 2.  
 
Reconstitute by adding 1.0ml purified water and mix gently by inversion several times and 
leave for a minimum of 15 minutes.  When using a new vial aliquot 200 µl portions into 
eppindorf tubes and store at –200C immediately. Using the pre programmed calibration 
rack 250 µl of low control and 250 µl of high control are put in positions 9 and 10 
respectively. 
 
Specimen Requirements and Means of Identification 
 
Participants who receive a FIT kit receive an invitation to test. In with the letter is a label 
containing the participants name, kit number CHI number and a space to write the 
sample date. This must be taken from the letter by the participant and attached to the 
leak-proof bag that holds the tube supplied in the invitation pack. 
 
The participant receives an instruction leaflet detailing the sample collection method. 
 
The participant must write the sample date on the label. The samples are stable for 10 
days after application of faeces. 
 
Samples are tested the day they arrive in the laboratory. If this does not happen, the 
samples can be stored at 4oC overnight in Fridge 2. Once tested the samples are stored 
at –20oC for one week to allow results letters to be sent to participants and any queries to 
be dealt with. Samples are identified using a 10-digit numeric barcode label 
 
 
Method 
 
Calibration 
 
Calibration is performed once a month or whenever the Lot of latex changes.  The 
calibration method is a six point nonlinear calibration using OC Standard REF V-IX50. 
 
Refer to Simple Operation Manual 
 
 
Performance of Examination 
 
Kits that arrive in the laboratory are Booked-in and Sorted, see TSCRPU 3. 
 
Proceed with testing of non-problematic kits as follows, for all others see TSCRPU 6.  
 
Start-up Analyser 
 
a) Using the maintenance schedule TSCRPU 34 F1.1, ensure that the drain tank is 
empty, the purified water, wash solution and buffer are full. If these are topped up 
prime them, see section e 
b) The IQC and latex are removed from the fridge in preparation for putting on the 
machine. Prepare the IQC, during the fifteen minutes they reconstitute turn the OC 
sensor on using the button at the front right hand side of the machine. 
c) The front cover of the analyser can be lifted when the MENU screen is displayed 
d) Place the latex on the machine. The lids from the latex should be removed and 
placed alongside the lid for the buffer on the front central section of the machine 
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The cover on the latex positions can then be lifted and two bottles of latex inserted. 
The latex cover must then be replaced followed by the large front cover 
e) Prime the machine if necessary – that is if purified water, wash or buffer have been 
topped up or replaced 
a. To prime the machine on the touch screen press SUPPORT, then PREP 
FUNCTIONS/SUPPORT 
b. Then select PRIME from tabs 
c. Select NORMAL PRIME and select YES for any of the items that have been 
changed 
d. Press START, when the prime is completed return to the main MENU 
e. If buffer has been replaced go to LATEX and RESET buffer. 
f) The IQC can now be dispensed into cups for testing. Using a IQC rack (dark blue 
in colour) place two clear cups in the IQC positions at the far right of the rack. 
Using a pipette measure out 200µl of the low IQC and dispense into the cup on the 
left, repeat with the high IQC dispensing into the cup on the right.  
g) Aliquots of IQC can be stored in the freezer for up to five days. They must have the 
type of control and date they were frozen clearly written on them. 
h) Place the rack on the tray on the right hand side of the machine 
i) Check that all the fluids are topped up, the lids are off the latex and that nothing is 
obscuring the path of the rack. On the screen press TEST then START, the 
machine performs a self-check before starting. If the self check fails get a senior to 
look at the problem 
j) When the IQC results are printed out they must be checked against the local 
ranges for the current batch. If they are within the range they are accepted. If they 
are outside the range troubleshooting is performed in the following order - check 
the fluids, rerun the controls, make up new controls or recalibrate the machine. 
 
Sample Runs 
a) Log onto PC 
b) Ensure that the Zebra printer is selected as the default printer 
c) Click on the barcode icon 
d) Pick up a box of kits that have been booked and sorted and take it through to 
the PC. Starting at the front of the box where the earliest kits are remove the 
first kit 
e) Scan the kit label, the barcode should be read and a label printed automatically. 
f) If the label does not print automatically it should be batched and kept to the end 
of a run, the number can be typed in manually, the label will print automatically 
when the 10th digit is entered. 
g) The label should be checked against the number on the bag. NB. If the labels 
do not match then reprint the label. When the labels match, the sample tube 
should be removed from the bag and the new label attached to the tube 
h) The sample bags must be kept on order in batches with the rack number written 
on the batch.  
i) The tube can now be loaded into a light blue sample rack. Repeat process until 
10 tubes are loaded into the rack, or all the labels have been completed 
j) Place the rack on the tray at the right hand side of the machine 
k) On the screen press TEST then START 
l) If more samples are to be set running on the machine press SET SAMPLE and 
then START 
m) Once testing of the first 100 samples has been completed another set of IQC 
should be run and accepted. This process continues until that days samples are 
complete. 
n) Samples are stored and disposed as per TSCRPU 10 
 
Recording and Calculation of Results 
 
IQC results and patient results are sent in separate reports. 
 
To send IQC reports. 
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a) The analyser must be finished before exporting data.  
b) Ensure that the PC is switched on, the printer is set to HP DeskJet 1600 and 
the MAST Data Integration Software (DIS) is open. 
c) From the analyser menu select SUPPORT 
d) Select PROCESS IQC 
e) Highlight the type of IQC - QC 1 for low control results and QC2 for high control 
results, and then select the current LOT. 
f) Using the tab select INTRA-DAY/INTER-DAY 
g) Highlight the data you want to send, press SELECT S (to start) and SELECT to 
finish 
h) When you are ready to export the data press OUTPUT then EXT MEDIA, then 
START. 
i) When the second set of results are set there is an option to ADD or DELETE, 
press ADD 
j) The data has now been sent to DIS, to close QC menu press CONTINUE, 
REGISTER. 
 
At the PC check the QC results for consistency, verify the results and print them. 
IQC results must be verified before a run of samples are tested.  
 
To send participant results. 
 
k) The analyser must be finished before exporting data.  
l) Ensure that the PC is switched on, the printer is set to HP Deskjet 1600 and the 
MAST Data Integration Software (DIS) is open. 
m) From the analyser menu select SUPPORT 
n) Select PROCESS DATA 
o) The most recent sample run is located at the top left hand corner of the screen. 
It is identified by the date and time it happened. 
p) Highlight the data you want to send, press SELECT S (to start) and SELECT to 
finish. This selects a complete run. 
q) Once isolated, highlight the individual test data you wish to export and select 
TEST DATA. 
r) All the results from the run now appear press SELECT S (to start) press the 
bottom result visible (all the results visible will turn blue) scroll down once, press 
the bottom result so that all results turn blue repeat this until the whole run is 
selected 
s) When you are ready to export the data press OUTPUT then EXT MEDIA, then 
START. 
t) The data has now been sent to DIS, to close SUPPORT menu press 
CONTINUE, REGISTER. 
 
Log into the MAST DIS. At the PC check the participant results for consistency –ensuring 
there is a variety of results and no trends that would indicate a problem within the run, 
then press verification complete for that set of results and print them. 
 
These printed results must be checked against the analyser printout to ensure that there 
has not been any error during transmission of results. The analyser printout should be 
ticked for each result that is correctly matched. If any results do not match it must be 
brought to the attention of a senior immediately 
 
Two Screeners enter results into BoSS from the printed work list. One person reads from 
the printed results sheet, the second person types the kit number into BoSS before 
entering the result. Both people ensure the correct result is entered then proceed to the 
next participant result. When entering the result, 0 is entered for a negative result, 3 is 
entered for a positive result. All results printouts are kept with the original analyser data 
stapled to them. 
 
Maintenance is carried out as per the schedule attached (TSCRPU 34 F1.1) 
174 
  
All maintenance procedures are found in the CLOSE MODE, MAINTENANCE, 
PROCEDURE screens on the analyser. 
Limitations of the Procedure, Most Frequent Problems and Troubleshooting 
Almost no reaction occurs with non-human haemoglobin. 
 
Almost no effect on the measurement value was found from bilirubin (25mg/dl), lipids 
(0.6% intra lipid), ascorbic acid (40 mg/ml), protein (2.5 g/dl bovine serum albumin), 
glucose (4.0 g/dl) or barium sulphate (25 mg/dl). 
 
A senior member of staff must perform troubleshooting. If there is a communication error, 
shut down the machine and start it up again. If the controls are out of the limits, make a 
new batch and repeat them. If there is a mechanical fault (rack not ejecting or stuck rack) 
stop the run and remove the obstruction.  
 
Advice on trouble shooting problems can be sought from Iain McElarney on 07855 
416564, office 0151 933 7277 or imcelarney@mastgrp.com. 
 
Range of Expected Results 
The OC Sensor DIANA, Eiken Chemical Co., Ltd is calibrated to measure 0 – 1000 ng 
Hb/ml of buffer, with a prozone check function above 1000 ng Hb/ml buffer 
 
Validation and Reporting 
The control values are checked against the locally set range obtained after analysing 
QC1low and QC high ten times. Data attached.  
Screeners enter results into the BoSS system. A senior Screener or Biomedical Scientist 
can change the result that same day. At 9 pm the results are moved to mailer files for 
printing result letters to participants. 
 
Reference Intervals 
A result is reported as positive when the amount of haemoglobin measured is over 400 
ng/ml buffer. This will be a training data set and will be changed to give a 2% positivity 
rate. 
 
Performance Criteria 
BETWEEN RUN PRECISION 
 
OC 2    OC 1  
MEAN 148.7 623.9   MEAN 153.9 616.9 
SD 7.7 28.6   SD 6.1 23.1 
CV(%) 5.2 4.6   CV(%) 3.9 3.7 
 
WITHIN-RUN PRECISION 
 
SAMPLE 1 SAMPLE 2 SAMPLE 3 SAMPLE 4 LOW HIGH 
MEAN 25.8 47.1 72.4 83.5 172.1 708.4 
SD 6.5 8.1 3.9 6.1 5.8 21.1 
CV(%) 25.2 17.2 5.4 7.3 3.4 3.0 
 
Two-tailed distribution, two sample equal variance 
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T test 
Low 
0.1100 
High 
0.5548 
 
See also Manufacturers Performance Data  
 
Disposal of Materials 
See TSCRPU 10 
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APPENDIX 2 FORMAT OF DATA SHEET PRODUCED FROM INTERFACE WITH OC-SENSOR 
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APPENDIX 3 FFLT LABORATORY REPORT 
FIT as a First line Test Evaluation – Overview of Laboratory Phase 
The “FIT as a First line Test” evaluation (FFLT) within the Scottish Bowel Screening 
Programme got underway on 01 July 2010. All those eligible participants within NHS 
Tayside and NHS Ayrshire & Arran were sent one Eiken Chemical Co FIT specimen 
collection tube (SFIT) rather than the usual hema-screen gFOBT. The Laboratory phase 
has ended and data from this are being collected. The data in this report represent final 
outcomes. 
1. Number of invitations sent out and tubes returned. 
SFIT kits ceased being sent to participants on 12 January 2011. As of 12 January 2011, 
the number of SFIT kits [flow-pack with tube, return envelope and zip-lock bag, 
information on how to do the test and the Know the Facts leaflet] sent out from the Centre 
as initial invitations was 66225.. The number of tubes that have been received in the 
Laboratory as of 12 April 2011 was 40125. Thus, initial calculations indicate overall 
response to the invitation to participate in the study was 60.6%. Of the total number of 
samples received in the laboratory 1405 were initially Untestable and the participant was 
sent a second sampling device in order to complete their testing cycle. The number of 
participants who completed their cycle with a positive or negative result was 38720; this is 
58.5% of the invited population. 
 
2.   Number of days between sample being dated by participant and result entry in 
Laboratory. 
 
The graph below shows that 98% of SFIT tubes were returned to the Laboratory within 10 
days or less from the date written on the label by the participant (this includes time spent 
in the post).  
 
The graph also shows that in December and January, the adverse weather and its 
consequences for the post caused the number of expired SFIT to rise dramatically. This 
pattern was not replicated in other months 
 
Graph 1 Data for whole study return of SFIT kits 
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3. Turnaround of SFIT analyses in Centre Laboratory 
Table 1. Data for complete study  
Calendar Days 
to Report 
Result   SFIT Cumulative % 
        
1   37438 93.3 
2   1858 95.4 
3   308 99.2 
4   215 99.5 
5   197 99.5 
6   78 99.8 
7   29 99.9 
8   2 100 
        
Total   40125   
 
These data show that more than 95% of SFIT kits can be assayed in the Laboratory 
within 2 days in normal circumstances. The current QIS standard demands that 95% of 
kits are tested in the laboratory within 5 working days (7 calendar days) of receipt. 
4. FFLT samples returned by Month 
Table 2. Data for complete study 
 Males 
 
 Females  
 Samples 
Returned 
Cumulative 
Samples Returned 
Samples 
Returned 
Cumulative 
Samples Returned July 2010 1285 1285 1643 1643 
August 2010 2513 3798 2764 4407 
September 2010 2825 6623 3316 7723 
October 2010 3146 9769 3598 11321 
November 2010 2842 12611 3216 14537 
December 2010 1851 14462 1893 16430 
January 2011 2797 17259 3340 19770 
February 2011 621 17880 714 20484 
March /April 2011 178 18058 178 20662 
 
5.  Laboratory outcome data  
The numbers of unlabelled, undated, and spoiled SFIT kits are proportionately lower than 
for gFOBT. The number of SFIT kits with mechanical damage (reported as non technical 
fail with the participants being sent another SFIT kit) is noticeably higher than for gFOBT. 
There have been no manufacturer related technical fails of SFIT.  Note that there were a 
significantly higher number of “expired” kits in December, simply due to the non-delivery 
of mail within the usual time frame caused by adverse weather and consequent transport 
problems. All participants who have encountered a pre analytical problem are sent a 
repeat sampling device. 
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Table 3. Laboratory outcome data for the complete study 
ITEM SFIT     
    % 
1 Invitations 66225  
    
 Testable SFIT   
2 Positive 943 2.4 
3 Negative 37777 97.6 
4 Total tested 38720  
5 Total tested/Invitations  58.5 
6 Total tested/Tested and Untestable  96.5 
     
 Untestable SFIT   
7 Spoiled 47 0.12 
8 Unused 0 0 
9 Expired 1311 3.39 
10 Incomplete 0 0 
11 Non-technical fail 36 0.10 
12 Unresolved ID query 11 0.03 
13 Technical Fail 0 0 
14 Total Untestable 1405 3.5 
    
15 Tested and Untestable 40125  
16 Response rate  60.6 
17 Unlabelled 172 0.43 
18 Undated 134 0.33 
 
6. Return of Repeat samples 
Table 4. Return of Repeat samples data for the complete study 
Expired SFIT    Non Technical Fail SFIT   Spoiled SFIT   
Condition Number % Condition Number % Condition Number % 
Returned 1134 86.5 Returned 34 94.4 Returned 41 83.7 
Not returned 171 13.0 Not returned 2 5.6 Not returned 8 16.3 
Total 1305   Total 36   Total 49   
                  
Neg 1051 80.2 Neg 34 94.4 Neg 31 63.3 
Pos 32 2.4 Pos 0 0.0 Pos 3 6.1 
Expired 40 3.1 Expired 0 0.0 Expired 1 2.0 
Spoiled 4 0.3 Spoiled 0 0.0 Spoiled 6 12.2 
Closed 167 12.7 Closed 2 5.6 Closed 8 16.3 
FOBT returned 6 0.5 FOBT returned 0 0.0 FOBT returned 0 0.0 
FOBT not Returned 3 0.2 FOBT not Returned 0 0.0 FOBT not Returned 0 0.0 
Others 8 0.6 Others 0 0.0 Others  0 0.0 
Total 1311   Total 36   Total 49   
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The return rate for repeat samples was more than 80% in each category. This is higher 
than the uptake of the initial screening test. Experience in the Programme indicates that 
the return rate of qualitative FIT is approximately 95%, which again is higher than uptake 
for the initial screening test. 
 
7.   Analysis of quantitative results 
Statistical evaluation of the data from the study shows that there is a difference in faecal 
haemoglobin concentrations between males and females. Females had a faecal 
haemoglobin concentration of 283 ng/mL at the 97.5% percentile (95% CI: 257 – 316) 
and males 519 ng/mL (95% CI: 468 – 575). Confidence intervals in the data are very 
large, of course, because of the nature of population studies.  To obtain 2.0% positivity, 
the cut-off concentration for females would have to be approximately 388 ng/mL and 684 
ng/mL for males. 
There is a steady increase in faecal haemoglobin concentration with age in both sexes.  
The faecal haemoglobin that would be used to give ca. 2.0% positivity in a 50 year old 
female would be 270 ng/mL, whereas the cut-off that could be used for a 70 year old 
female would be 680 ng/mL. There is a similar pattern seen in males. A 50 year old male 
could be reported as positive at 390 ng/mL, while his 70 year old counterpart reported 
positive at 950 ng/mL. 
 
Table 5. Laboratory age and gender data for complete study 
Males         
 Returned 
samples 
Percentiles      
 2% positivity 
 
 n 2.5 25 75 95 97.5  Cut off to give 2 % positivity 
 
AGE         
50 - 54 4075 0 0 7 104 281  390 
55 - 59 4160 0 0 9 154 415  525 
60 - 64 3489 0 0 12 185 520  670 
65 - 69 3497 0 0 17 253 713  950 
70 - 74 2837 0 0 21 347 737  950 
TOTAL 18058        
         
Females         
 Returned 
samples 
Percentiles       
 n 2.5 25 75 95 97.5   
AGE         
50 - 54 4543 0 0 6 68 170  270 
55 - 59 4730 0 0 7 92 243  350 
60 - 64 4058 0 0 8 101 235  340 
65 - 69 3985 0 0 10 129 317  430 
70 - 74 3346 0 0 15 192 534  680 
TOTAL 20662        
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Summary 
 The number of participants who completed their cycle was 58.5%. This is higher than 
that reported in the Programme KPI. 
 98% of SFIT kits were returned to the Laboratory within 10 days of sample collection. 
 In the Laboratory, turnaround time for analysis and reporting of SFIT results at 2 days is 
greater than 95%. 
 The SFIT positivity during the course of the evaluation was 2.4%; this is slightly higher 
than planned.  
 The number of participants who were sent a second test kit (except expired kits) is low 
compared to the Programme data. 
 Analysis of quantitative data compares favourably with the published reports of other 
groups. 
 The adverse weather led to problems for the Programme as well as the SFIT evaluation 
and this must be discussed in detail elsewhere 
 
PJM/CGF/JAS 
30 September 2011 
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APPENDIX 4 FFLT HELPLINE REPORT 
 
Fit as a First Line Test  
Summary of Call Recall Aspects 
 
 
Introduction of a quantitative Faecal Immunochemical Test (FIT) as a first line 
test pilot (FFLT) within a population screening programme required careful 
planning and preparation. Call recall aspects included; training staff, preparing 
Helpline information, designing new instruction leaflets and agreeing lines to take 
regarding implications of introducing a new test within an existing programme. 
Careful consideration had been given to setting the test outcomes to reflect the 
same level of positive referrals as with the standard test kit. It was important that 
people who were offered this test kit understood this was not a study and that 
they were not receiving a lesser service. The following text was agreed to be 
inserted into the standard invitation letter:  
 You have been issued with a collection tube to return your sample. It is 
different from the kit you may have seen in other bowel screening leaflets. 
This is easier to use, offers the same high standard of result and can be 
tested by machine.  
The Know the Facts leaflet issued with the pack showed photographs of the 
standard test kit and it was hoped this sentence would reduce confusion over the 
different test kits in use at that time. 
 
Helpline Information  
Helpline staff were very involved in preparing the mail for these new kits as it is 
part of their role to prepare all mail for the Centre. They were familiar with the 
method of obtaining samples and trained in the expected method of sampling via 
the tube test. There were question and answer sessions held for staff and there 
was confidence that any calls would not be over complex. 
Helpline Outcomes 
There were very, very few calls with questions about how to do this test. 205 calls 
over a 6 month period of the 66,225 invitations issued. (0.3% of the invitations as 
compared to 6% currently). It was quickly obvious that participants could easily 
follow the new instructions. There was virtually no impact on the Helpline 
attributable to this test. There was some evidence that participants preferred the 
tube test and the single sample method to the standard kit. This evidence came 
in the form of enquiry to the Helpline for a tube test to be issued rather than the 
standard FOBT. Awareness of the availability of the new tube test appeared to be 
where two people in the same household were invited at different times and each 
had a different test kit due to the time period of the pilot. 
See detailed information in Appendices 1 and 2 
 
Information Materials 
Feedback from a focus group who were known to have manual dexterity and/or 
visual impairment and the experience of call recall staff who listen to daily 
feedback from the public was used to assist in planning the instructions for doing 
the test. 
Evidence from previous feedback was that opening the standard bowel screening 
invitation pack envelope could often land in the contents falling to the floor and 
the recipient unsure of what order the items should be read. The Welsh 
Screening programme utilises a paper wallet to avoid this problem. Effort was 
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taken to create a wallet to contain the items and this wallet was used to display 
all messages in a simple layout. The layout gave room for  large font text and 
included a simple “ IKEA” style format which had no text. It was expected that this 
would assist those who are unable to read English. 
The 3 test items (the tube, the zip-lock bag and the return plasticised envelope) 
were all enclosed in a plastic flow pack which assisted hand filling of the wallets 
by staff at the Centre. This helped ensure components were complete, and gave 
the pack a more professional finished look. 
 
The new wallet utilised: 
 Clear arrows to point out the direction of the step by step instructions to 
rather than numbering. 
 very accurate diagrams of the bar-coded tube test 
 very clear illustration of the bar-coded label being removed from the letter 
and applied to the zip-lock bag. 
 Exact diagrammatic replication of the bar code label 
 replication of the checklist on the back of the return envelope 
 for the first time an illustration of a roll of toilet paper 
 for the first time an illustration of a bowel motion in the toilet 
 a summarised view of the instructions without any text on the reverse  
Information Materials Outcomes 
There was valuable feedback previously obtained via a group known to have 
manual dexterity and/or visual impairments. This feedback was carried out using 
the standard Faecal Occult Blood test kit (FOBT) and was known as phase one. 
The same group were asked to feedback on the new FFLT pack and instructions 
and the key points are summarised as follow: 
 
95% of participants found the print size to be accessible.  This is compared to 
85.3% of the volunteers in phase one where the standard FOBT kit and 
instructions were focus group tested. 
 
- 100% of participants thought that the instructions were easy to follow.  Many 
commented that the instructions were a great improvement on the original. 
- Only 39.1% of participants encountered handling problems due to their 
disability using the tube collection device kit.  This is compared to 61.8% of 
the volunteers in phase one. 
- 78.3% of participants felt that the tube collection device kit was easier to use 
than the original. 
The wallet required to be hand inserted into an envelope with a folded letter and 
the Know the Facts Leaflet. This manual process would not be transferable to a 
national screening programme and would require full automation. 
 
Conclusions  
There were no issues encountered or reported by the public in the introduction of 
the FIT as a First Line Test pilot within a population screening programme in 
Scotland. Participants appeared to be able to follow the instructions without 
needing to call the Helpline for more information. A process of automation would 
need to be identified to prepare mail that contained and FIT tube test kit. The 
participants appeared to prefer the tube test and the single sample method to the 
standard kit.  
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Appendix 1 
Top 5 Questions 
 
There does not appear to be much sample on the stick. 
49 
Information in 'Know the Facts' leaflet - participant confused as it refers to' 
3 visits to the toilet' 26 
Request for tube test instead of FOBt 23 
How to do tube test (Verbal explanation given) 
22 
Query about the study - Why is this test different to one I completed 
previously? 16 
Difficulty opening  or closing zip top bag 
16 
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Appendix 2 
 
Total Number of SFIT Invitation Packs issued 1st July 2010 - January 2011= 66,225 Number 
of calls  Total number  of Helpline calls received 1st July - 7th February = 31,070 
Only 205 calls specific to the SFIT kit were received in this 6 month period from 66,225 invited 
Helpline Questions during SFIT study (Data collected 1st July 2010 - 7th February 2011) 
Query about the study - Why is this test different to one I completed previously? 
16 
There does not appear to be much sample on the stick. 
49 
Query  regarding expiry time 
12 
How to do tube test (Verbal explanation given) 
22 
Damage to tube by Child/ Animal/ other - concern about liquid content of tube 
4 
Should I not have 3 tubes to complete? 6 
Difficulty opening  or closing zip-lock bag 
16 
Are 3 samples not better than 1? (concern about intermittent bleeding) 7 
I forgot to put tube into zip lock bag (label applied to tube or envelope) 
4 
I applied label to tube instead of bag 3 
Information in 'Know the Facts' leaflet - participant confused as it refers to' 3 visits to the toilet' 
26 
Request for FOBt instead of tube test 
2 
Request for tube test instead of FOBt 23 
Difficulty removing lid from tube 
1 
Participant thought zip lock bag was the envelope to return the kit 2 
Concern that the label goes onto the bag instead of the tube (How will they know the sample is mine if the bag is separated from the tube?) 
4 
stick has broken from lid of tube 
1 
What should I do with the liquid in the tube? 
2 
Should I remove the liquid from the tube? 
3 
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Should I fill the bag with stool sample? 
1 
Concern that excess sample seeped down side of tube 1 
Total number of calls 205 
Additional  Comments made to helpline staff regarding the Tube Test  
Participant thought test was fantastic - more hygenic, quick & easy  
One participant accidentally stood on tube kit which burst open  
One lady was angry that her tube test had expired by the time it reached the laboratory during extreme adverse weather - She felt that kits should not have 
been issued during periods of mail delays  
Participant commented that he thought that the instructions were very clear 
Gentleman stated that he had not completed Fobt kit 2 years ago as he believed it to be too 'fiddly' to complete, however he was more than happy to complete 
tube test as it seemed much easier. 
One lady had requested a tube test for her husband as they both thought it was much 'easier' to complete than the Fobt kit 
Participant commented that the tube test was a better, easier test to complete 
One participant commented that they found the test much easier to do than the Fobt 
One disabled person found the kit easier to use and felt it should be available for all disabled people. 
One gentleman found the test to be a better test for him as due to his working hours, he found it difficult to collect 3 samples in 10 days. 
One lady thought it was a more hygenic test as she did not like keeping the Fobt kit in the house between samples when she completed the test 2 years ago 
3 participants commented that they preferred the Tube test as they found it easier to complete than the red and white card test 
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APPENDIX 5 SCOTTISH BOWEL SCREENING PROGRAMME INVITATION LETTER 
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APPENDIX 6 SCOTTISH BOWEL SCREENING PROGRAMME POSITIVE LETTER 
 
 
 
 
 
 
 
 
Scottish Bowel Screening 
Centre  
Kings Cross  
Clepington Road  
Dundee  
DD3 8EA  
 
 
 
Dear  
 
You recently sent us your completed bowel screening kit for testing. Thank you for taking the 
time to do the test and post it to the Bowel Screening Centre. 
 
Your test result shows that there were hidden traces of blood in your bowel motion (poo). 
This doesn’t mean that you have cancer, but it does mean you should get the cause of the 
bleeding checked out. 
 
There can be lots of simple explanations, including bleeding gums, inflammation in the 
stomach, polyps (non-cancerous growths) in the bowel, piles (haemorrhoids), or broken skin 
around your bottom (back passage). A more serious explanation could be that early bowel 
cancer sometimes bleeds.  
 
A colonoscopy is the best way of looking for the cause of bleeding, which in some, but not 
all, cases may be due to bowel cancer.  
 
What is a colonoscopy? 
 
 It’s usually an outpatient appointment, so you shouldn’t need to stay in hospital for 
more than a few hours.  
 A thin, flexible tube with a camera will be used to examine your bowel. This means the 
doctor or nurse can fully examine your bowel. 
 The tube will reach your bowel by passing through your bottom (back passage).  
 Your colonoscopy will take about half an hour and is a very safe examination. 
 If ‘polyps’ are found, most of them can be removed at the time of the test. Polyps are 
small growths of cells on the bowel wall. Removing polyps can give you long-term 
protection from bowel cancer.  
 
Remember, very few of the people who need a colonoscopy will have bowel cancer. 
 
PRIVATE AND CONFIDENTIAL 
 
 
Date 24 September 2015 
Reference No:  
  
 
Enquiries to 
 
0800 0121 833 
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Your NHS Board will contact you in the next few days to explain the colonoscopy more fully 
to you. You will also be able to ask any other questions you may have about bowel 
screening.  
 
If you wish to contact them yourself, the contact details are: …INSERT BOARD DETAILS 
HERE… 
 
Your GP has a copy of your test result and will know that a colonoscopy is planned for you. 
 
If you are still aged between 50 and 74 then we will invite you to take another bowel 
screening test in two years’ time.  
 
 
Yours sincerely 
 
 
Professor Bob Steele 
Clinical Director 
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APPENDIX 7 INVITATION TO FIT IN THE SYMPTOMATIC STUDY 
Caron Innes 
Research Nurse 
Ninewells Hospital  
Dundee 
                                                                                                                
DD1 9SY 
Name of Patient                                                                                         
Address 
Date 
Dear Sir/Madam, 
Thank you for agreeing to take part in this Study. 
I enclose an information sheet which provides more details about the 
study and how to collect the sample. It also contains the sample tube, a 
zip-lock bag and a return envelope for you to send everything 
back.  Returning the sample will be taken as consent to participate in the 
study. Please remember to date the tube when you have taken the sample 
and post it as soon as possible. 
You could bring your sample to your Colonoscopy appointment and hand 
it to one of the Nurses, if you prefer. 
Please feel free to contact me if you have any further questions.  
Yours faithfully 
 
 
Caron Innes 
 
Phonexxxxxxxx 
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APPENDIX 8 FIT IN THE SYMPTOMATIC INFORMATION SHEET 
 
PATIENT INFORMATION SHEET 
Quantitative Faecal Immunochemical Testing in Patients with Large 
Bowel Symptoms.  (A Potential New Screening Test) 
You are being invited to take part in a research study which will be used 
as part of an educational qualification. Before you decide, it is important 
for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and 
discuss it with others if you wish.  Ask us if there is anything that is not 
clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. 
If you wish this information sheet in another language please contact the 
research team who will be happy to assist. 
Thank you for reading this. 
1. What is the purpose of the study? 
We hope to develop a stool test that can be used in the screening for 
some bowel disorders. This would be useful as it would hopefully reduce 
the number of people being referred for colonoscopy, as the test would 
identify people who did not need colonoscopy but another form of test. 
2. Why have I been invited? 
You have been invited because you are awaiting a colonoscopy, which 
your GP has requested, as you have some bowel symptoms.  We would 
like to measure the amount of blood you have in your stool and compare it 
with the results of your colonoscopy. 
3. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to 
take part you will be given this information sheet to keep.  Returning the 
sample to the research team will be taken as consent to participate in this 
study. 
If you decide to take part you are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time or a decision 
not to take part will not affect the standard of care that you receive. 
4. What will happen to me if I take part? 
You will be asked to kindly send us 1 sample from a bowel motion, before 
you start taking the medicine to clear your gut for the colonoscopy. 
Your doctor will contact you with the results of your colonoscopy as usual. 
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5. What do I have to do? 
We will give you 1 small tube and instructions that will enable you to take 
the stool sample.  We will also give you a suitable stamped addressed 
envelope in which to return the sample to us.  
To take the sample; 
 Place layers of toilet paper in the toilet bowl to catch your 
sample.  Do your stool sample onto the toilet paper. It doesn’t 
matter if your sample touches the toilet water.   
 Twist open the green cap of the tube and pull it out. 
 Collect a sample by scraping the green stick on the bowel motion 
until the grooved end of the stick is covered.  
 Place the stick back into the tube and push closed. Wash your 
hands.  
 Put the date on the tube. Then place the tube into the zip-lock bag 
and close it. 
 Put it in the return mailing envelope for posting.   
 Review the checklist on the back of the envelope and post without 
delay. 
6. What are the possible disadvantages and risks of taking part? 
There are no risks involved for you taking part in this study.  We 
understand that not everyone will feel able to take a stool sample from 
their own bowel movements and if this applies to you then we would 
understand why you would decline to participate in the study. 
7. What are the possible benefits of taking part? 
There is no benefit for you taking part in this research.  We hope to use 
your donated samples to develop a test that will help people in the future. 
8. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the 
research will be kept strictly confidential.  All samples will be made 
anonymous with a unique study number to identify them, they will not be 
identified with your name. 
We will use these samples in our current study.  You will not be identified 
in this research.  After the study all the samples will be destroyed. 
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9. What will happen to the results of the research study? 
The results will be published in scientific journals and presented at 
meetings of scientists and doctors. 
10. Who is organising and funding the research? 
The study has been organised by Professor Fraser and his research team 
in the Scottish Bowel Screening Centre.  The equipment is being provided 
by MAST diagnostics (the company which makes the test). 
The Tayside Committee on Medical Research Ethics, which has 
responsibility for scrutinising proposals for medical research on humans, 
has examined this proposal and has raised no objections from the point of 
view of medical ethics.  It is a requirement that the research records are 
made available to monitors from NHS Tayside, whose role is to check that 
research is properly conducted and the interests of those taking part are 
adequately protected. 
If you believe that you have been harmed in any way be taking part in this 
study, you have the right to pursue a complaint and seek any resulting 
compensation through MAST diagnostics who are acting as the research 
sponsor.  Details about this are available from the research team. 
11. Contact for further information 
If you have any questions or you wish to obtain further information about 
this study, you may contact Caron Innes at; 
 
Ninewells Hospital and Medical School 
Dundee 
Telephone numberxxxxxxxxxxxx  
Thank you for considering taking part in this study.  
 
 
 
 
